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Abstract 
Caenorhabditis elegans, a small free-living nematode, has been used to 
investigate many biological processes including apoptosis, the cell cycle, gene regulation, 
cell polarity, metabolism, aging, and development. Transgenic C. elegans have been 
broadly utilized as a human disease model to study mechanisms of pathology for diseases 
such as obesity, diabetes, cancer, Duchenne’s muscular dystrophy, and several 
neurodegenerative diseases.  In these studies we used C. elegans to further investigate 
muscle development and as a model for facioscapulohumeral muscular dystrophy 
(FSHD) pathophysiology. 
A previous genetic screen in C. elegans investigating early muscle development 
isolated mutants producing a pat (paralyzed, elongation arrested at two-fold) phenotype.   
This project focused on identifying and characterizing one of the pat genes, pat-9. 
Positional cloning and reverse genetics were used to identify T27b1.2 as encoding the 
pat-9 gene.  Characterization of the PAT-9 protein revealed that it is an exclusively 
nuclear zinc finger protein required for muscle development.  This nuclear localization 
for PAT-9 makes it unique among the pat family of genes.  Considering the pat-9 mutant 
phenotype shows severely disrupted muscle attachment sites despite PAT-9 not localizing 
to those sites, PAT-9 may function in the regulation of expression for some necessary 
structural component of the muscle attachment sites.  
For the FSHD project, a C. elegans homolog of the FSHD candidate gene FRG1 
(FSHD region gene 1), ZK1010.3, was identified, cloned, renamed frg-1, and 
characterized. Surprisingly, both the endogenous and overexpressed FRG-1 was localized 
to the nucleus and the cytoplasm, contrary to what had been reported in the literature for 
human FRG1.  Interestingly, in adult body wall muscle, FRG-1 associated with the 
cytoplasmic dense bodies whose primary function in C. elegans is to transfer mechanical 
force from muscle contraction to the cuticle by attaching the muscle fiber to the muscle 
cell membrane and the surrounding extracellular matrix (ECM).  Thus, dense bodies are 
functionally similar to the vertebrate Z-disk and contain homologs of many of the same 
Z-disk proteins. Many other types of muscular dystrophy, such as Duchenne, Becker, 
certain limb-girdle dystrophies and some rare congenital muscular dystrophies result 
from mutations affecting vertebrate orthologs of dense body components. To date, our 
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study of FRG-1 in C. elegans renders FRG-1 the only FSHD candidate gene with a direct 
link to muscle structure.  In addition, overexpression of FRG-1 affects its distribution 
between the nucleus and cytoplasm, and 25% of transgenic animals overexpressing FRG-
1 showed disruptions in body wall musculature, including smaller, misaligned, missing 
and disconnected muscle cells.  FRG-1 is highly evolutionarily conserved suggesting 
human FRG1 may have the similar expression and function.  This data strongly supports 
a role for mis-expressed FRG1 in mediating the disruption of muscle cell membrane 
integrity and muscle weakness in FSHD patients.  
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CHAPTER 1: INTRODUCTION 
Caenorhabditis elegans as a model organism 
Caenorhabditis elegans (Caeno, recent; rhabditis, rod; elegans, nice) is a small, 
free-living nematode that lives in soil and feeds on bacteria and fungi.  The Bristol (N2) 
strain, the most commonly used wild-type strain, was isolated by L.N. Staniland near 
Bristol, England (Dougherty, 1956).  C. elegans is an attractive model system for 
biological and biomedical research due to the small size of adult animals (about 1.5-mm 
long), transparent body, documented development, rapid life cycle, a fully sequenced 
genome, a well maintained database (www.wormbase.org), and it is easy to maintain in 
the laboratory.  C. elegans can easily grow on agar plates or in liquid culture for large-
scale cultivation at a range of temperatures which dictate growth rate.  Their life cycle at 
22˚C is shown in Figure 1-1.  In addition, they have sexual reproduction, allowing for 
crossing between males and hermaphrodites, or can undergo self-fertilization.  C. elegans 
gene expression is also easy to manipulate through generation of transgenic animals by 
DNA injected into the adult gonad or through RNAi procedures.  The RNAi or 
overexpression phenotypes or expression patterns of epitope-tagged transgenes can be 
observed in F1 progeny or transgenic lines, which can be maintained for several 
generations.  Overall, C. elegans is a powerful system to study numerous fundamental 
biological processes. 
C. elegans has been used for many biomedical research areas, including 
apoptosis, cell cycle, gene regulation, cell polarity, metabolism, aging, and as a human 
disease model. The Nobel Prize in Physiology or Medicine has been awarded two times 
to scientists using C. elegans as a model organism for biomedical research, in 2002 and 
2006; in 2008 a third C. elegans Nobel Prize in Chemistry was awarded to scientists for 
the discovery and development of the green fluorescent protein (GFP) (Chalfie; Melino, 
2007; Millan, 2009; Saavedra, 2003).  Transgenic C. elegans as human disease models 
have been broadly utilized to study disease pathology for neurodegenerative diseases, 
obesity, diabetes, cancer, and Duchenne’s muscular dystrophy.  For example C. elegans 
has a very well characterized nervous system. Transgenic C. elegans are paralyzed in 24 
hours upon expressing the human β-amyloid peptide and analysis of these animals 
supports the theory that β-amyloid aggregates induce oxidative stress and 
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neurodegeneration in Alzheimer’s disease (Link, 1995; Link, 2001).  Similarly, C. 
elegans has been used as a model to investigate the molecular pathology of Duchenne's 
muscular dystrophy. C. elegans body-wall muscle expresses the dystrophin homolog dys-
1.  The dys-1 mutants are hyperactive and hypersensitive to acetylcholine while the dys-1 
and hlh-1 (CeMyoD) double mutants show progression of degeneration of body wall 
muscles, which is consistent with the phenotype in the mdx mouse. Drug screening 
utilizing dys-1 and hlh-1 double mutants is a convenient and low cost animal alternative 
compared with screening using mouse or dog (Gieseler, 2000; Jones, 2009; Morcos, 
2009; Saito, 2002; Schmidt, 2007; Segalat, 2002).  Because C. elegans is easy to 
manipulate genetically and can be cultivated on microtitre plate, C. elegans human 
disease models can be utilized for high-throughput screening to identify compounds 
which have therapeutic effects on the human disease models and potentially translate to 
the human condition (Savel, 2006).   
 
Conservation of C. elegans muscle structure and focal adhesion with vertebrates 
The anatomy of C. elegans is  very simple with adults comprised of 959 cells from 
an invariant lineage. The body wall musculature is arranged in four quadrants running the 
length of the animal (Figure 1-2), with two dorsal strips and two ventral strips. The 
ventral left quadrant contains 23 cells while the other quadrants each contain 24 cells. 
The myofilament lattice of the body wall muscle has a striated pattern. The basic 
functional unit of C. elegans body wall muscle is analogous to the sarcomere of 
vertebrate skeletal muscle. The myosin thick filaments overlap with two sets of actin thin 
filaments in each unit. The thin filaments attach to the dense body, a structure analogous 
to the vertebrate Z-disk. The myosin thick filaments attach to a structure that is analogous 
to vertebrate M line. Both dense body and M line are anchored to muscle cell membrane 
and maintain the alignment of myofilaments. However, despite the similarity between C. 
elegans and vertebrate muscles there are major differences between these two. First, C. 
elegans body wall muscle is obliquely striated. The myofilaments are longitudinal while 
the striations are at an angle of 5-7º to the myofilaments.  Vertebrate skeletal muscle is 
cross striated, which means the orientation of the myofilaments and the striation is 
perpendicular. Second, the composition and size of myofilaments in nematodes differ 
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from those of vertebrate. C. elegans myofilaments are longer and thicker than those in 
vertebrate. Third, similar to vertebrates, the ends of C. elegans muscle cells contain 
attachment plaques, to which the actin thin filaments are attached to in only one direction. 
The attachment plaques are similar to the vertebrate myotendinous junction, a structure 
for transmission of tension in vertebrate muscle. In C. elegans most tension is transmitted 
through the dense body and M-line, the structures that attach myofilaments to the muscle 
cell membrane (Francis, 1985; Francis, 1991; Waterston, 1980; Williams, 1994) 
Vertebrate focal adhesions, containing a cytoplasmic complex of cytoskeletal and 
signaling proteins, are homologous to C. elegans muscle cell attachments.  Many of the 
proteins known to be components of vertebrate focal adhesions are orthologs of known 
components of C. elegans dense bodies and M-lines (Figure 1-2).  C. elegans dense 
bodies and M-lines are integral parts of the sarcomere and are homologous to the Z-discs 
and M-lines, respectively, of vertebrate striated muscle.  Because they attach the 
sarcomeres to the basal membrane of the muscle cell, thus forming a physical 
transmembrane linkage to the basal lamina that is shared by muscle and hypodermis, the 
dense bodies and M-line attachments transmit contractile force generated in muscle cells 
to the surface of the animal. This feature is required for locomotion.  
In both C. elegans and vertebrates, integrins provide a physical connectivity 
between the intracellular environment and the extracellular milieu; these transmembrane 
receptors link the extracelluar matrix (ECM) with the actin cytoskeleton and promote cell 
adhesion.  Integrin function has been primarily investigated in the context of ligand 
induced-integrin clustering in vertebrate cell culture, otherwise known as focal adhesions. 
The extensive studies conducted on integrin function have revealed a wide range of 
cellular processes that integrin receptors influence, including gene expression, survival, 
differentiation, cell growth, proliferation and migration (Cary, 1999; Guan, 1997; 
Schatzmann, 2003).  Studies during the past several decades have identified many new 
components of focal adhesions; yet, it is still unclear how this structure is maintained 
during repeated contraction and relaxation.  The need to understand the mechanism for 
the maintenance of focal adhesions is underscored by their clinical significance including 
involvement in cardiac myocyte hypertrophy and degenerative muscular atrophies.  For 
example, integrin function is required for proper cardiac development and cardiac 
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myocyte attachment to extracellular matrix, growth and viability. Unregulated integrin 
activation leads to both contractile dysfunction and arrhythmias (Valencik, 2006).  C. 
elegans is an attractive organism in which to study assembly and maintenance of focal 
adhesions, which are called muscle attachments.  In C. elegans, we are able to view the 
muscle in a whole live animal, allowing us to uncover the true extracellular matrix 
(ECM) attachment in vivo, which is not possible in tissue culture. 
Dense body and M-line structures are fairly well documented in C. elegans.  
UNC-52/perlecan is located at the base of both dense bodies and M-lines within the basal 
lamina. PAT-2/α-integrin and PAT-3/β-integrin are located in the cell membrane 
(Hresko, 1994). Traveling further internally, dense bodies and M-lines both contain 
UNC-97/PINCH, UNC-112/Mig-2, PAT-4/ILK, PAT-6/actopaxin and talin.  The dense 
bodies also contain vinculin, and in the membrane-distal region, α-actinin.  The M-line, 
which does not contain vinculin, has the M-line-specific proteins UNC-89 and UNC-98 
in its membrane-distal domain (Lin, 2003; Mackinnon, 2002; Mercer, 2003; Moulder, 
1996; Norman, 2007; Rogalski, 2000).  Genetic analyses in C. elegans have shown that 
dense bodies and M-lines not only serve as attachments but their proteins also play a 
critical role during sarcomere assembly, which occurs approximately mid-way through 
embryogenesis.  
 
The Pat phenotype and known pat genes 
A genome-wide genetic screen to identify genes critical for muscle attachment 
assembly revealed that mutations ablating many of the afore-mentioned proteins cause a 
developmental arrest phenotype referred to as “Pat” (paralyzed, arrested elongation at the 
two fold stage) (Hresko, 1994; Williams, 1994).  Pat embryos do not move within the 
eggshell due to nearly complete muscle paralysis and embryonic elongation ceases early 
at the two-fold stage (embryo is twice the length of the egg).  Pat embryos, however, do 
hatch alive but are misshapen, non-motile embryos that eventually die (Hresko, 1994). 
Mutations in the genes that encode the membrane-associated components of the muscle 
focal adhesions (unc-52, unc-112, pat-3, pat-4 and pat-6) display the most severe Pat 
phenotypes in which neither thin filaments (actin) nor thick filaments (myosin) are 
assembled into the myofilament lattice (Moerman, 2006).  
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In C. elegans body-wall muscle, myosin thick filaments anchor to the M-line and 
actin thin filaments anchor to the dense body.  The dense body and M-line are both 
integrin containing structures and function as a linkage between the muscle cell and basal 
lamina.  The structure contains many homologues to components of vertebrate focal 
adhesions including UNC-52, the homolog of vertebrate perlecan.  UNC-52, located at 
the basement membrane between muscle cell and hypodermis, is the most upstream 
molecule in the muscle attachment assembly pathway.  The unc-52 null allele shows 
body-wall muscle disruption in cell polarization and cells lack organized myosin and 
actin filaments.  There is evidence that integrin and perlecan have a direct interaction in 
vertebrates but this has yet to be shown in C. elegans (Rogalski, 1995; Rogalski, 2001).  
C. elegans UNC-112 is homologous to the human protein MIG-2 and is involved in the 
organization of muscle attachment proteins (Rogalski, 2000). The unc-112 mutant 
animals exhibit the same severe Pat phenotype as the unc-52 mutants showing the 
disrupted organization of myosin and actin; however, cell polarization is not affected.  
The proper localization of UNC-112 requires the presence of UNC-52 and PAT-3/β-
integrin while UNC-112 is required for the proper localization of the subsequent 
molecular components in muscle attachment sites (Rogalski, 2000; Xu, 2006).  
Integrins are heterodimers and are involved in many cellular functions including 
cell adhesion, signaling transduction, cell migration and axon outgrowth (Baum, 1997). 
C. elegans has two α-integrin subunits, ina-1 and pat-2, but only one β-integrin, pat-3, in 
its genome; however, only mutants in pat-2 give a Pat phenotype; (Baum, 1997; Berks, 
1995). The α- and β-integrins form heterodimeric transmembrane cell surface receptors. 
αpat-2/βpat-3 forms the RGD-binding heterodimer and αina-1/βpat-3 forms a laminin-
binding heterodimer (Brown, 2000). Immunoprecipitation of PAT-3/beta-integrin 
identified association of multiple alpha-integrins at different development stages. 
Integrins are expressed in many tissues including striated muscle, gonads, and neurons. 
INA-1/PAT-3 heterodimers are involved in axon navigation. ina-1 mutant animals have 
no defect in muscle attachments, however, animals homozygous for null ina-1 die at 
early larval stage (Brown, 2000) . The PAT-2/PAT-3 heterodimer has an important role 
in both assembly of muscle attachments and migration of gonad distal cells and is 
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indispensible for the proper localization of other protein molecules to the dense body and 
M-line (Lee, 2001; Tucker, 2008). 
PAT-4, the homolog of mammalian integrin-linked kinase (ILK), is an adaptor in 
muscle attachments (Mackinnon, 2002).  ILK was first identified by interaction with the 
β-integrin cytoplasmic domain in a yeast two-hybrid screen (Liu, 2000).  In C. elegans, 
PAT-4/ILK requires UNC-52, PAT-3/β-integrin and UNC-112 for its proper localization 
in muscle attachments.  In yeast two-hybrid analysis the protein kinase domain interacts 
with the N-terminus of UNC-112; its ankyrin repeats interact with the first LIM domain 
of UNC-97/PINCH, which is consistent with evidence in vertebrates.  Interestingly, the 
pat-4 kinase-dead construct rescues pat-4 mutant lethal phenotype indicating the kinase 
function of PAT-4 is not required for muscle attachment assembly or viability.  
Mammalian ILK has four ankyrin repeats, which bind to the first LIM domain of UNC-
97/PINCH, and a pleckstrin homology domain, capable of interacting with 
phosphoinositide lipids.  Overexpression of ILK results in translocation and accumulation 
of the Wnt signaling pathway molecule β-catenin in the nucleus, however, there is no 
evidence to show that PAT-4 is involved in Wnt/β-catenin signaling pathway in C. 
elegans. The activity of ILK is elevated in PTEN (phosphatase and tensin homolog) 
mutant cells.  Mutations in PTEN, a tumor suppressor gene, are often involved in the 
development of cancer.  Thus, ILK is an important therapeutic target for solid tumor 
therapy and a small molecular inhibitor of ILK’s kinase activity could be valuable for 
tumor therapy (Yoganathan, 2000).  
  PAT-6, the C. elegans homolog of vertebrate actopaxin, is critical for the 
assembly of muscle attachments. PAT-6/actopaxin is indispensible for recruitment of 
UNC-89 and myosin filaments. The proper localization of PAT-6/actopaxin requires 
UNC-52/perlecan, PAT-3/β-integrin, UNC-112 and PAT-4/ILK.  In yeast two-hybrid 
assays, PAT-4/ILK binds to PAT-6/actopaxin; PAT-4/ILK can also interact with UNC-
112 and PAT-6/actopaxin simultaneously, and UNC-97/PINCH is part of this complex.  
This evidence supports that these molecules form a complex and function as a scaffold 
for attachment of myofilaments to the cell membrane.  In vertebrates, an ILK complex 
with UNC-97/PINCH and PAT-6/ACTOPAXIN is called the IPAP1 complex and plays 
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an important role in mediating integrin-signaling pathways that regulate cardiac myocyte 
hypertrophy and resistance to apoptosis (Chen, 2005; Lin, 2003).  
UNC-97, a LIM domain protein required for cell substratum attachments, is 
homologous to vertebrate PINCH.  UNC-97 null mutants are Pats, however, other alleles 
show an Unc (uncoordinated) phenotype.  In UNC-97 mutant animals the cell 
polarization is disrupted and the myosin and actin filaments are disorganized.  The proper 
localization of UNC-97/PINCH requires UNC-52/percelan and PAT-3/β-integrin.  Unlike 
other Pats, UNC-97 shows expression not only in muscle attachments, but also in a 
speckled pattern in body-wall muscle nuclei.  UNC-97 interacts with UNC-98, a novel 
component of muscle attachment sites and a zinc finger protein that similarly shows the 
dual localization between the M-line and the nucleus. (Mercer, 2003; Norman, 2007; 
Qadota, 2007).  
Among the pat family, only pat-9 and pat-12 remain to be characterized.  This 
thesis focuses on pat-9.  The single pat-9 allele st558 causes embryo defects and 
developmental arrest that most closely resemble those caused by pat-4 and pat-6 loss-of 
function alleles. In pat-9 mutants, the recruitment of both actin thin filaments and myosin 
thick filaments to the muscle cell membrane appears to be disrupted. Previous discovery 
of novel focal adhesion components in C. elegans, such as UNC-97/PINCH and UNC-
112/Mig-2, has resulted in intense interest in the human orthologs of these proteins by 
research in the vertebrate integrin adhesion community. PAT-9 had not yet been 
molecularly isolated. Our work on identifying pat-9 and characterizing PAT-9's role in C. 
elegans muscle development will provide new insights into the assembly of integrin 
attachment complexes and associated cytoskeleton reorganization. 
In summary, the integrin complex in C. elegans is evolutionarily conserved.  The 
genetic analysis of C. elegans pat mutants has revealed the assembly dependency among 
proteins in muscle attachment sites (Figure 1-3). However, more novel molecular 
components are being identified and fit in this pathway such as UNC-98, UNC-96, UNC-
95, and in this study, PAT-9 and FRG-1, as discussed below (Broday, 2004; Mercer, 
2006; Miller, 2008; Qadota, 2007). Understanding of sarcomere assembly in C. elegans 
provides invaluable information for better understanding of myogenesis in vertebrates.  
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Introduction to Facioscapulohumeral muscular dystrophy (FSHD) 
Characteristics of FSHD 
FSHD is the most common of the nine types of muscular dystrophy in adults. The 
clinical syndrome of FSHD was first described in 1885 by Landouzy and Dejerine. It is 
an autosomal dominant disease with prevalence of 1: 20,000 (Tawil, 2008). The majority 
of affected individuals show symptoms when in their early 20s.  It is characterized by 
progressive atrophy of muscles in the face, upper arm, and shoulder girdle. In more 
severe cases the abdominal muscle, pelvic girdle and foot extensor muscles are also 
affected (Olsen, 2006).  The symptoms of weak abdominal muscles, called Beevor's sign, 
is positively correlated in patients with a typical FSHD phenotype, and weakly correlated 
with atypical FSHD and other types of muscular dystrophy (Eger, 2009).  The clinical 
spectrum ranges widely with about 20% of FSHD patients developing severe symptoms 
and becoming wheelchair-bound in their early 20s, while patients with mild symptoms 
have a relatively normal life (Lunt, 1995).   Besides the skeletal muscles, FSHD has 
manifestations in other organs and tissues. About 60-75% FSHD patients develop hearing 
loss and retinal vasculopathy, similar symptoms as Coats’ disease (Fitzsimons, 1987).  A 
small fraction of FSHD patients show cardiomyopathy and respiratory disease that are 
considered to correlate with severe muscle weakness.  Since cardiac and respiratory 
system involvement is uncommon, the life span of FSHD patients is not significantly 
compromised (Stubgen, 2009).  
Histological studies on FSHD muscle biopsies show some typical features of 
muscular dystrophies including variations in myofiber size, muscle tissue necrosis, and 
occasional phagocytosis, but there is great variation within muscle sections (Lin, 1991). 
Retinal vasculopathy or hearing loss has no correlation with age (Padberg, 1995).  
Inflammatory cell infiltration, connective tissue proliferation, and fiber architectural 
changes are also found and slow to fast myofiber differentiation is impaired (Arahata, 
1995; Lin, 1991).  Fat cell infiltration is observed and is associated with disrupted energy 
metabolism (Kan).  Expression profiles from FSHD patient samples show disruption of 
the MyoD-dependent transcription network and deficiency of molecules in response to 
oxidative stress, which indicates reactive oxygen species may be responsible for the 
transformation and accumulation of malfunctioning muscle fibers (Celegato, 2006).  
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Immunohistology shows altered structures at the sarcolemma in FSHD samples. Muscle 
attachments were misaligned and significantly increased with the nearest myofibrils, 
indicating that the integrity of the muscle attachments is compromised in FSHD (Reed, 
2006). Myoblasts from affected FSHD muscles are more susceptible to induced oxidative 
stress compared with myoblasts from normal muscle and they also show abnormal 
morphology after differentiation, which can explain the weakness of skeletal muscle in 
FSHD patients (Barro, 2008). At the molecular level apoptosis is detected in several 
types of muscular dystrophy, and expression of the pro-apoptotic caspase 3 protein was 
detected in FSHD muscle (Sandri, 2001). Overexpression of fibroblast growth factors 
found in FSHD muscle (Saito, 2000) could explain the muscle fibrosis and disease 
severity in FSHD patients (Saito, 2000). 
In addition to histological analysis, there have been several attempts to determine 
differential gene expression profiles in FSHD patient-derived muscle versus unaffected 
controls.  Gene expression profiles of FSHD-derived muscle biopsies identified many 
differentially expressed genes that are involved in muscle differentiation, and many of the 
transcripts that are differentially expressed in FSHD are direct MyoD targets (Winokur, 
2003).   A similar subsequent analysis found 44 genes specifically upregulated in FSHD 
versus control and unique to FSHD (not found to be misexpressed in other muscular 
dystrophies), however this analysis identified a high number of genes involved in 
vascular smooth muscle or endothelial cells (Osborne, 2007).  Finally, a third global 
expression array yielded expression profiles matching to a number genes involved in 
posttranslational modification, histone modifications, and miRNAs, suggesting the 
altered regulation of the transcription network in FSHD pathogenesis (Arashiro, 2009).  
Overall, no consistent pattern has emerged from microarray analyses of FSHD patient 
muscle. 
FSHD is not only involved in muscle degeneration but retinal vasculopathy and 
hearing loss as well (Fitzsimons, 1987; Voit, 1986; Yasukohchi, 1988).  FSHD 
expression profiles also show the upregulation of genes involved in angiogenesis, which 
provides a connection between FSHD and retinal vasculopathy (Gurwin, 1985; Osborne, 
2007). Severe FSHD is also associated with mental retardation and the expression of 
fragile X related protein 1 (FXR1P) is altered in FSHD patients (Bindoff, 2006; 
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Davidovic, 2008).  Overall, there is great variation in the clinical symptoms, molecular 
and histological changes, and gene expression profiles among FSHD patients, 
highlighting the complexity of the disease. 
 
The FSHD genetic lesion 
The genetic defect in FSHD1A, the most common form (>98% of cases) of 
FSHD, was first identified in early 90s by studying a small population of FSHD patients, 
which linked the disease to chromosome 4q35 (Wijmenga, 1993; Wijmenga, 1991; 
Wright, 1993). A 4q35-specific DNA probe (p13E-11) identified a reduced size genomic 
DNA fragment when digested with the EcoRI restriction enzyme specifically in affected 
individuals.  Within these smaller EcoRI fragments were a variable copy number of 
repeated DNA units called D4Z4, which are 3.3 kb DNA repeats found in multiple direct 
repeat arrays within the genome. Around 95% of the FSHD patients tested were found to 
carry a D4Z4 array of between 1 - 10 units, as indicated by the resulting EcoRI fragment 
being 10 – 38 kb in size, compared to the healthy population where the tandem repeats 
contain 11- 100 units. There is a weak correlation between the number of tandem 
repeated units and the severity of the disease. However individuals with complete 
deletion of the 4q35 D4Z4 array do not have any symptoms, which indicates that at least 
one D4Z4 repeat is required for the development of the disease (van der Maarel, 2007). A 
highly homologous array of D4Z4 repeats is located on chromosome 10, however, only 
contractions on 4q are pathogenic, indicating additional sequence specific to chromosome 
4 is also required.  The two homologous regions can be distinguished since sequence 
variations render the D4Z4 at 4q resistant to digestion with the BlnI restriction enzyme 
and D4Z4 on 10q is resistant to digestion with the XapI restriction enzyme (Rossi, 2007).  
It has been reported that D4Z4 repeat translocation happens between 4q and 10q.  This 
evidence indicates the potential sequence variation or SNP in D4Z4 repeats on 4q and 
10q.  Recently, van der Maarel and colleagues identified sequence variations upstream, 
downstream, and within the D4Z4 repeated region (Lemmers, 2007), including a 
relatively stable simple sequence-length polymorphism (SSLP) upstream of D4Z4 
tandem repeats, a G/C single-nucleotide polymorphism (SNP) within D4Z4, and 
subtelomeric variations (termed A and B) distal to D4Z4. However, only 4q D4Z4 
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contractions when combined with haplotype 4qA 161 are pathogenic (Lemmers, 2004; 
Lemmers, 2007; Lemmers, 2001).  Thus, for FSHD1A, patients have between 1 and 10 
D4Z4 repeats at 4q35 combined with subtelomere 4qA and sequence polymorphism 161.  
In addition, a small number of affected individuals (FSHD1B) clinically exhibit FSHD 
but contain the normal number of D4Z4 repeats at 4q35.  The genetic cause of FSHD1B 
is unknown, which further indicates the complexity of the mechanisms leading to FSHD 
disease pathology (Fisher, 1997; Funakoshi, 1997; Gilbert, 1995; Speer, 1997).  
 
FSHD Disease Models  
FSHD pathology is not like many other diseases that can be explained by a 
mutation in particular protein coding gene.  There is also a strong epigenetic aspect of 
FSHD that has been well studied.  It is proposed that FSHD is caused by aberrant 
upregulation of a gene or genes, although the identity of the gene responsible is still in 
question.  The gene(s) may lie within the D4Z4 array, be near the array on 4q35, or 
potentially could be unlinked physically to the array. 
Researchers found that D4Z4 has a high GC content and the D4Z4 repeated 
region has some characteristics of heterochromatin such as high DNA methylation.  In 
addition, each D4Z4 repeat has the characteristics of a CpG island (Lee, 1995).  Heavy 
DNA methylation on CpG islands negatively regulates gene expression (Bird, 2002).  In 
unaffected individuals, the putative genes in this repeated region are not actively 
transcribed. (van Deutekom, 1996). In healthy populations about 50% of CpGs are 
methylated in the D4Z4 repeated region; however it decreases to 25% in FSHD patients.  
DNA methylation is also linked to specific histone post-translational modifications and 
some of these are altered in FSHD (de Greef, 2007; Tsien, 2001; van Deutekom, 1996; 
Wright, 1993).  This suggests that epigenetic modifications and potentially histone 
modification play a critical role in FSHD pathogenesis. 
D4Z4 repeat arrays are also located on several other chromosomes as confirmed 
by fluorescence in situ hybridization (FISH).  Deletion of D4Z4 repeats may change the 
chromatin structure and directly cause misregulation of localized gene expression (de 
Greef, 2007; Tsien, 2001).  Similarly, epigenetic changes of D4Z4 arrays could be 
pathogenic.  Phenotypic FSHD patients (FHSD1B) have no D4Z4 contraction, but 
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hypomethylation at CpGs was identified, consistent with FSHD1A patients. No mutations 
were identified in the exon regions of genes involved in methylation such as DMMT3B 
that is mutated in immunodeficiency, centromeric instability, and facial anomalies 
syndrome (de Greef, 2007). Thus, there are individuals with hypomethylation in D4Z4 
repeated region but without any FSHD phenotype, which indicates that hypomethylation 
at CpGs in D4Z4 is not sufficient for FSHD pathogenesis.  
Studies show that the 4q35 region behaves more like unexpressed euchromatin 
and not like constitutive heterochromatin in both FSHD myoblasts and control myoblasts. 
This result is confirmed by lack of 4q35 FISH with markers for heterochromatin (DAPI, 
HP1alpha, and H3K9 tri-methylation) and lack of co-localization with markers for 
actively transcribed euchromatin (H4K8 acetylation and H3K4 methylation) (Yang, 
2004). This study shows that 4q35 region resembles unexpressed euchromatin, and the 
histone modification status was no different between FSHD patient myoblasts and normal 
control myoblasts.  However, it does not rule out the possibility that candidate genes in 
the proximal region of D4Z4 repeats are differentially expressed due to the D4Z4 
contraction, that could alter the histone modification status of the proximal region (Yang, 
2004). Chromatin immunoprecipitation (ChIP) analysis with PCR primers specific for the 
4q35 D4Z4 repeats show that histone H3K9 tri-methylation is lost only in this proximal 
region, and H3K9-dependent HP1 binding is also disrupted in FSHD (Zeng, 2009).  
Thus, the 4q35 D4Z4 repeat contraction alters the epigenetic landscape in the 
surrounding region, bordering and outside the D4Z4 array, and this may in turn lead to 
FSHD. 
Additional regulatory mechanisms have been suggested for the D4Z4 array 
including repressor binding, chromatin looping, and changes in nuclear localization 
(Masny, 2004; Ottaviani, 2009; Pirozhkova, 2008).  However, while all the models have 
supporting evidence, none have been proven.  In vitro, D4Z4 repeats can bind to a protein 
complex containing a known transcriptional repressor called YY1 and other architectural 
proteins.  Loss of repressor binding due to decreased D4Z4 units is proposed to explain 
why the deletion of D4Z4 causes up-regulation of genes in proximity of D4Z4 tandem 
repeats (Gabellini, 2002).  There is also evidence that chromosome structural 
rearrangements happen due to the D4Z4 deletion in FSHD patients. Vassetzky and 
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colleagues demonstrated that the D4Z4 repeat has an enhancer activity.  In normal 
control, myoblasts, the D4Z4 array and the FSHD candidate gene FRG1 (discussed 
below), are located in different chromatin loops.  However, in FSHD they are located 
within the same chromatin loop. Chromosome conformation capture (3C) analysis 
identified the interaction between 4qA/B and frg1 only in FSHD cells.  Thus, loss of 
D4Z4 repeats directly changes the confirmation of the chromosome 4 long arm.  Their 
model therefore proposes that the binding of the enhancer in the D4Z4 array causes the 
upregulation of FRG1 and ANT1 transcription (Pirozhkova, 2008).  Winokur and 
colleagues suggest that FSHD could be a nuclear envelope disease just like several other 
neuromuscular disorders. The nuclear lamina protein lamin A/C is indispensible for the 
FSHD critical region to localize to the nuclear envelope.  This localization is mediated by 
a sequence in 4q35.2, not in the D4Z4 array. Using 3D-FISH, the 4q35.2 and D4Z4 are 
not always paired in FSHD patient cell lines. Thus, the deletion of D4Z4 changes the 
confirmation and localization of chromosome 4 and repressed genes could be improperly 
activated (Masny, 2004).  
Despite much research in the area, it is still not clear how the D4Z4 deletion leads 
to FSHD or which gene or genes are affected.  This may be in part due to much of the 
work being carried out in cell culture systems or muscle biopsies from already affected 
muscle.  This thesis will attempt to address the issue using C. elegans as a whole animal 
model for muscle development to investigate the spatiotemporal expression and function 
of one of the FSHD candidate genes, FRG1, for the potential to cause FSHD-like 
pathology. 
 
FSHD region gene 1 (FRG1) is a leading FSHD candidate gene 
FSHD region gene 1 (FRG1) was the first gene mapped to human chromosome 
4q35 and is a leading candidate gene for mediating FSHD pathogenesis. FRG1 is highly 
conserved from vertebrates to invertebrates.  FRG1 transcripts are detected in all human 
tissues tested including skeletal muscle, brain and placenta, which indicates that FRG1 
has multiple functions in muscle and non-muscle tissue and it also has a function in early 
development (van Deutekom, 1996). Some studies on FRG1 show FRG1 is up regulated 
in FSHD patient samples; however, other groups reported inconclusive or contradictory 
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results in its expression levels (Gabellini, 2006; Jiang, 2003; Osborne, 2007).  
Regardless, FRG1 is still the most attractive candidate gene for FSHD pathogenesis for a 
number of reasons. It is reported that in FSHD patient cell lines the sequence in 4qA/B 
subtelomere interacts with FRG1 promoter, which changes the confirmation of the 
chromosome 4q, resulting in the binding of D4Z4 enhancer to FRG1 (Pirozhkova, 2008). 
Transgenic mice showed an FSHD-like phenotype when FRG1 was 25-40 fold 
overexpressed.  Cross-sectional, specific force and maximum shortening velocity studies 
showed the shift from Type 2B (fast fiber) to Type 1 (slow fiber) in the FSHD-like 
skeletal muscle.  Myosin heavy chain also shifted to slow type in FSHD-like mice 
compared with wild-type animals (D'Antona, 2007; Gabellini, 2006).  Studies of FRG1 in 
another vertebrate animal model also provided evidence that FRG1 overexpression could 
play a critical role in FSHD.  In Xenopus laevis, mis-regulation of FRG1 expression by 
either transgenic overexpression or morpholino knockdown disrupted normal 
development of the musculature and myotome organization, which indicates that 
maintenance of precise level of FRG1 protein is crucial.  It supports the disease model 
that mis-regulation of FRG1 plays a causal role in FSHD pathogenesis (Hanel, 2009).  
Besides a putative function in skeletal muscle, FRG1 transcripts are also detected 
in placenta, brain, blood vessels, and other tissues.  Furthermore, 60-75% of FSHD 
patients also exhibit retinal vasculopathy and hearing loss.  FSHD patient samples show 
increased levels of FRG1 transcripts in vascular and endothelial tissues and expression 
profile of FSHD patient samples identified genes that have function in smooth muscle 
and endothelia cells (Osborne, 2007). Thus, FRG1 likely has a function outside of 
skeletal muscle. Mis-regulation of FRG1 in developing Xenopus causes abnormal 
vascular development, providing a link between FRG1 and the vasculopathy observed in 
FSHD patients (Wuebbles, 2009). 
FRG1 is a highly evolutionarily conserved gene (van Deutekom, 1996).  The 
deduced human FRG1 amino acid sequence shares 97% identify with mouse, 81% 
identity with Xenopus and 46% identity with C. elegans.  Although FRG1 is 
evolutionarily conserved, its function is still not understood in any organism.  Sequence 
analysis for functional domains predicted that FRG1 contains an N-terminal nuclear 
localization signal, a fascin-like domain found in actin bundling proteins, a lipocalin 
 15
domain functioning as a hydrophobic particle transporter, and a C-terminal bipartite 
domain.   Overexpressed FRG1 in mammalian cell culture is completely nuclear and 
localizes to nucleoli, Cajal bodies and nuclear speckles (van Koningsbruggen, 2004; van 
Koningsbruggen, 2007).   FRG1 also co-fractionated with components of the human 
spliceosome. A yeast two-hybrid analysis identified several speckle and Cajal body 
proteins, including SMN, PABPN1, and FAM71B, which bind to FRG1. Some of the 
proteins are also involved in other types of neuromuscular disorders. These results 
support FRG1 as having a role in RNA biogenesis and in the human spliceosome (van 
Koningsbruggen, 2007). Interestingly, it has been reported mis-splicing of specific RNAs 
in FSHD patient samples (Davidovic, 2008) and transgenic mice overexpressing FRG1 
show disrupted splicing of muscle specific genes, including skeletal muscle troponin T 
(Tnnt3) and myotubularin related protein 1 (Mtmr1), which are also mis-spliced in other 
types of neuromuscular disease (Gabellini, 2006).  Exactly what role FRG1 plays in RNA 
biogenesis in not known and no specific function for FRG1 has been described. 
Here we utilized C. elegans as a model system to study FRG1 and FRG1-
mediated pathogenesis in an animal model for FSH muscular dystrophy. We identified 
the C. elegans homolog of FRG1, ZK1010.3 (renamed frg-1). We have examined its 
endogenous expression pattern and discovered its cytoplasmic function as an actin 
bundling/cross-linking protein.  In addition, we successfully constructed an FSHD-like 
disease model by overexpressing frg-1 under control of the frg-1 promoter. In FSHD 
patients the integrity of muscle cell membrane is disrupted, but there was no direct 
evidence to show that any of the FSHD candidate genes have a role in muscle attachment 
sites (Reed, 2006). The functional analysis of FSHD leading candidate gene frg-1 in C. 
elegans provided a better understanding of the disease mechanism and contributed an 
alternative point of view to muscular dystrophy pathology.   
 
 
 
 
 
 
 16
References 
 
Arahata, K., T. Ishihara, H. Fukunaga, S. Orimo, J.H. Lee, K. Goto, and I. Nonaka. 1995. 
Inflammatory response in facioscapulohumeral muscular dystrophy (FSHD): 
immunocytochemical and genetic analyses. Muscle Nerve. 2:S56-66. 
Arashiro, P., I. Eisenberg, A.T. Kho, A.M. Cerqueira, M. Canovas, H.C. Silva, R.C. 
Pavanello, S. Verjovski-Almeida, L.M. Kunkel, and M. Zatz. 2009. 
Transcriptional regulation differs in affected facioscapulohumeral muscular 
dystrophy patients compared to asymptomatic related carriers. Proc Natl Acad Sci 
U S A. 106:6220-5. 
Barro, M., G. Carnac, S. Flavier, J. Mercier, Y. Vassetzky, and D. Laoudj-Chenivesse. 
2008. Myoblasts from affected and non affected FSHD muscles exhibit 
morphological differentiation defects. J Cell Mol Med. 
Baum, P.D., and G. Garriga. 1997. Neuronal migrations and axon fasciculation are 
disrupted in ina-1 integrin mutants. Neuron. 19:51-62. 
Berks, M. 1995. The C. elegans genome sequencing project. C. elegans Genome 
Mapping and Sequencing Consortium. Genome Res. 5:99-104. 
Bindoff, L.A., N. Mjellem, K. Sommerfelt, B.K. Krossnes, F. Roberts, J. Krohn, R.S. 
Tranheim, and I.D. Haggerty. 2006. Severe fascioscapulohumeral muscular 
dystrophy presenting with Coats' disease and mental retardation. Neuromuscul 
Disord. 16:559-63. 
Bird, A. 2002. DNA methylation patterns and epigenetic memory. Genes Dev. 16:6-21. 
Broday, L., I. Kolotuev, C. Didier, A. Bhoumik, B. Podbilewicz, and Z. Ronai. 2004. The 
LIM domain protein UNC-95 is required for the assembly of muscle attachment 
structures and is regulated by the RING finger protein RNF-5 in C. elegans. J Cell 
Biol. 165:857-67. 
Brown, N.H. 2000. Cell-cell adhesion via the ECM: integrin genetics in fly and worm. 
Matrix Biol. 19:191-201. 
Cary, L.A., and J.L. Guan. 1999. Focal adhesion kinase in integrin-mediated signaling. 
Front Biosci. 4:D102-13. 
Celegato, B., D. Capitanio, M. Pescatori, C. Romualdi, B. Pacchioni, S. Cagnin, A. 
Vigano, L. Colantoni, S. Begum, E. Ricci, R. Wait, G. Lanfranchi, and C. Gelfi. 
2006. Parallel protein and transcript profiles of FSHD patient muscles correlate to 
the D4Z4 arrangement and reveal a common impairment of slow to fast fibre 
differentiation and a general deregulation of MyoD-dependent genes. Proteomics. 
6:5303-21. 
Chalfie, M. The 2009 Lindau Nobel Laureate meeting: Martin Chalfie, Chemistry 2008. J 
Vis Exp. 
Chen, H., X.N. Huang, W. Yan, K. Chen, L. Guo, L. Tummalapali, S. Dedhar, R. St-
Arnaud, C. Wu, and J.L. Sepulveda. 2005. Role of the integrin-linked 
kinase/PINCH1/alpha-parvin complex in cardiac myocyte hypertrophy. Lab 
Invest. 85:1342-56. 
D'Antona, G., L. Brocca, O. Pansarasa, C. Rinaldi, R. Tupler, and R. Bottinelli. 2007. 
Structural and functional alterations of muscle fibres in the novel mouse model of 
facioscapulohumeral muscular dystrophy. J Physiol. 584:997-1009. 
 
 17
 
Davidovic, L., S. Sacconi, E.G. Bechara, S. Delplace, M. Allegra, C. Desnuelle, and B. 
Bardoni. 2008. Alteration of expression of muscle specific isoforms of the fragile 
X related protein 1 (FXR1P) in facioscapulohumeral muscular dystrophy patients. 
J Med Genet. 45:679-85. 
de Greef, J.C., M. Wohlgemuth, O.A. Chan, K.B. Hansson, D. Smeets, R.R. Frants, C.M. 
Weemaes, G.W. Padberg, and S.M. van der Maarel. 2007. Hypomethylation is 
restricted to the D4Z4 repeat array in phenotypic FSHD. Neurology. 69:1018-26. 
Dougherty, E.C., and E.L. Hansen. 1956. Axenic cultivation of Caenorhabditis briggsae 
(Nematoda: Rhabditidae). V. Maturation on synthetic media. Proc Soc Exp Biol 
Med. 93:223-7. 
Eger, K., B. Jordan, S. Habermann, and S. Zierz. 2009. Beevor's sign in 
facioscapulohumeral muscular dystrophy: an old sign with new implications. J 
Neurol. 
Fisher, J., and M. Upadhyaya. 1997. Molecular genetics of facioscapulohumeral muscular 
dystrophy (FSHD). Neuromuscul Disord. 7:55-62. 
Fitzsimons, R.B., E.B. Gurwin, and A.C. Bird. 1987. Retinal vascular abnormalities in 
facioscapulohumeral muscular dystrophy. A general association with genetic and 
therapeutic implications. Brain. 110 ( Pt 3):631-48. 
Francis, G.R., and R.H. Waterston. 1985. Muscle organization in Caenorhabditis elegans: 
localization of proteins implicated in thin filament attachment and I-band 
organization. J Cell Biol. 101:1532-49. 
Francis, R., and R.H. Waterston. 1991. Muscle cell attachment in Caenorhabditis elegans. 
J Cell Biol. 114:465-79. 
Funakoshi, M., K. Goto, B.Y. Kim, and K. Arahata. 1997. [Facioscapulohumeral 
muscular dystrophy (FSHD)]. Nippon Rinsho. 55:3181-5. 
Gabellini, D., G. D'Antona, M. Moggio, A. Prelle, C. Zecca, R. Adami, B. Angeletti, P. 
Ciscato, M.A. Pellegrino, R. Bottinelli, M.R. Green, and R. Tupler. 2006. 
Facioscapulohumeral muscular dystrophy in mice overexpressing FRG1. Nature. 
439:973-7. 
Gabellini, D., M.R. Green, and R. Tupler. 2002. Inappropriate gene activation in FSHD: a 
repressor complex binds a chromosomal repeat deleted in dystrophic muscle. Cell. 
110:339-48. 
Gieseler, K., K. Grisoni, and L. Segalat. 2000. Genetic suppression of phenotypes arising 
from mutations in dystrophin-related genes in Caenorhabditis elegans. Curr Biol. 
10:1092-7. 
Gilbert, J.R., M.C. Speer, J. Stajich, R. Clancy, K. Lewis, H. Qiu, L. Yamaoka, A. 
Kumar, J. Vance, C. Stewart, and et al. 1995. Exclusion mapping of chromosomal 
regions which cross hybridise to FSHD1A associated markers in FSHD1B. J Med 
Genet. 32:770-3. 
Guan, J.L. 1997. Role of focal adhesion kinase in integrin signaling. Int J Biochem Cell 
Biol. 29:1085-96. 
Gurwin, E.B., R.B. Fitzsimons, K.S. Sehmi, and A.C. Bird. 1985. Retinal telangiectasis 
in facioscapulohumeral muscular dystrophy with deafness. Arch Ophthalmol. 
103:1695-700. 
 18
Hanel, M.L., R.D. Wuebbles, and P.L. Jones. 2009. Muscular dystrophy candidate gene 
FRG1 is critical for muscle development. Dev Dyn. 238:1502-12. 
Hresko, M.C., B.D. Williams, and R.H. Waterston. 1994. Assembly of body wall muscle 
and muscle cell attachment structures in Caenorhabditis elegans. J Cell Biol. 
124:491-506. 
Jiang, G., F. Yang, P.G. van Overveld, V. Vedanarayanan, S. van der Maarel, and M. 
Ehrlich. 2003. Testing the position-effect variegation hypothesis for 
facioscapulohumeral muscular dystrophy by analysis of histone modification and 
gene expression in subtelomeric 4q. Hum Mol Genet. 12:2909-21. 
Jones, K.T., and K. Ashrafi. 2009. Caenorhabditis elegans as an emerging model for 
studying the basic biology of obesity. Dis Model Mech. 2:224-9. 
Kan, H.E., D.W. Klomp, M. Wohlgemuth, I. van Loosbroek-Wagemans, B.G. van 
Engelen, G.W. Padberg, and A. Heerschap. Only fat infiltrated muscles in resting 
lower leg of FSHD patients show disturbed energy metabolism. NMR Biomed. 
Lee, J.H., K. Goto, C. Matsuda, and K. Arahata. 1995. Characterization of a tandemly 
repeated 3.3-kb KpnI unit in the facioscapulohumeral muscular dystrophy 
(FSHD) gene region on chromosome 4q35. Muscle Nerve. 2:S6-13. 
Lee, M., E.J. Cram, B. Shen, and J.E. Schwarzbauer. 2001. Roles for beta(pat-3) integrins 
in development and function of Caenorhabditis elegans muscles and gonads. J 
Biol Chem. 276:36404-10. 
Lemmers, R.J., M. Wohlgemuth, R.R. Frants, G.W. Padberg, E. Morava, and S.M. van 
der Maarel. 2004. Contractions of D4Z4 on 4qB subtelomeres do not cause 
facioscapulohumeral muscular dystrophy. Am J Hum Genet. 75:1124-30. 
Lemmers, R.J., M. Wohlgemuth, K.J. van der Gaag, P.J. van der Vliet, C.M. van 
Teijlingen, P. de Knijff, G.W. Padberg, R.R. Frants, and S.M. van der Maarel. 
2007. Specific sequence variations within the 4q35 region are associated with 
facioscapulohumeral muscular dystrophy. Am J Hum Genet. 81:884-94. 
Lemmers, R.J.L., P. de Kievit, M. van Geel, M.J. van der Wielen, E. Bakker, G.W. 
Padberg, R.R. Frants, and S.M. van der Maarel. 2001. Complete allele 
information in the diagnosis of facioscapulohumeral muscular dystrophy by triple 
DNA analysis. Ann Neurol. 50:816-9. 
Lin, M.Y., and I. Nonaka. 1991. Facioscapulohumeral muscular dystrophy: muscle fiber 
type analysis with particular reference to small angular fibers. Brain Dev. 13:331-
8. 
Lin, X., H. Qadota, D.G. Moerman, and B.D. Williams. 2003. C. elegans PAT-
6/actopaxin plays a critical role in the assembly of integrin adhesion complexes in 
vivo. Curr Biol. 13:922-32. 
Link, C.D. 1995. Expression of human beta-amyloid peptide in transgenic Caenorhabditis 
elegans. Proc Natl Acad Sci U S A. 92:9368-72. 
Link, C.D., C.J. Johnson, V. Fonte, M. Paupard, D.H. Hall, S. Styren, C.A. Mathis, and 
W.E. Klunk. 2001. Visualization of fibrillar amyloid deposits in living, transgenic 
Caenorhabditis elegans animals using the sensitive amyloid dye, X-34. Neurobiol 
Aging. 22:217-26. 
Liu, S., D.A. Calderwood, and M.H. Ginsberg. 2000. Integrin cytoplasmic domain-
binding proteins. J Cell Sci. 113 ( Pt 20):3563-71. 
 
 19
 
Lunt, P.W., P.E. Jardine, M.C. Koch, J. Maynard, M. Osborn, M. Williams, P.S. Harper, 
and M. Upadhyaya. 1995. Correlation between fragment size at D4F104S1 and 
age at onset or at wheelchair use, with a possible generational effect, accounts for 
much phenotypic variation in 4q35-facioscapulohumeral muscular dystrophy 
(FSHD). Hum Mol Genet. 4:951-8. 
Mackinnon, A.C., H. Qadota, K.R. Norman, D.G. Moerman, and B.D. Williams. 2002. C. 
elegans PAT-4/ILK functions as an adaptor protein within integrin adhesion 
complexes. Curr Biol. 12:787-97. 
Masny, P.S., U. Bengtsson, S.A. Chung, J.H. Martin, B. van Engelen, S.M. van der 
Maarel, and S.T. Winokur. 2004. Localization of 4q35.2 to the nuclear periphery: 
is FSHD a nuclear envelope disease? Hum Mol Genet. 13:1857-71. 
Melino, G., P. Nicotera, and G. Macino. 2007. In the beginning there was RNA, then 
came transcription regulation: the Nobel Prize Lectures 2006. Cell Death Differ. 
14:1975-6. 
Mercer, K.B., D.B. Flaherty, R.K. Miller, H. Qadota, T.L. Tinley, D.G. Moerman, and 
G.M. Benian. 2003. Caenorhabditis elegans UNC-98, a C2H2 Zn finger protein, 
is a novel partner of UNC-97/PINCH in muscle adhesion complexes. Mol Biol 
Cell. 14:2492-507. 
Mercer, K.B., R.K. Miller, T.L. Tinley, S. Sheth, H. Qadota, and G.M. Benian. 2006. 
Caenorhabditis elegans UNC-96 is a new component of M-lines that interacts 
with UNC-98 and paramyosin and is required in adult muscle for assembly and/or 
maintenance of thick filaments. Mol Biol Cell. 17:3832-47. 
Millan, M.I., and D. Becu-Villalobos. 2009. [The green fluorescent protein that glows in 
bioscience]. Medicina (B Aires). 69:370-4. 
Miller, R.K., H. Qadota, K.B. Mercer, K.M. Gernert, and G.M. Benian. 2008. UNC-98 
and UNC-96 interact with paramyosin to promote its incorporation into thick 
filaments of Caenorhabditis elegans. Mol Biol Cell. 19:1529-39. 
Moerman, D.G., and B.D. Williams. 2006. Sarcomere assembly in C. elegans muscle. 
WormBook:1-16. 
Morcos, M., and H. Hutter. 2009. The model Caenorhabditis elegans in diabetes mellitus 
and Alzheimer's disease. J Alzheimers Dis. 16:897-908. 
Moulder, G.L., M.M. Huang, R.H. Waterston, and R.J. Barstead. 1996. Talin requires 
beta-integrin, but not vinculin, for its assembly into focal adhesion-like structures 
in the nematode Caenorhabditis elegans. Mol Biol Cell. 7:1181-93. 
Norman, K.R., S. Cordes, H. Qadota, P. Rahmani, and D.G. Moerman. 2007. UNC-
97/PINCH is involved in the assembly of integrin cell adhesion complexes in 
Caenorhabditis elegans body wall muscle. Dev Biol. 309:45-55. 
Olsen, D.B., P. Gideon, T.D. Jeppesen, and J. Vissing. 2006. Leg muscle involvement in 
facioscapulohumeral muscular dystrophy assessed by MRI. J Neurol. 253:1437-
41. 
Osborne, R.J., S. Welle, S.L. Venance, C.A. Thornton, and R. Tawil. 2007. Expression 
profile of FSHD supports a link between retinal vasculopathy and muscular 
dystrophy. Neurology. 68:569-77. 
 
 
 20
Ottaviani, A., S. Rival-Gervier, A. Boussouar, A.M. Foerster, D. Rondier, S. Sacconi, C. 
Desnuelle, E. Gilson, and F. Magdinier. 2009. The D4Z4 macrosatellite repeat 
acts as a CTCF and A-type lamins-dependent insulator in facio-scapulo-humeral 
dystrophy. PLoS Genet. 5:e1000394. 
Padberg, G.W., O.F. Brouwer, R.J. de Keizer, G. Dijkman, C. Wijmenga, J.J. Grote, and 
R.R. Frants. 1995. On the significance of retinal vascular disease and hearing loss 
in facioscapulohumeral muscular dystrophy. Muscle Nerve. 2:S73-80. 
Pirozhkova, I., A. Petrov, P. Dmitriev, D. Laoudj, M. Lipinski, and Y. Vassetzky. 2008. 
A functional role for 4qA/B in the structural rearrangement of the 4q35 region 
and in the regulation of FRG1 and ANT1 in facioscapulohumeral dystrophy. 
PLoS One. 3:e3389. 
Qadota, H., K.B. Mercer, R.K. Miller, K. Kaibuchi, and G.M. Benian. 2007. Two LIM 
domain proteins and UNC-96 link UNC-97/pinch to myosin thick filaments in 
Caenorhabditis elegans muscle. Mol Biol Cell. 18:4317-26. 
Reed, P., N.C. Porter, J. Strong, D.W. Pumplin, A.M. Corse, P.W. Luther, K.M. 
Flanigan, and R.J. Bloch. 2006. Sarcolemmal reorganization in 
facioscapulohumeral muscular dystrophy. Ann Neurol. 59:289-97. 
Rogalski, T.M., E.J. Gilchrist, G.P. Mullen, and D.G. Moerman. 1995. Mutations in the 
unc-52 gene responsible for body wall muscle defects in adult Caenorhabditis 
elegans are located in alternatively spliced exons. Genetics. 139:159-69. 
Rogalski, T.M., G.P. Mullen, J.A. Bush, E.J. Gilchrist, and D.G. Moerman. 2001. UNC-
52/perlecan isoform diversity and function in Caenorhabditis elegans. Biochem 
Soc Trans. 29:171-6. 
Rogalski, T.M., G.P. Mullen, M.M. Gilbert, B.D. Williams, and D.G. Moerman. 2000. 
The UNC-112 gene in Caenorhabditis elegans encodes a novel component of cell-
matrix adhesion structures required for integrin localization in the muscle cell 
membrane. J Cell Biol. 150:253-64. 
Rossi, M., E. Ricci, L. Colantoni, G. Galluzzi, R. Frusciante, P.A. Tonali, and L. 
Felicetti. 2007. The Facioscapulohumeral muscular dystrophy region on 4qter and 
the homologous locus on 10qter evolved independently under different 
evolutionary pressure. BMC Med Genet. 8:8. 
Saavedra, E.A. 2003. [Nobel Prize for Medicine 2002: Brenner, Horvitz, Sulston and the 
Caenorhabditis elegans worm]. Medicina (B Aires). 63:179-82. 
Saito, A., I. Higuchi, M. Nakagawa, M. Saito, Y. Uchida, M. Inose, T. Kasai, T. Niiyama, 
H. Fukunaga, K. Arimura, and M. Osame. 2000. An overexpression of fibroblast 
growth factor (FGF) and FGF receptor 4 in a severe clinical phenotype of 
facioscapulohumeral muscular dystrophy. Muscle Nerve. 23:490-7. 
Saito, R.M., and S. van den Heuvel. 2002. Malignant worms: what cancer research can 
learn from C. elegans. Cancer Invest. 20:264-75. 
Sandri, M., A.H. El Meslemani, C. Sandri, P. Schjerling, K. Vissing, J.L. Andersen, K. 
Rossini, U. Carraro, and C. Angelini. 2001. Caspase 3 expression correlates with 
skeletal muscle apoptosis in Duchenne and facioscapulo human muscular 
dystrophy. A potential target for pharmacological treatment? J Neuropathol Exp 
Neurol. 60:302-12. 
Savel, J., and F. Clostre. 2006. [A Nematode Nobel Prize: Caenorhabditis elegans]. Ann 
Pharm Fr. 64:291-307. 
 21
Schatzmann, F., R. Marlow, and C.H. Streuli. 2003. Integrin signaling and mammary cell 
function. J Mammary Gland Biol Neoplasia. 8:395-408. 
Schmidt, E., M. Seifert, and R. Baumeister. 2007. Caenorhabditis elegans as a model 
system for Parkinson's disease. Neurodegener Dis. 4:199-217. 
Segalat, L. 2002. Dystrophin and functionally related proteins in the nematode 
Caenorhabditis elegans. Neuromuscul Disord. 12 Suppl 1:S105-9. 
Speer, M.C., M.A. Pericak-Vance, J.M. Stajich, J. Sarrica, M. Jordan, A.D. Roses, J.M. 
Vance, and J.R. Gilbert. 1997. Further exclusion of FSHD1B from the telomeric 
region of 10q. Neurogenetics. 1:151-2. 
Stubgen, J.P., and C. Schultz. 2009. Lung and respiratory muscle function in 
facioscapulohumeral muscular dystrophy. Muscle Nerve. 39:729-34. 
Tawil, R. 2008. Facioscapulohumeral muscular dystrophy. Neurotherapeutics. 5:601-6. 
Tsien, F., B. Sun, N.E. Hopkins, V. Vedanarayanan, D. Figlewicz, S. Winokur, and M. 
Ehrlich. 2001. Methylation of the FSHD syndrome-linked subtelomeric repeat in 
normal and FSHD cell cultures and tissues. Mol Genet Metab. 74:322-31. 
Tucker, M., and M. Han. 2008. Muscle cell migrations of C. elegans are mediated by the 
alpha-integrin INA-1, Eph receptor VAB-1, and a novel peptidase homologue 
MNP-1. Dev Biol. 318:215-23. 
Valencik, M.L., D. Zhang, B. Punske, P. Hu, J.A. McDonald, and S.E. Litwin. 2006. 
Integrin activation in the heart: a link between electrical and contractile 
dysfunction? Circ Res. 99:1403-10. 
van der Maarel, S.M., R.R. Frants, and G.W. Padberg. 2007. Facioscapulohumeral 
muscular dystrophy. Biochim Biophys Acta. 1772:186-94. 
van Deutekom, J.C., R.J. Lemmers, P.K. Grewal, M. van Geel, S. Romberg, H.G. 
Dauwerse, T.J. Wright, G.W. Padberg, M.H. Hofker, J.E. Hewitt, and R.R. Frants. 
1996. Identification of the first gene (FRG1) from the FSHD region on human 
chromosome 4q35. Hum Mol Genet. 5:581-90. 
van Koningsbruggen, S., R.W. Dirks, A.M. Mommaas, J.J. Onderwater, G. Deidda, G.W. 
Padberg, R.R. Frants, and S.M. van der Maarel. 2004. FRG1P is localised in the 
nucleolus, Cajal bodies, and speckles. J Med Genet. 41:e46. 
van Koningsbruggen, S., K.R. Straasheijm, E. Sterrenburg, N. de Graaf, H.G. Dauwerse, 
R.R. Frants, and S.M. van der Maarel. 2007. FRG1P-mediated aggregation of 
proteins involved in pre-mRNA processing. Chromosoma. 116:53-64. 
Voit, T., A. Lamprecht, H.G. Lenard, and H.H. Goebel. 1986. Hearing loss in 
facioscapulohumeral dystrophy. Eur J Pediatr. 145:280-5. 
Waterston, R.H., J.N. Thomson, and S. Brenner. 1980. Mutants with altered muscle 
structure of Caenorhabditis elegans. Dev Biol. 77:271-302. 
Wijmenga, C., R.R. Frants, J.E. Hewitt, J.C. van Deutekom, M. van Geel, T.J. Wright, 
G.W. Padberg, M.H. Hofker, and G.J. van Ommen. 1993. Molecular genetics of 
facioscapulohumeral muscular dystrophy. Neuromuscul Disord. 3:487-91. 
Wijmenga, C., G.W. Padberg, P. Moerer, J. Wiegant, L. Liem, O.F. Brouwer, E.C. 
Milner, J.L. Weber, G.B. van Ommen, L.A. Sandkuyl, and et al. 1991. Mapping 
of facioscapulohumeral muscular dystrophy gene to chromosome 4q35-qter by 
multipoint linkage analysis and in situ hybridization. Genomics. 9:570-5. 
 22
Williams, B.D., and R.H. Waterston. 1994. Genes critical for muscle development and 
function in Caenorhabditis elegans identified through lethal mutations. J Cell 
Biol. 124:475-90. 
Winokur, S.T., Y.W. Chen, P.S. Masny, J.H. Martin, J.T. Ehmsen, S.J. Tapscott, S.M. 
van der Maarel, Y. Hayashi, and K.M. Flanigan. 2003. Expression profiling of 
FSHD muscle supports a defect in specific stages of myogenic differentiation. 
Hum Mol Genet. 12:2895-907. 
Wright, T.J., C. Wijmenga, L.N. Clark, R.R. Frants, R. Williamson, and J.E. Hewitt. 
1993. Fine mapping of the FSHD gene region orientates the rearranged fragment 
detected by the probe p13E-11. Hum Mol Genet. 2:1673-8. 
Wuebbles, R.D., M.L. Hanel, and P.L. Jones. 2009. FSHD region gene 1 (FRG1) is 
crucial for angiogenesis linking FRG1 to facioscapulohumeral muscular 
dystrophy-associated vasculopathy. Dis Model Mech. 2:267-74. 
Xu, X., S.C. Rongali, J.P. Miles, K.D. Lee, and M. Lee. 2006. pat-4/ILK and unc-
112/Mig-2 are required for gonad function in Caenorhabditis elegans. Exp Cell 
Res. 312:1475-83. 
Yang, F., C. Shao, V. Vedanarayanan, and M. Ehrlich. 2004. Cytogenetic and immuno-
FISH analysis of the 4q subtelomeric region, which is associated with 
facioscapulohumeral muscular dystrophy. Chromosoma. 112:350-9. 
Yasukohchi, S., Y. Yagi, T. Akabane, A. Terauchi, K. Tamagawa, and Y. Mizuno. 1988. 
Facioscapulohumeral dystrophy associated with sensorineural hearing loss, 
tortuosity of retinal arterioles, and an early onset and rapid progression of 
respiratory failure. Brain Dev. 10:319-24. 
Yoganathan, T.N., P. Costello, X. Chen, M. Jabali, J. Yan, D. Leung, Z. Zhang, A. Yee, 
S. Dedhar, and J. Sanghera. 2000. Integrin-linked kinase (ILK): a "hot" 
therapeutic target. Biochem Pharmacol. 60:1115-9. 
Zeng, W., J.C. de Greef, Y.Y. Chen, R. Chien, X. Kong, H.C. Gregson, S.T. Winokur, A. 
Pyle, K.D. Robertson, J.A. Schmiesing, V.E. Kimonis, J. Balog, R.R. Frants, A.R. 
Ball, Jr., L.F. Lock, P.J. Donovan, S.M. van der Maarel, and K. Yokomori. 2009. 
Specific loss of histone H3 lysine 9 trimethylation and HP1gamma/cohesin 
binding at D4Z4 repeats is associated with facioscapulohumeral dystrophy 
(FSHD). PLoS Genet. 5:e1000559. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 23
Figures 
 
 
Figure 1-1. C. elegans life cycle at 22˚C. Eggs are laid 150 min after fertilization. It 
takes about 14 hr for embryonic development. L1 larva will become L2 larva or Dauer 
larva, which depends on the environment. L2 larva will develop to L3 larva after 8 hours, 
then L4 larva and finally become a young adult. When harsh environmental condition is 
over Dauer larva will develop into L4 larva directly 
(http://www.wormatlas.org/hermaphrodite/introduction/Introframeset.html). 
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Figure 1-2. C. elegans muscle attachment. a. “Skinned” worm showing the four body 
wall muscle quadrants.  b. Cross section of body wall with the cuticular exoskeleton, 
hypodermis, and shared hypodermal-muscle basal lamina peeled away to reveal the basal 
surface of the muscle cells.  The black lines and spots indicate the location of M-lines and 
dense bodies, respectively.  c and d.  Diagram of sarcomeres showing that dense bodies 
link actin filaments and M-lines link myosin thick filaments to the cell membrane 
(Moerman, 2006).  
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Figure 1-3. “Assembly dependence” pathways for dense body and M-line. Dense 
body and M-line have their common and unique components. The assembly of the 
molecules below depends on the molecules above (Moerman, 2006). 
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CHAPTER 2: C. ELEGANS PAT-9, A C2H2 ZINC FINGER 
TRANSCRIPTION FACTOR, PLAYS A CRITICAL ROLE IN THE 
ASSEMBLY OF MUSCLE ATTACHMENTS 
 
Introduction 
  
The nematode Caenhorabditis elegans provides an established, developmentally 
well-documented, and evolutionarily conserved system to study muscle development and 
specifically, muscle attachments (Moerman and Williams, 2006). The structure and 
function of the C. elegans sarcomere, the basic muscle contraction unit, has been studied 
for decades.  In C. elegans, myosin thick filaments are anchored to the M-line and actin 
thin filaments are anchored to the dense body, a structure analogous to the vertebrate Z-
disk.  C. elegans dense bodies and M-lines are sites of attachment that body wall muscle 
cells make to the adjacent hypodermis. The overall mechanism of C. elegans muscle 
function is highly evolutionarily conserved and most of the known proteins have 
vertebrate orthologs functioning within their focal adhesions (Moerman and Williams, 
2006).  
Many of the molecules that constitute C. elegans muscle attachments were 
initially identified by genetic screening for mutants with disorganized myofilaments and 
embryonic arrest and their assembly has been characterized (Williams and Waterston, 
1994). Two main classes of mutants came out of these screens, Pat (Paralyzed, arrested 
elongation at two-fold) and Unc (Uncoordinated).  These comprise proteins that localize 
to the M-lines, dense bodies, and both.  UNC-52/perlecan, which is in the extracellular 
matrix (ECM) of body wall muscle (Rogalski, 1993), binds to PAT-3/ß-integrin, a 
transmembrane protein, initiating the assembly of downstream molecules in attachment 
sites close to the membrane. Close to the basal membrane, UNC-112, UNC-97/PINCH, 
PAT-4/ILK, PAT-6/actopaxin and UNC-95 are localized at both the dense body and M-
line (Broday, 2004; Hobert, 1999; Lin, 2003; Mackinnon, 2002). DEB-1/vinculin, ALP-1, 
talin and α-actinin are localized only at the dense body (Barstead, 1991; Barstead and 
Waterston, 1991; Francis and Waterston, 1985; McKeown, 2006; Moulder, 1996). UNC-
89, UNC-98, and UNC-96 are found only in the M-lines (Benian, 1996; Mercer, 2003; 
Mercer, 2006). A fourth class of sarcomeric protein is particularly interesting, those found 
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at the sarcomere and in the nucleus.  For example, an UNC-98::GFP fusion protein shows 
its localization in body wall muscle nuclei and the dense body (Mercer, 2003).  
In a continuing effort to identify new components required for muscle attachment 
site assembly, we focus on the Pat group of C. elegans mutants.  Mutations in the genes 
that encode the membrane-associated components of the muscle attachment sites, such as 
unc-52, pat-2, pat-3, unc-112, unc-97,  pat-4 and pat-6, display the most severe Pat 
phenotype, in which neither thin filaments nor thick filaments are assembled into the 
myofilament lattice. Our previous studies indicate that PAT-4/ILK, UNC-97/PINCH and 
PAT-6/actopaxin serve intermediary members of the linkage formed between the integrins 
and myofilaments (Lin, 2003; Mackinnon, 2002). In vertebrate PAT-6/actopaxin, PAT-
4/ILK and UNC-97/PINCH also play an important role in cardiac muscle mediated by 
integrin signaling pathway (Chen, 2005). ALP, which stabilizes α-actinin complex, is 
associated with cardiomyopathy in mice (Pashmforoush, 2001).  
The above evidence shows that the structural and functional components in 
muscle attachments are evolutionally conserved. Recent studies show that the 
transcription factors that control C. elegans muscle differentiation are also evolutionally 
conserved (Fukushige, 2006). The body wall muscle of C. elegans is functionally similar 
to vertebrate skeletal muscle; pharyngeal muscle is functionally similar to vertebrate 
cardiac muscle. HLH-1/ceMyoD, UNC-120/SRF and HND-1/HAND, three myogenic 
regulatory factors identified in C. elegans, are necessary for body wall muscle 
differentiation.  In mammal MyoD, one the four helix-loop-helix myogenic regulators, 
plays a critical role in skeletal muscle development; SRF and HAND have a role in 
regulation of smooth muscle and cardiac muscle development.  During the later stage of 
embryogenesis, UNC-97/PINCH, UNC-98 and ALP-1 are localized in both attachments 
and body wall muscle nuclei. CeTBX-2, homologous to human T-box transcription factor 
TBX3, is involved in C. elegans pharyngeal muscle development; CeTBX-2 is also 
expressed in body wall muscle nuclei from the 1.5-fold stage to the 3-fold stage (Roy 
Chowdhuri, 2006). All the above nuclear proteins have analogs in vertebrates, although 
their nuclear functions are still not fully understood. This evidence further supports that 
muscle development is fundamentally evolutionally conserved in both structural 
components and transcriptional regulators.  
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Here, we identified and characterized a novel gene in pat family, pat-9.  In pat-9 
mutants, the recruitment of both actin thin filaments and myosin thick filaments to the 
muscle cell membrane appears to be disrupted.  Similar to other Pat genes, pat-9 is 
expressed in C. elegans body wall muscle during embryogenesis. Unlike other genes in 
the pat family that are structural and functional components of muscle attachments, pat-9 
encodes a C2H2 zinc finger transcription factor that is strictly nuclear suggesting a 
regulatory as opposed to a structural function for PAT-9. 
 
Results 
pat-9 encodes a C2H2 Zinc finger transcription factor 
We used a combination of positional cloning and candidate gene approaches to 
molecularly isolate pat-9 gene (Williams and Waterston, 1994). SNP mapping data 
indicated that the pat-9(st558) mutation was located to the right of the F38E9 marker on 
Chromosome X, and located near the T25D1 marker, as we failed to detect 
recombination events located between this marker and pat-9 (Table 2-1).  There are 23 
genes in 200kb region centered at T25D1. Based on SAGE data, we identified 9 
candidate genes that are expressed in muscle, which include F38E9.5, F38E9.2, F38E9.1, 
cah-3, T25D1.2, T27B1.2, cdh-9, F59C12.3 and C06G1.4 (Table 2-2).  RNA interference 
(RNAi) on each predicted gene was performed by feeding the animals with bacteria 
expressing specific dsRNAs.  The RNAi for T27B1.2 was the only one that gave a 
significant number of Pat F1 progenies(10%, N>200), dumpy animals(5%, N>200) and 
abnormal young larva(2%, N>200) (Figure 2-1).  RNAi for none of the other genes 
produced an abnormal phenotype, which is consistent with the RNAi on Wormbase.org.   
The hypothetical gene T27b1.2, identified by the C. elegans genome sequencing 
consortium near the right end of chromosome X, is predicted to encode a C2H2 zinc 
finger transcription factor (Figure 2-2). A subsequent transformation rescue experiment 
confirmed that a genomic DNA fragment containing T27b1.2 and 3.3kb upstream 
noncoding genomic DNA completely rescues the phenotype of pat-9 homozygote (Figure 
2-3).  To identify the pat-9 mutation at the molecular level, we amplified the T27B1.2 
gene from pat-9 mutants st558 segregated by strain RW1385. DNA sequence analysis 
revealed a single point mutation (GÆA) in the splice donor site of 3rd exon, this G 
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residue is 100% conserved in C.elegans (Figure 2-2).  This mutation is predicted to lead 
to aberrant splicing resulting in a non-functional PAT-9 protein.  To test whether each 
exon in T27b1.2 is incorporated into the mature pat-9 mRNA in pat-9 mutant animals, 
total RNA was extracted from both pat-9 mutant animals and N2 animals. Reverse 
transcriptase PCR was performed to amplify T27b1.2 cDNA (Figure 2-4C) with primers 
specific to each exon and the products were cloned into pGEM-T easy vector for 
sequencing. We found that the point mutation results in mis-splicing between exon 3 and 
exon 4 (Figure 2-4A). The predicted amino acid sequence based on the cDNA sequence 
indicates in a premature stop codon (Figure 2-4B).  Additionally, sequencing identified 
an additional 6 nucleotides between the predicted exon 2 and exon 3 spliced differently 
from the gene model on Wormbase (Figure 2-4A). Together, this evidence provides 
unambiguous confirmation of the pat-9 identity being T27b1.2.   
  
PAT-9 is localized exclusively in nuclei through all developmental stages 
PAT-9 expression was determined in embryos, larvae and adults using a 
functional pat-9::gfp transgene and confirmed using immunostaining fro PAT-9.  The two 
PCR fragments that rescued the pat-9 phenotype contain 3kb of genomic sequence 
upstream of the initiator methionine.  Therefore, the 3.3kb segment upstream of the 
methionine was considered as containing the functional pat-9 promoter for use in 
generating the PAT-9 transgene expression plasmid. The transgene was designed to 
express full length PAT-9, with GFP fused to its N terminus in the vector pPD118.20 
(Addgene-Fire Lab).  Expression of PAT-9::GFP from this plasmid was first detected in 
the early embryo stage. When the embryos reach the 1.5-fold stage of development, PAT-
9::GFP localized exclusively in body wall muscle nuclei in each body wall muscle 
quadrant. The expression levels of PAT-9::GFP have no significant difference from 
embryo stage to larval stage, but it decreases in adults (Figure 2-5 A, B and C).  To 
confirm the transgenic expression pattern, antiserum against the PAT-9 C terminus, 
which does not contain any predicted zinc finger, was generated. The PAT-9 
immunostaining on N2 animals showed the same pattern as the one in pat-9::gfp rescue 
animals. Endogenous PAT-9 was exclusively expressed in nuclei through all 
developmental stages (Figure 2-5 D, E and F) and PAT-9 was expressed in very early 
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stages.  In addition, PAT-9 was expressed in germ cell-like nuclei in the cytoplasmic 
syncytium of the C. elegans gonad, where most nuclei are arrested in meiosis (Figure 2-5 
G, H and I).  Overall, the expression profile for PAT-9 is consistent with being important 
for muscle, however, its exclusively nuclear localization indicates it is not a structural 
component of the sarcomere. 
 
Identify nuclear localization signal in PAT-9 Protein 
A search of the PAT-9 sequence for putative conserved domains using the Pfam 
protein conserved domain database (http://www.pfam.org) identified 3 putative C2H2 
zinc fingers, however, no nuclear localization signal (NLS) was predicted.  To identify 
the NLS in PAT-9, we made several PAT-9 truncations fused to GFP. We artificially put 
a methionine at the beginning of each construct and we use myo-3 promoter to 
specifically express all transgenes in body wall muscle. A transgenic line with Pmyo-3::gfp 
(pPD118.20) was used as control (Figure 2-6A). Pmyo-3::zf1::gfp, containing the N-
terminal sequence and 1st putative zinc finger, localized in the cytoplasm indicating that 
there is no NLS in N-terminus through the 1st zinc finger (Figure 2-6B). In Pmyo-3::pat-
9C::gfp, all three putative zinc fingers are removed leaving only the C-terminal half of 
the sequence and it localized in the cytoplasm as well indicating there is no NLS in C-
terminal half of PAT-9 (Figure 2-6C).  The final construct, Pmyo-3::zf123::gfp, contains all 
three putative zinc fingers and it was exclusively localized in muscle nuclei (Figure 2-
6D), indicating the NLS for PAT-9 is located within or between 2nd and 3rd zinc finger.  
 
PAT-9 is required for muscle attachment assembly 
In Pat mutants, actin and myosin filaments are not recruited properly to muscle 
attachment sites suggesting that assembly of muscle attachments is disrupted. To 
investigate the dependence of expression and localization of muscle attachment proteins 
on PAT-9, the pat-9(st558) allele was used to ablate functional PAT-9 expression and the 
embryos were stained with antibodies to components of the muscle attachments (Figure 
2-7).  Immunostaining showed that UNC-52/perlecan (an ECM component) (Figure 2-
7A’), PAT-3/integrin (Figure 2-7B’), PAT-4/ILK (Figure 2-7C’), DEB-1/vinculin (a 
membrane-proximal dense body component) (Figure 2-7D’), and myosin (Figure 2-7E’), 
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were all expressed in pat-9(st558) embryos. However, compared with N2 animals at the 
2-fold stage, UNC-52/perlecan was not located in a continuous strip in the basal lamina 
of pat-9(st558) mutants. We have shown that muscle attachments have distinct assembly 
pathway.  UNC-52/perlecan is the beginning of the assembly pathway; therefore PAT-
3/integrin, PAT-4/ILK, DEB-1/vinculin and myosin are not organized well. In wild type 
embryos, pat-3/integrin, PAT-4/ILK, DEB-1/vinculin are located in an ordered array of 
dense body and M line (Figure 2-7A-E). In contrast, in pat-9(st558) mutant embryos, 
these proteins are not organized well. In many mutant embryos the dorsal body-wall 
muscle quadrants have pulled away from the body-wall, direct evidence that the muscle 
attachments have not been properly formed.  Furthermore, myosin filaments are not 
recruited properly in pat-9(st558) mutant embryos. In wild-type animals, myofilaments 
are organized, recognizable, and attached to the muscle cell membrane through muscle 
attachments forming two arrays of muscle cells that are parallel in each body wall muscle 
quadrant. In contrast, in pat-9(st558) mutants, myofilaments are not recruited properly. 
Thus, although many components of muscle attachments are expressed, PAT-9 is 
required for their proper assembly. 
 
Discussion 
We have shown that pat-9 gene (T27b1.2) encodes a C2H2 type zinc finger 
nuclear protein and it is exclusively localized in body wall muscle nuclei during 
embryogenesis.  Thus, PAT-9 is the first exclusively nuclear protein among all pat genes 
that have been identified and characterized.  In mammals, a large portion of DNA-
binding transcriptional regulators contain C2H2 zinc fingers (Iuchi, 2001). In C. elegans 
C2H2 zinc-finger transcription regulators play critical roles in many biological aspects, 
including body wall muscle development, synaptic transmission, egg-laying behavior and 
fertility, et al (Lakowski, 2003; Mercer, 2003; Wang, 2006). Potentially, PAT-9 functions 
as a transcription factor for one or more factors required in muscle attachment site 
assembly.  In support of this hypothesis, the recently published EDGEdb, a transcription 
factor-DNA interaction database, a yeast one-hybrid binding assay showed that PAT-9 
bound to the promoters of daf-3 and tbx-2, which are involved in C. elegans pharynx 
development and dauer formation (Lakowski, 2003). In addition to suggesting PAT-9 is a 
 32
transcription factor, this data also indicates that PAT-9 has multiple roles during 
development including roles outside body wall muscle development.  
The transcription factor TBX-2 is specifically required for development of ABa-
derived pharyngeal muscles (Roy Chowdhuri, 2006). Interestingly, tbx-2::gfp expression 
was also observed in body wall muscles at bean stage and later, in 2- to 3-fold embryos 
similarly to that seen for pat-9.   As with pat-9, there is a muscle defect in tbx-2 mutants 
at the embryo stage. More interestingly, based on recently published EDGEdb, a 
transcription factor-DNA interaction database, PAT-9 (same as ztf-19) is predicted to 
bind to the promoter of tbx-2 (Barrasa, 2007). TBX-2 is expressed from early embryo 
stage to adult; RNAi reveals that tbx-2 is critical for early larval development; pat-9 
RNAi animals show embryo lethality and larval arrest. Both transcription factors are 
indispensable for embryogenesis and early larval development. We hypothesize that 
PAT-9 regulates tbx-2 expression. 
PAT-9 is required for proper organization of myofilaments and for recruitment to 
the M line. In pat-9 mutants UNC-52/perlecan as the most upstream of assembly 
pathway, is expressed in basal lamina; PAT-3/integrin is not well organized at the basal 
membrane. Subsequently PAT-4/ILK and DEB-1/vinculin aren’t recruited properly to the 
nascent attachment sites. The distinct assembly dependence pathways for dense bodies 
and M lines show that the recruitment of the protein below is depend upon the protein 
above(Lin, 2003; Mackinnon, 2002). Therefore it is reasonable to make the prediction 
that neither of the following molecular components in attachment sites downstream of 
integrin, UNC112, UNC-97/PINCH, PAT-6/actopaxin, et al, would be assembled 
properly in the attachment sites.  If we compare the pat-4 and pat-6 mutants with pat-9 
mutants, in both pat-4 and pat-6, PAT-3/integrin aren’t affected since both proteins are 
downstream of PAT-3 in the assembly pathway. However, in pat-9 mutants integrin isn’t 
properly organized at the basal membrane, which directly causes the disruption of the 
integrity of attachment complex. The immunostaining on pat-9 mutant animals show 
consistent results that the dorsal body-wall muscle quadrants have pulled away from the 
body wall. In pat-9 mutants, expression and localization of UNC-52 isn’t enough to 
initiate the assembly of attachment sites, and integrin has two-way signaling, we suggest 
that PAT-9 may initiate a signal inside the muscle cell that is critical for assembly of 
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attachments. Lack of PAT-9 causes the loss of a critical inside-out signal from integrin.  
The assembly of muscle attachments is regulated by transcriptional regulators and 
organization of the proper protein molecules in the cytoplasm.  Our study shows that 
PAT-9 is indispensible for establishing and maintaining the integrity of muscle 
attachment sites and most likely functions at the transcription level. 
 
Materials and Methods  
Strains and genetics 
Standard methods were used for culturing C. elegans (Brenner, 1974). The 
following strains were used: N2 wild-type strain; RW1385 (mnDp1(X; V)/+V; unc-
3(e151) pat-9(st558) X). Because homozygote pat-9 is lethal, a segment of duplication of 
X Chromosome (mnDp1) containing wild-type pat-9 and unc-3 genes was fused to one of 
its V Chromosome. This strain will segregate quarter of pats, quarter of early arrested 
embryos containing two duplications and half of normal progeny with the same genotype 
as RW1385.  
pat-9 rescue line ( +/+V; unc-3(e151) pat-9(st558) X; pat-9::gfp); the rescue 
animal lost the duplication mnDp1 and had homozygote unc-3 and pat-9; pat phenotype 
was rescue by wild-type pat-9 gene in the extrachromosomal array, homozygote unc-3 
had toiled tail and Unc phenotype, all extrachromosomal arrays contain the dominant 
transformation marker pRF4(rol-6), therefore the rescued strain will segregate either 
rollers with coiled tail or  pats. The following contructs were made using vector 
pPD118.20 (Andrew Fire kit): pat-9::gfp contains pat-9 genomic coding region and 
3.3kb upstream putative regulatory sequence; gfp is fused to the N terminus of pat-9. 
DeltaZf123N contains only the C terminal fragment of pat-9, N terminal sequences, three 
putative zinc finger and predicted NLS were removed; deltaZf123 contain predicted NLS 
and C terminus; Zf123 contain N terminus and three putative zinc fingers; Zf123N 
contain N terminus, three putative zinc fingers and predicted NLS; Zf1 contain N 
terminus and the first putative zinc finger. Transgenic lines were made using standard 
microinjection approach, pRF4(rol-6) as injection marker.  
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Molecular biology 
The above inserted pat-9 fragments were made by RT-PCR using Superscript III 
(Invitrogen). N2 worm total RNA is isolated using A TRIZOL based method with slight 
modification: add 800ul Trizol to 200ul packed worms; vortex, incubate at room 
temperature for 20 minutes; spin full speed at 4 degree for 10 minutes; remove 
supernatant to a new tube; add 500 ul Chloroform, vortex 15 sec, incubate at room 
temperature for 3 min; spin 15 min at 4 degree full speed; remove upper phase to a new 
tube, add 1 ul glycogen; add 500ul isopropanol, mix, room temperature for 10min; spin 
full speed 10 min at cold room; wash pellet with 500ul 70% EtOH; spin 5 min at cold 
room; remove supernatant; air dry the pellet, add 10ul DEPC-H2O, store at -80 degree.  
The following primer pairs were used for reverse transcriptase-PCR 
amplification: pat-9C (pat-9 C-terminal)(primer 2 and primer 3),  zf1(primer 1 and 
primer 5), zf123 (primer 1 and primer 4). The above RT-PCR fragments were digested 
with Not I and Kpn I and inserted into Vector pPD118.20 Not I and Kpn I site to make 
Pmyo-3::pat-9C::gfp, Pmyo-3::zf1::gfp and Pmyo-3::zf123::gfp respectively. All plasmids 
were verified by sequencing. Cosmid T27b1 was verified to contain the whole T27b1.2 
gene by sequencing with primer BW-580, BW581, BW582 and BW583. For the initial 
transformation rescue experiment  pat-9 3.3kb promoter and coding region were 
amplified separately with primer pairs (BW-608, BW610), and (BW611, BW612) 
respectively, cosmid T27b1 as the template. Two PCR fragments had 500bp overlap. See 
Table 2-3 for primer sequences.  
To study expression and localiztion pat-9::gfp was made as following steps: 3.3kb 
pat-9 promoter was PCR amplified using primer BW613 and BW630.This fragment was 
digested with PstI and KpnI,  replace myo-3 promoter of  pPD118.20, to make Ppat-9::gfp. 
pat-9 genomic fragment was PCR amplified using primer BW631 and BW596, which 
includes 980bp downstream of the 6th exon, digested with KpnI and DraIII and replace 
KpnI – DraIII region of  Ppat-9::gfp, to make Ppat-9::pat-9; finally gfp was amplified and 
digested with KpnI, inserted into Ppat-9::pat-9, to make pat-9::gfp. Pat-9 promoter and 
genomic coding region were amplified using cosmid T27b1 as template; gfp was 
amplified using vector pPD118.20 as template. See Table 2-3 for primer sequences. 
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To make anti-PAT-9 antibody a plasmid for bacterial expression of PAT-9::HIS 
fusion was made. Partial pat-9 cDNA fragment (C terminus aa 176-470) was RT-PCR 
amplified using primers (5’- catatgaatggaggacttccagcatcatcg-3’,  
5’-gcggccgcccactgctcatgtggcacagtctt-3’), digested with NdeI and NotI  to replace the Nde 
I-Not I region of pET23a.  
 
RNA interference 
pat-9 feeding RNAi was performed as previously described (Timmons, 2001) 
Plasmid for bacterial expression of pat-9 dsRNA was made by inserting pat-9 cDNA 
between T7 promoters of vector pPR2.42 (from Dr. Newmark), plasmid was transformed 
into competent HT115(DE3) and plated onto standard LB plates with Tetracycline and 
Kanamycin. Grow up culture from single colony in 2x YT media containing antibiotics 
and induce expression of dsRNA with 1mM IPTG when the culture reached 
OD600=0.3~0.4. NGM plates were made freshly with 50ug/ml Kan, 12.5ug/ul Tet and 
0.4mM IPTG. Seed NGM plates with the induced culture and dry at room temperature 
over night. L4-stage hermaphrodite worms were placed on NGM plates and were 
incubated for 48 h at 18C. Then, 5 worms as a replication were transferred onto plates 
seeded with the same bacteria and were allow to lay eggs for 24h at 18C before being 
removed. Progeny were scored for pat phenotype and any other developmental 
abnormalities after another 24 h; both the first plates and second plates were scored.   
 
Embryo immunostaining 
Populations of embryos were fixed and stained as previously described (Barstead, 
1991). We used affinity-purified goat anti- mouse IgG conjugated to rhodamine 
(Chemicon International) diluted 1: 100 as second antibody. The following monoclonal 
antibodies, diluted in PBS supplemented with 0.5% Tween-20 and 30% normal goat 
serum: MH2 (antibody to perlecan), MH25 (antibody to integrin), MH24 (antibody to 
vinculin), PAT-4 polyclonal antibody, 5-6(Myosin heavy chain A),  MH27 (hypodermal 
cell junctions). Polyclonal PAT-9 antiserum was obtained from rabbits injected with 
PAT-9:: HIS recombinant protein.  
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Adult worm immunostaining  
Immunostaining on adult animals was performed based on the approaches by 
Finney and Ruvkun (Finney and Ruvkun, 1990) .Mixed stage N2 were harvested and 
washed thoroughly in PBS to remove bacteria. Worms were resuspended in 4% 
paraformaldehyde in 100 mM sodium  phosphate buffer and quick frozen on dry ice. 
After thaw on ice, animals were incubated on ice for 1 hour to finish fixation.  After three 
washes in 1% Triton X-100, 100 mM Tris (pH 7.5), animals were incubate in 1% Triton 
X-100, 100 mM Tris (pH 7.5) and 1% β-Mercaptoethanol at 37°C for 2 hours to reduce 
the cuticle. After 3 washes in 10mM NaBO3 (PH9.2), the worms were incubated for 1 
hour in 10mM NaBO3 and 0.3%H2O2. Animals then were washed 3 times with 10mM 
NaBO3 (PH9.2) and stored for further processing in AbA buffer (1 × PBS, 0.1% Triton 
X-100, 1% BSA, 0.05% NaN3). AbA buffer was used for antibody dilution. Primary 
antibody (polyclonal rabbit anti-PAT-9) was diluted 1:500, incubate at cold room 
overnight. Wash with AbB buffer (1 × PBS, 0.1% Triton X-100, 0.1% BSA, 0.05% 
NaN3) 3 times, incubate with secondary antibody(Alexa 488 goat anit-rabbit) at cold 
room overnight, wash with AbB 3 times. Pellet as above and remove most of the 
supernatant. Mount a portion of the animals for microscopy. 
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Figures and Tables  
 
 
 
Figure 2-1. pat-9 feeding RNAi. A) Wild type animals at 2.5-fold stage B) Wild type 
larva, C) pat-9 mutant animals segregated from strain RW1385; pat-9 feeding RNAi  
causes abnormal development at embryonic stage (pat) (D), larval stage (E) and adult 
stage (dpy) (F) . bars, 10 μm.  
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Figure 2-2. Molecular isolation of pat-9. SNP mapping, SAGE data and RNA 
interference support that T27b1.2 is pat-9. T27b1.2 was amplified from pat-9 mutant 
animals. GÆA mutation was identified at the splicing donor site of 3rd exon, which is 
highlighted in red.  An analysis of predicted PAT-9 amino sequence identifies three 
C2H2 zinc fingers (http://pfam.sanger.ac.uk).  
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Figure 2-3. Transformation rescue of pat-9 by T27b1.2. A genomic DNA fragment 
containing T27b1.2 and 3.3kb upstream noncoding genomic DNA completely rescues the 
phenotype of pat-9 homozygote. The rescued animals are roller (A) which indicates that 
they carry the transgene; coiled tail phenotype (B) is due to the homozygous unc-3, 
which indicates that they are pat-9 homozygous mutants.  
A B
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Figure 2-4. pat-9 Sequence alignment. A) T27b1.2 cDNA sequence alignment of gene 
model from Wormbase, wild type animal and pat-9 mutants identified 6 nucleotides in 
the 3rd exon in both wild type animals and pat-9 mutants (yellow line). The GÆA 
mutation is highlighted in red. This point mutation at splicing donor site results is-
splicing the following exons and generates a pre-mature stop codon (red square). B) 
T27b1.2 amino acid sequence alignment shows the difference among gene model in 
WormBase, wild type and pat-9 mutants, highlighted in corresponding color as in shown 
in A). Both A and B only show the partial sequence alignment. The remaining alignment 
is identical, which is not shown.  C) reverse transcriptase-PCR was used to identify 
whether each exon is transcribed in pat-9 mutant animals. 
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Figure 2-5. Characterization of PAT-9 expression. Localization of the PAT-9 protein 
as determined by use of a PAT-9::GFP translational fusion in transgenic rescued pat-
9(st558) stain. Fluorescence microscopy of localization of the PAT-9::GFP within muscle 
nuclei in A)2-fold embryo, B) larva and C) adult animal. The anti-PAT-9 antibody stains 
body wall muscle nuclei of wild-type embryos (D), as well as the nuclei of young larvae 
(E) and adults (F); PAT-9 immuno-staining shows that PAT-9 is expressed in germ-like 
nuclei in cytoplasmic syncytium of the C.elegans gonad (G), H, DAPI, and I merge of G 
and H; J, anti-PAT-9 antibody stains adult N2 worm,  K, DAPi, and L, merge of J and K. 
Bars, 10 μm. 
  
 44
 
 
Figure 2-6. PAT-9 domain dissection. Different constructs with truncated PAT-9 were 
tested for its localization in nuclei. A) Transgenic animals carrying Pmyo-3::gfp 
(pPD118.20) transgene serve as control. B) Pmyo-3::zf1::gfp containing the N-terminal 
sequence and the first zinc finger of PAT-9 localized predominantly in cytoplasm. C) 
Pmyo-3::pat-9C::gfp containing only C-terminal sequence localized in both cytoplasm and 
nuclei, which is similar to what we see in Pmyo-3::gfp control. D) Pmyo-3::zf123::gfp 
containing three zinc fingers localized exclusively in nuclei. E, DAPI. F, merge of GFP 
and DAPI. Bars, 10μm. 
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Figure 2-7. Muscle attachment sites are disrupted in pat-9 mutants. Wild type (a, b, 
c, d and e) and pat-9(st558) (a’, b’, c’ d’ and e’) embryos were stained with monoclonal 
antibodies to UNC-52/perlecan (a and a’), PAT-3/beta-integrin (b and b’), PAT-4/ILK (c 
and c’), DEB-1/vinculin (d and d’) and MYO-3/MHC-A (e and e’). Arrows show the 
structure stained by the above antibodies. All the animals are co-stained with MH27, 
which stains hypodermal cell junctions, and allow us to readily identify the orientation 
and age of the embryos. Bar, 10 μm. 
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Table 2-1. SNP Mapping results. 
Digest site SNP 
Marker 
primers 
N2 HA 
PCR 
Size(bp) 
Size after 
digestion (bp) 
Recombinants 
with N2 
Sequence/Total 
F09B12      142/189 
W09B12      5/189 
T24D11 BW-415 
BW-416 
Eco57I NONE 600 275,324 6/170 
F38E9 BW-417 
BW-418 
NONE HphI 683 293,389 5/170 
T25D1 BW-419 
BW-420 
PacI NONE 576 253,322 0/170 
F35B3      0/189 
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Table 2-2. Nine Candidate Genes.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Candidate 
Gene 
Size(coding/transcripts)bp Protein cDNA 
F38E9.5 1002/5132 WP:CE28307 yk483d11 
F38E9.2 2856/14508 WP:CE30977 yk414e5 
F38E9.1 1710/3841 WP:CE28305 yk839g10 
cah-3 741/1872 WP:CE04755 yk443f12 
T25D1.2 1317/2154 WP:CE05018 PCR from 
N2 
T27B1.2 1848/3962 WP:CE05028 yk64f5 
cdh-
9(F59C12.1) 
1797/5187 WP:CE04682 PCR from 
N2 
F59C12.3 1641/6141 WP:CE35728 yk782b11 
C06G1.4 1926/3692 WP:CE03967 yk668g10 
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Table 2-3. Primers. 
 
 
Primer Restriction digestion  Site Amplified Region            Sequence 5’Æ3’ 
BW-580  EcoR V  GGT ACT GAA CCT GAC TGA 
ACT TGA TTG AAC CTG ACT 
GAA AAT CCT CCC TC 
BW-581   N/A (Nhe I in coding 
sequence) 
CAT AAT CAA TAT CAA TTC 
AAA ATT ATC GAT TTT ATC 
GAA AAG TTG TCG CT 
BW582   N/A (Nhe I in coding 
sequence) 
ACT TCC CGA CTC TAT ACT 
CAC CTC ACA AAT GAT GAG 
GTG CCC AGC CAA TT 
BW-583   Aat II 
These four primers are 
used for checking if 
cosmid T27B1 contains 
the whole T27B1.2 
GGG GGG GAC GTC AAA TAG 
TCC GGC GTT AAA GGC TCA 
TGG GAT TAA CTT TCG G 
BW-608   Nar I GGG GGG GGC GCC GCA TCT 
AAA ATC ACT CAT CAA AAA 
TAA G 
BW-610   N/A GTT ATT GTT CAT TGG GTC 
CGT GTG GGT C 
BW-611   N/A CAT CAT CCT CCC TTC TTT 
CCA ACT TTG TCA 
BW-612   N/A 
For transformation rescue 
amplify pat-9 promoter 
and coding region 
separately, two 
fragments, which have 
500bp overlap.  
 TTA ACT TTC GGT AAT TGC 
CAA ACG CAC TTT 
BW-613   Pst I 5’ primer for   pat-9 
promoter 
GGG GGG CTG CAG TTA AGT 
TGT TGT GTT TTG TTT TGT T 
BW-630   Kpn I 3’primer for pat-9 
promoter 
AAA AAA GGT ACC GGT GAC 
AAA GTT GGA AAG AAG GGA 
GGA TGA TGG AAC CCG TGA 
BW-631   Kpn I 5’primer for updated pat-
9 coding region 
AAA AAA GGT ACC ATG GAG 
AAT CGG ACG CCG ATG CAA 
CAC CAC AGT GGG TA 
BW-596   Dra III 3’ primer for pat-9 
including poly A  
AAA AAA CAC ATT GTG AGC 
TGC CGT TCG CAT TCC GTA 
CAT TTA TGT TAG TTG C 
 49
Table 2-3. Primers (Continued). 
 
 
Primer Restriction digestion  Site Amplified Region            Sequence 5’Æ3’ 
BW-625 Kpn I CCC CCC GGT ACC ATG AGT 
AAA GGA GAA GAA CTT TTC 
ACT GGA GTT GTC CCA ATT 
CT 
BW-626   Kpn I 
Amplify GFP 
coding region and 
fuse to pat-9 N 
terminus 
AAA AAA GGT ACC CGC CGC 
CGC CGC TGG GCT TTT GTA 
TAG TTC GTC CAT GCC ATG 
TGT AAT CCC 
Primer1   Not I 5’ primer for Pat-9 
deletion construct 
including Pmyo-
3::zf1::gfp and 
Pmyo-3::zf123::gfp 
GCG GCC GCA TGG AGA ATC 
GGA CGC CGA T 
Primer2         Not I 5’ primer for pat-9 
deletion construct 
Pmyo-3::pat-
9C::gfp 
GCG GCC GCA CAT ATG CCA 
CAG CAG CGA A 
 
Primer3          Kpn I 3’ primers for pat-9 
deletion construct 
Pmyo-3::pat-
9C::gfp 
GGT ACC CAC TGC TCA TGT 
GGC ACA GT 
 
Primer4         Kpn I 3’ primers for pat-9 
deletion construct 
Pmyo-3::zf123::gfp 
GGT ACC AAT GTA GTT GCC 
AAG GAG CT 
 
Primer5         Kpn I 3’ primers for pat-9 
deletion construct 
Pmyo-3::zf1::gfp 
GGT ACC GGC TTC TGG CCG 
GTG TGA GA 
 
PAT95 N/A 5’ primers for 
T27b1.2 RT-PCR 
ATGGAGAATCGGACGCCGA
T 
EXON1 N/A 3’ primers for 
T27b1.2 exon 1 
ATGAACTCTTGATCAGTGTT 
EXON2 N/A 3’ primers for 
T27b1.2 exon 2 
GGCAGCGAGAGCTCGACCA
T 
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Table 2-3. Primers (Continued). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Primer Restriction digestion  Site Amplified Region           Sequence 5’Æ3’ 
EXON3 N/A 3’ primers for 
T27b1.2 exon 3 
CTTGTGATTCCAGAGTGTCG 
EXON4 N/A 3’ primers for 
T27b1.2 exon 4 
TGTCGTCGTGATCAGTGGAT 
EXON5 N/A 3’ primers for 
T27b1.2 exon 5 
GCATCGTGTCGTCCAGCGAC 
EXON6 N/A 3’ primers for 
T27b1.2 exon 6 
CTGCTGCACAACACTCACTC 
3’UTR N/A 3’ primers for 
T27b1.2 3’UTR 
CTACACAGAGAGATCACTGC 
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CHAPTER 3: FACIOSCAPULOHUMERAL MUSCULAR 
DYSTROPHY REGION GENE-1 (FRG-1) IS AN ACTIN BUNDLING 
PROTEIN ASSOCIATED WITH MUSCLE ATTACHMENT SITES 
(Writing adapted from Liu Q, Jones TI, Tang VW, Brieher WM, Jones PL (2010). 
J Cell Sci. 123(Pt 7):1116-23) 
 
Introduction 
FSHD is an autosomal dominant myopathy typically characterized by progressive 
atrophy of muscles in the face, upper arms, and shoulder girdle, with progression to the 
abdominal, pelvic-girdle and foot extensor muscle in more severe cases (Pandya, 2008; 
van der Maarel, 2005; van der Maarel, 2007). The genetic lesions responsible for >95% 
of FSHD patients are deletions within DNA repeats on chromosome 4q35 resulting in 
epigenetic changes and the disrupted regulation of gene expression (Lunt, 1995; Tawil, 
2008; van Deutekom, 1993; Wijmenga, 1992; Zeng, 2009).  FRG1, based initially on its 
proximity to the FSHD genetic lesion, is a likely candidate gene for causing FSHD 
pathophysiology (van Deutekom, 1996).  However, multiple expression analyses have 
produced inconclusive, and often contradictory, results with respect to altered mRNA 
expression levels in FSHD affected muscle (Arashiro, 2009; Gabellini, 2006; Jiang, 2003; 
Osborne, 2007; Winokur, 2003).  Circumventing the inconsistencies of the RNA 
expression data, both mice and Xenopus transgenically overexpressing FRG1 in skeletal 
muscle exhibit FSHD-like phenotypes (Gabellini, 2006; Hanel, 2009; Wuebbles, 2009).  
In addition, ubiquitous FRG1 overexpression not only disrupts normal vertebrate muscle 
development, but also leads to a tortuous vasculature similar to the retinal vasculopathy 
exhibited by >50% of FSHD patients (Gieron, 1985; Wuebbles, 2009).  Thus, 
overexpression of FRG1 alone has the capacity to recapitulate the major clinical 
pathophysiology seen is FSHD; the molecular mechanism for how increased FRG1 
expression levels could promote this is not known. 
FRG1 is expressed in and required for normal development of the vertebrate 
musculature and vasculature (Hanel, 2009; Wuebbles, 2009).  Although the precise 
function of FRG1 is not known, overexpression studies in human cell culture have 
characterized it as a nuclear protein implicated in RNA biogenesis (Rappsilber, 2002; van 
Koningsbruggen, 2004; van Koningsbruggen, 2007).  Supporting a role in RNA 
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processing, FRG1 overexpressing mice and cell lines exhibit mis-splicing of some 
muscle-related genes, similar to what is seen in some FSHD patient-derived muscle cells 
(Davidovic, 2008; Gabellini, 2006; van Koningsbruggen, 2007).  However, analysis of 
the inferred FRG1 protein sequence indicates that in addition to two nuclear localization 
signals (NLSs), FRG1 also contains a lipocalin motif, potentially involved in transport of 
hydrophobic particles (Flower, 1996), and a predicted fascin domain, found in some 
proteins that bundle and organize actin filaments into structures used to stabilize cellular 
processes such as cell mobility and cell adhesion (Edwards, 1995; Kureishy, 2002).  
These suggest FRG1 may have functions other than or in addition to RNA biogenesis.  
To gain insight into how FRG1 overexpression would lead to FSHD, we have 
sought to first understand the normal function of FRG1 during development.  Since 
FRG1 is very highly conserved from invertebrates to vertebrates (Figure 3-1) (Grewal, 
1998), and invertebrate striated muscle, including C. elegans body-wall muscle, 
resembles vertebrate skeletal muscle (Lecroisey, 2007; Moerman, 2006), investigating 
FRG1’s function and potential role in mediating muscular dystrophy is highly amenable 
to analysis in invertebrate model organisms.  Here, we analyzed the C. elegans ortholog 
of FRG1, frg-1 (ZK1010.3), for biological activity, expression and subcellular 
distribution in body-wall muscle, and for the effects of FRG-1 overexpression on the 
adult body-wall musculature. 
 
Results 
FRG-1 is a conserved actin bundling protein 
FRG1 is highly evolutionarily conserved between vertebrates and invertebrates 
(Grewal, 1998) with human FRG1 sharing 41% identity (58% similarity) with the C. 
elegans FRG-1 across the full length of the protein  (Figure 3-1); however, its function 
has remained elusive.  Analysis of the predicted amino acid sequence for conserved 
domains (Pfam 23.0, http://pfam.sanger.ac.uk/) indicated that FRG-1, as with all FRG1 
orthologs, contained a single fascin-like domain (PF06220) (Adams, 2004; Edwards, 
1995).  Fascins are a conserved family of small, globular actin bundling proteins that 
stabilize actin filaments for cellular processes.  Each vertebrate fascin protein contains 
four fascin domains, two of which contain single actin binding sites (Edwards, 1995; 
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Kureishy, 2002).  To determine if FRG-1, with its single fascin domain, could similarly 
bundle actin filaments, in vitro actin bundling assays were performed (Figure 3-2).  Actin 
bundling reactions, using either the recombinant C. elegans FRG-1 or human FRG1 
proteins (Figure 3-2E), visualized by negative staining through electron microscopy 
clearly show the formation of F-actin bundles stimulated by FRG-1 (Figure 3-2A, C) and 
FRG1 (Figure 3-2B, D) indicating that FRG-1 has an evolutionarily conserved actin 
bundling activity. 
Further analyses of the FRG-1 actin bundling characteristics were carried out in 
vitro.  Unlike fascin, FRG-1 contains only a single fascin-like domain.  However, in order 
to bundle actin, proteins either possess multiple actin binding domains or they must 
multimerize to generate the necessary multiple actin binding sites.  A glutaraldehyde 
cross-linking experiment carried out on purified recombinant FRG-1 indicated that FRG-
1 forms homodimers and homotetramers in solution (Figure 3-2F), thus providing the 
multiple actin binding sites necessary for actin bundling.   
Specific actin bundling activity should show concentration dependence.  This was 
addressed for FRG-1 using an F-actin sedimentation assay (Figure 3-2G).  It has been 
previously shown that F-actin does not sediment under low speed (20,000 x g) 
centrifugation conditions unless complexed into super-molecular aggregates by a cross-
linking protein (Meyer, 1990).  Recombinant FRG-1 was incubated with polymerized F-
actin for 1 hr then centrifuged at 12,000 x g and the amount of actin and FRG-1 in the 
pellets (bundled F-actin/FRG-1) and supernatants (free F-actin and FRG-1) were 
determined by gel electrophoresis.  Saturable binding was reproducibly achieved by the 
cosedimentation of increasing concentrations of recombinant FRG-1 with a fixed amount 
of F-actin.  Nonlinear regression analysis of the binding data from three independent 
experiments yielded an average dissociation constant (Miller) of 1.28 ± 0.01 µM and 
saturation (Bmax) at 0.28 ± 0.004 mol/mol, which corresponds to one FRG-1 per 3.6 actin 
monomers.  Since FRG-1 likely associates with actin as dimer, its Kd is 0.64 ± 0.01 µM 
and Bmax is 0.14 ± 0.004 mol/mol, corresponding to one FRG-1 dimer per 7 actin 
monomers.  In either case, the Hill slope (h) is higher than n=1 (6.78± 0.47 for monomer, 
5.79± 0.64 for dimer) suggesting that FRG-1 and F-actin bind in multiple sites with 
positive co-operativity. 
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FRG-1 is both a nuclear protein and a cytoplasmic protein associated with the dense 
body  
To determine the distribution and subcellular localization of endogenous FRG-1 
during muscle development an antibody against FRG-1 (Figure 3-1, Figure 3-3) was 
generated for immunostaining.  The vertebrate FRG1 protein has been characterized as a 
nuclear protein in cell culture (van Koningsbruggen, 2004) and an analysis of the 
predicted FRG-1 amino acid sequence (Prosite release 20.49 http://ca.expasy.org/prosite/) 
identified a bipartite NLS in the amino terminus (Figure 3-1), similarly localized with one 
of the vertebrate FRG1 NLSs.  During C. elegans embryogenesis FRG-1 was in fact 
primarily nuclear, however, diffuse cytoplasmic staining was also evident (Figure 3-4A-
C, Figure 3-3A-C).  In body-wall muscle of larval stage animals, the cytoplasmic FRG-1 
began to form foci and showed a surprisingly striated and punctate immunostaining 
(Figure 3-3D-F) suggestive of the dense body.  Similarly, in adult animals the 
cytoplasmic FRG-1 immunostaining retained its striking dense body-like pattern (Figure 
3-3M and N, arrowheads).  In C. elegans, dense bodies are focal adhesion site associated 
structures that physically anchor the muscle cell’s actin cytoskeleton to the basal lamina 
and hypodermis and orient in long rows along the muscle appearing at regular intervals 
alternatively with the M-lines (Moerman, 2006).  Since a cytoplasmic pool of FRG1 had 
never been described in any organism, much less at the muscle attachment sites, the C. 
elegans genome was analyzed for FRG-1 related proteins that potentially were 
misleading.  However, there are no other FRG-1-like proteins known or predicted in the 
C. elegans genome.  Over the full protein sequence, FRG1 proteins are unlike any other 
proteins, however the fascin-like domain places FRG1 orthologs in the fascin family of 
cytoplasmic actin bundling proteins.  Interestingly, analyzing the C. elegans genome for 
fascin domain-containing proteins revealed that FRG-1 is the only such protein in C. 
elegans (Figure 3-5) and is most related to the fascin-like domain of vertebrate FRG1 
suggesting that FRG-1 may the ancestral fascin domain family protein.  Together with 
our antibody characterization (Figure 3-4) we conclude that this cytoplasmic 
immunostaining is FRG-1. 
To determine if larvae and adults retained a nuclear FRG-1 pool in body-wall 
muscle required altering the immunostaining procedure as described for some nuclear 
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proteins at these stages.  Unfortunately, this procedure destroyed the cytoplasmic 
structures but successfully revealed FRG-1’s presence in the body-wall muscle nuclei in 
larva (Figure 3-3G-I, arrow), and adults (Figure 3-4D-F, Figure 3-3J-L), localized 
primarily to the DAPI-poor regions indicative of nucleoli (Shaw, 2005).  Thus, 
endogenous FRG-1 in C. elegans is both a nuclear protein and a cytoplasmic protein 
throughout development, appearing to concentrate in nucleoli and dense bodies, 
respectively, of body-wall muscle cells. 
To confirm the association of FRG-1 with the dense bodies, co-immunostaining 
for PAT-3/ β-integrin, a transmembrane ECM receptor concentrated in all dense bodies 
and M-lines (Gettner, 1995), was carried out (Figure 3-6).  Both FRG-1 and PAT-3/ β-
integrin immunostaining produced identical yet only partially overlapping and generally 
adjacent punctate patterns (Figure 3-6A-C) indicating that FRG-1 is a component of all of 
the body-wall muscle dense bodies.  Using confocal microscopy and focusing on only the 
dense bodies positioned at the edge of the animal allowed visualization of proteins 
positioned along the dense body structure as it protruded into the muscle cytoplasm 
(Figure 3-6D-F).  Clearly FRG-1 does not overlap with PAT-3/β-integrin at the base of 
the dense body; instead FRG-1 immunostaining appeared adjacent to PAT-3/β-integrin 
along the cytoplasmic finger-like projection of the dense body, where actin thin filaments 
attach (Figure 3-6M).  Considering that FRG-1 is an F-actin bundling protein, it was not 
surprising that FRG-1 was absent from M-lines, structures anchoring myosin thick 
filaments (Figure 3-6B, C, arrows) (Moerman, 2006). 
To further confirm the immunological determination that the endogenous FRG-1 
is associated with the dense body and further characterize its localization, transgenic 
strains co-expressing fluorescently tagged FRG-1 (Pmyo-3::frg-1::yfp) and α-actinin-
associated LIM protein 1α (ALP-1α) (Pmyo-3::alp-1a::cfp) transgenes from the strong 
muscle-specific myosin heavy chain (myo-3) promoter were generated (Figure 3-6G-I)). 
ALP-1 is a conserved dense body protein that interacts with α-actinin (ATN-1), a 
conserved actin bundling protein (Barstead, 1991; Han, 2009; Xia, 1997).  Transgenic 
animals expressing FRG-1::YFP in muscle cells showed a cytoplasmic dense body-like 
pattern (Figure 3-6G, green) appearing identical to the endogenous FRG-1 
immunostaining (Figure 3-3M and N).  However, unlike the case with PAT-3/β-integrin 
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(Figure 3-6C and F), the FRG-1::YFP fusion protein precisely co-localized with ALP-
1α::CFP in body-wall muscle dense bodies (Figure 3-6G-I, I’), confirming the 
immunocharacterization of endogenous FRG-1.  Finally, an adult C. elegans strain 
(RB1812) carrying a homozygous partial deletion in atn-1 was co-immunostained for 
FRG-1 and PAT-3/β-integrin (Figure 3-6J-L).  The PAT-3/β-integrin immunostaining 
showed punctuate staining, indicating localization of PAT-3/β-integrin was maintained, 
however both dense bodies and M-lines appeared abnormal (Figure 3-6K).  In contrast, 
the FRG-1 immunostaining pattern no longer showed overlap or adjacent staining with 
PAT-3/β-integrin but instead appeared filamentous (Figure 3-6L compared with Figure 3-
6C), indicating integrins did not directly localize FRG-1.  These data further place FRG-1 
distal to PAT-3/β-integrin and the basal lamina in the region of the dense bodies 
containing ALP-1, ATN-1, and where actin thin filaments attach to these dense body 
projections (Figure 3-6M) (Han, 2009), further supporting FRG-1 as a component of the 
actin-associated machinery of the dense body. 
To begin a FRG-1 structure/function analysis, a FRG-1 mutant strain, frg-
1(tm2803), containing a homozygous partial deletion in frg-1 beginning after amino acid 
K121 (Figure 3-1) and deleting roughly half the protein including the C-terminal half of 
the fascin domain, was obtained.  Immunostaining for FRG-1 on frg-1(tm2803) animals 
showed that a truncated FRG-1 was stably retained at body-wall muscle dense bodies 
(Figure 3-7B), indicating the C-terminal half of the protein is dispensable for dense body 
association, while phalloidin staining showed no differences in the F-actin or musculature 
structure and organization (Figure 3-7C, D).  Consistent with its ability to maintain 
association with the dense body structure, recombinant FRG-1(tm2803) still bundled F-
actin (Figure 3-7A).  Interestingly, there was no detectable FRG-1 in the nuclei of any 
cells in frg-1(tm2803) animals at any developmental stages, despite the ~15kDa protein 
containing the N-terminal NLS indicating the C-terminal portion of FRG-1 is required for 
nuclear/nucleolar localization.  Thus, the nuclear and cytoplasmic localizations for FRG-
1 can be separated.  Our data suggest that the C-terminal portion of FRG-1, lacking a 
predicted NLS, is required for the release of FRG-1 to the nucleus but not for FRG-1’s 
actin bundling activity or dense body association. 
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Overexpressed FRG-1 shows an altered subcellular distribution in body-wall muscle 
In transgenic C. elegans, the myo-3 promoter drives strong, muscle-specific 
expression of FRG-1::GFP (Figure 3-6G, 8A) generating a strong nuclear fluorescence as 
well as dense body association.  Therefore, transgenic lines expressing FRG-1::GFP 
under the control of C. elegans frg-1 promoter (Pfrg-1::frg-1::gfp) were generated, 
providing a range of FRG-1 overexpression (Figure 3-8B-E) in all FRG-1 expressing cell 
types including body wall muscle.  Consistently all animals expressing FRG-1::GFP 
showed very strong nuclear localization regardless of overall expression levels (Figure 3-
8A-C).  However, different expression levels of FRG-1 affected the cytoplasmic and 
nuclear distributions. When the expression level of FRG-1 was visibly low, cytoplasmic 
FRG-1 localized strictly to the dense bodies (Figure 3-8B); however, when the expression 
level of FRG-1 was notably higher, FRG-1 appeared to spread along the actin filaments 
well beyond its normal distribution pattern (Figure 3-8C compared with Figure 3-8A, 8B, 
6A, 6G, and 3J).  This was in contrast to the Pmyo-3::frg-1::gfp  lines that did not show the 
aberrant coating of the F-actin cytoskeleton, indicating that FRG-1 expression from the 
more ubiquitously expressed frg-1 promoter was somehow different from FRG-1 
expression from the muscle-specific myo-3 promoter.  Similarly, expression levels 
affected the distribution of nuclear FRG-1.  Low FRG-1 overexpressing cells contained 
the majority of nuclear FRG-1 in the granular component of nucleoli (Figure 3-8D) while 
high FRG-1 expressing cells contained additional non-nucleolar aggregates of FRG-1 
(Figure 3-8E) not detected in endogenous nuclear FRG-1 staining.  Therefore, the normal 
cytoplasmic and the nuclear distributions are both affected by FRG-1 expression levels 
from the frg-1 promoter. 
 
Overexpression of FRG-1 from the frg-1 promoter disrupts the muscular organization of 
ventral body-wall muscle 
 FSHD pathophysiology very likely results from increased FRG1 gene expression, 
however, transgenic C. elegans overexpressing FRG-1 in muscle cells from the muscle-
specific myo-3 promoter showed no obvious movement or muscle phenotype (Figure 3-
9F).  However, in addition to skeletal muscle, FRG1 expression has been detected in all 
human tissues tested (van Deutekom, 1996) raising the possibility that FRG1 expression 
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in non-muscle cells may be important for generating FSHD pathology.  Similarly, C. 
elegans Serial Analysis of Gene Expression data 
(http://elegans.bcgsc.ca/home/sage.html) confirmed that frg-1 is not only expressed in 
muscle cells, but also in hypodermal cells, pharynx cells, pharyngeal marginal cells, 
pharyngeal gland cells and neurons.  In addition, in situ hybridization data from Dr. Yuji 
Kohara (http://nematode.lab.nig.ac.jp/db2/ShowGeneInfo.php?celk=CELK04952) 
indicate that expression of frg-1 starts as early as the two cell stage and its expression 
level decreases during larval development, but increases in adults.  Thus, because FRG-1 
expressed in non-muscle cells and from early points in development may impact upon the 
integrity of the adult musculature, the Pfrg-1::frg-1::gfp transgenic adult animals were 
assayed for muscle phenotypes (Figure 3-9).  During muscle development, myoblasts 
migrate to four quadrants, two dorsal and two ventral, and flatten both basally against the 
hypodermis and laterally against neighboring muscle cells, forming four continuous 
double rows of muscle cells along much of the length of the animal (Hresko, 1994; 
Moerman, 2006).  Phalloidin staining revealed that ~25% of Pfrg-1::frg-1::gfp adult 
transgenic animals showed a disruption of the body-wall musculature manifested as 
smaller, misaligned, missing, and disconnected muscle cells primarily at the muscle-
muscle junctions running down the center of the ventral muscle quadrants (Figure 3-9D 
and E compared with control N2 panel).  At the vulva, phalloidin staining on transgenic 
adult animals (Figure 3-9C) showed that ventral body-wall muscle cells were 
discontinuous underneath the vulval muscles (bracket) and body-wall muscle cells were 
smaller compared with control animals (Figure 3-9B).  Interestingly, the muscle defects 
were exclusively on the ventral side of the animal and never on the dorsal side, despite 
FRG-1 expression being confirmed throughout the dorsal and ventral musculature by 
GFP visualization.  Overall, FRG-1 overexpression, specifically in the spatiotemporal 
pattern dictated by the frg-1 promoter and not in muscle cells alone, disrupts the integrity 
of the adult ventral body wall musculature in C. elegans. 
 
Discussion 
A top priority in FSHD research is determining which gene (or genes) is 
misexpressed due to the 4q35 lesion and how its altered expression results in FSHD 
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pathogenesis.  Among the candidate genes, FRG1’s role in FSHD has been controversial 
and impeded by a lack of understanding of the biological function of FRG1.  Here, we 
have identified a conserved activity for FRG1, F-actin bundling.  However, FRG1 in 
vertebrates had been characterized as a nuclear protein involved in some aspect of RNA 
biogenesis based on studies in cell culture while overexpressed FRG1 strongly localized 
to the nucleus of these cells (Rappsilber, 2002; van Koningsbruggen, 2004; van 
Koningsbruggen, 2007).  Thus, the biological significance of identifying F-actin bundling 
activity for a nuclear protein such as FRG1 was initially not clear due to the controversial 
nature of both the form and function of nuclear actin (Pederson, 2005).  Here, 
characterizing endogenously expressed C. elegans FRG-1 as both a nuclear protein 
accumulating in the nucleolus, as described for the human protein as well and consistent 
with a role in RNA biogenesis, and associated with the dense body, a plasma membrane 
bound muscle adhesion structure that attaches to the actin cytoskeleton (Figure 3-6M), 
has suggested an explanation; FRG-1 is a multi-functional protein residing in distinct 
subcellular niches, primarily the nucleolus and the dense body.  During C. elegans larval 
stages there is an increase in the number of body-wall muscle sarcomeres and filaments 
and the dense bodies begin making projections into the cytoplasm, accumulating proteins 
such as the F-actin anchoring proteins ATN-1 and CeTalin (Francis, 1985; Moerman, 
2006).  The appearance of dense body FRG-1 immunostaining in the cytoplasm similarly 
coincides with this dense body proliferation, maturation, and actin-associated protein 
accumulation and supports a possible role for FRG-1 in stabilizing F-actin at the dense 
body. 
C. elegans dense bodies primarily function in muscles to transduce mechanical 
force from the muscle by attaching the sarcomeres to the muscle membrane and 
underlying extra-cellular matrix (ECM) via PAT-2/α-integrin and PAT-3/β-integrin 
heterodimers (Gettner, 1995; Hresko, 1994), essentially forming the mechanical anchor 
between sarcomeric actin and the ECM.  Therefore, the dense body is a structure that 
performs functions analogous to the vertebrate Z-disk and costameres together 
(Lecroisey, 2007; Moerman, 2006; Pardo, 1983; Street, 1983).  Identifying FRG-1 as 
being associated with dense bodies is a compelling result since FSHD pathophysiology 
includes reorganization of the sarcolemma (Reed, 2006) and numerous other muscular 
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dystrophies, including Duchenne (Hoffman, 1987; Monaco, 1986), Becker (Kunkel, 
1986), certain Limb-Girdle (LGMD2B, 2G, 2J) (Guglieri, 2008), and some rare 
congenital muscular dystrophies (Hayashi, 1998), as well as multiple other Z-disk 
diseases (Selcen, 2008), result from mutations affecting vertebrate orthologs of dense 
body components.  Thus, the localization of FRG-1 to muscle attachment sites raises new 
possibilities regarding FRG-1’s role in muscle development and disease beyond affecting 
RNA biogenesis; FRG-1 may perform two independent functions, stabilization of F-actin 
through bundling at the dense body and RNA processing in the nucleus, or alternatively, 
the two pools of FRG-1 may be functionally linked.  For example, dense bodies and focal 
adhesions have an additional role, serving as platforms for transducing biochemical and 
mechanical signals from the ECM and surrounding tissues to the nucleus (Lecroisey, 
2007; Romer, 2006) and FRG-1 would be particularly well suited for functioning in this 
capacity. 
The analysis of the frg-1(tm2803) strain is consistent with independent yet linked 
functions for FRG-1 in the cytoplasm and nucleus.  This strain produced a truncation of 
FRG-1 that was entirely cytoplasmic despite the presence of the NLS and being only 
~15kDa indicating it was anchored in the cytoplasm and being prevented from entering 
the nucleus.  The dense body staining and F-actin structure were indistinguishable from 
N2 animals.  Interestingly, when full-length FRG-1 was overexpressed in the Pmyo-3::frg-
1::gfp and Pfrg-1::frg-1::gfp transgenic lines, the nuclear FRG-1 was extremely intense 
when compared the dense body FRG-1.  Potentially overexpressed FRG-1 preferentially 
accumulated in the nucleus because it was unable to be retained efficiently in the 
cytoplasm.  Even small increases in the levels of FRG-1 could be detrimental strictly by 
affecting its subcellular distribution, thus affecting its nuclear protein levels and in turn 
its nuclear functions such as the regulation of alternative splicing of genes required for 
muscle development. 
 
Materials and Methods 
C. elegans strains and genetics 
Standard methods were used for culturing C. elegans (Brenner, 1974).  Bristol N2 
was used as wild type.  The strain frg-1(tm2803), originally ZK1010.3 (tm2803) was 
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obtained from the National BioResource Project at Tokyo Women’s Medical University, 
directed by Shohei Mitani.  The deletion in the frg-1(tm2803) was confirmed by genomic 
PCR (primers #1 and #5) and sequencing.  The strain RB1812: atn-1(ok84) was provided 
by the Caenorhabditis elegans Genetics Center, which is funded by the NIH National 
Center for Research Resources (NCRR), at the University of Minnesota.  Transgenic 
lines were generated by standard microinjection technique, using pRF4 (rol-6) as a 
marker when indicated, and the plasmids described below. 
 
Molecular biology 
Vectors were from the Fire Lab kit (Addgene, Cambridge, MA).  RT-PCR 
products were amplified with SuperScript III-Platinum Taq one-step RT-PCR kit 
(Invitrogen Corp, Carlsbad, CA) from N2 total RNA isolated by the Trizol (Invitrogen 
Corp, Carlsbad, CA) method as per manufacturer’s instructions, cloned into pGEM-T 
Easy vector (Promega Corp, Madison WI), and sequenced.  Primers are listed in Table 
S1.  To generate Pmyo-3::frg-1::gfp the frg-1 cDNA fragment was amplified by RT-PCR 
(primers #1 and #2) and subcloned into pPD118.20 by NotI and KpnI digestion.  To 
generate Pfrg-1::frg-1::gfp, 600bp upstream of the frg-1 transcription start site was PCR 
amplified (primers #3 and #4) from N2 genomic DNA and cloned into the plasmid Pmyo-
3::frg-1::gfp, digested with Pst I and Not I. To generate Pmyo-3::alp-1a::cfp ,the alp-1a 
cDNA was amplified by RT-PCR (primers #10 and #11), and subcloned into pPD136.61 
digested with BamH I and Kpn I.  The plasmid Pmyo-3::frg-1::yfp was similarly generated 
using vector pPD136.64 and the frg-1 cDNA. 
 
Antibodies 
Rabbit polyclonal CeFRG-1 antibody (GenScript USA Inc, Piscataway, NJ) was 
raised against the peptide EKIDPDTVENGGWRC conjugated to KLH, affinity purified 
against an E. coli generated GST-EKIDPDTVENGGWR protein, and then negatively 
absorbed against recombinant sepharose bound GST.  The MH25 monoclonal antibody 
against PAT-3/β-integrin (Francis, 1985) developed by R.H. Waterson was obtained from 
the Developmental Studies Hybridoma Bank developed under the auspices of the NICHD 
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and maintained at the University of Iowa Department of Biological Sciences, Iowa City, 
IA. 
 
Phalloidin staining 
Worms were fixed in 3.7% formaldehyde solution in PBS at RT for 10min, 
washed 3X with PBS, soaked in 500 ul of 100% acetone at -20°C for 5min, and then 
washed 3X with PBS.  Rhodamine phalloidin (Invitrogen Corp, Carlsbad, CA) was added 
(5 unit/ml) for 30 min at RT then washed with PBS and mounted for microscopy. 
 
Immunostaining  
For embryo staining, embryos were collected by bleaching, washed 4X with M9 
buffer, fixed (3.7% formaldehyde, 0.1M NaPhosphate buffer pH 7.0, 0.1mM EDTA) 
for10min at RT, washed 2X with PBS pH 7.0, transferred to PBST (PBS pH 7.0 + 0.5% 
Tween-20), incubated for 5 min at RT and pelleted.  FRG-1 antibody (1:500 in 70% 
PBST and 30% normal goat serum) was added and incubated ON at 4°C with rocking.  
After 4 PBST washes of 5 min each at RT, secondary antibody (Alexa 488 goat anti-
rabbit IgG, Invitrogen Corp, Carlsbad, CA) was diluted 1:1000 and incubated with 
embryos for at least 1h at RT.  Immunostained embryos were washed 3X with PBST and 
mounted for microscopy. 
For immunostaining of adult animals (Finney, 1990), worms were suspended in a 
4% paraformaldehyde, quick frozen on dry ice, thawed and incubated on ice for 1h.  
Worms were washed 3X in 1% Triton X-100, 100mM Tris (pH 7.5), incubated in 1% 
Triton X-100, 100mM Tris (pH 7.5), and 1% βME at 37°C for 2h for cytoplasmic or 4h 
for nuclear staining.  After 3 washes in 10mM NaBO3 (pH 9.2), the worms were 
incubated in 10mM NaBO3 and 0.3% H2O2 1h for cytoplasmic or 3h for nuclear staining, 
washed 3 times with 10mM NaBO3 (pH 9.2) and stored for further processing in Ab-A 
buffer (1× PBS, 0.1% Triton X-100, 1% BSA, 0.05% NaN3).  FRG-1 antibody (1:500) or 
MH25mAb (1:10) in Ab-A buffer, was added and incubated at 4°C overnight, then 
washed 3X in Ab-B buffer (1 × PBS, 0.1% Triton X-100, 0.1% BSA, 0.05% NaN3) prior 
to incubation with 2° antibody (Alexa 488 goat anti-rabbit IgG, Alexa 594 goat anti-
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mouse IgG, Invitrogen Corp, Carlsbad, CA) as above.  Immunostained animals were 
washed 3X with Ab-B buffer, pelleted as above and mounted for microscopy. 
 
Fluorescence microscopy 
C. elegans were examined by fluorescence microscopy using an Olympus BX60 
microscope equipped with a 100x NA 1.35 oil immersion lens.  Pictures were acquired 
with a SpotRT monochrome Model 2.1.1 camera and Spot Advanced software 
(Diagnostic Instruments, Inc., Sterling Heights, MI).  Images were processed using 
Adobe Photoshop CS2, ImageJ to adjust brightness, contrast, size, and merge or split 
channel. 
 
Actin bundling assays 
To generate recombinant protein, the cDNAs for human FRG1 and C. elegans 
FRG-1 were PCR amplified (primers #8 and #9 or #6 and #7, respectively), subcloned 
between the Nde I and Xho I restriction sites of pET-23b (Novagen, Gibbstown, NJ), 
transformed into E. coli BL21(DE3), induced with 0.5mM IPTG, and protein was 
purified using TALON resin (Clontech, Mountain View, CA) as per manufacturers 
instructions. Proteins were bound to MonoS resin using an AKTA-FPLC (GE Healthcare, 
Piscataway, NJ) for chromatography and step eluted between 400 and 600mM NaCl in 20 
mM Tris pH 8.0 and 10% glycerol.  Actin was purified from rabbit skeletal muscle as 
described (Pardee, 1982). 
For electron microscopy, G-actin (1 μM final) was incubated with 1μM of 
recombinant human FRG1, C. elegans FRG-1, or C. elegans FRG-1(tm2803) in 10 mM 
Hepes pH 7.8, 50 mM KCl, 2 mM MgCl2, and 2 mM EGTA) for 30 min at 4°C.  The 
reactions were spotted onto carbon-coated grids glow discharged, washed, and stained in 
2% uranyl acetate for electron microscopy using a JOEL 2100 TEM at 80KV.  Images 
were captured with a Gatan CCD (2000 x 2000). 
 Actin bundling sedimentation assays were carried out as described with minor 
modifications (Ono, 1997). Increasing amounts of recombinant FRG-1 (1 to 9 µM as 
monomer) were incubated with G-actin (final concentration 11.4 µM) in a total volume 
of 60 µl at room temperature for 1 hr. The samples were subjected to centrifugation at 
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12,000 x g for 10 min.  The amount of free and bound FRG-1/F-actin was determined by 
densitometry from Coomassie blue-stained 10% SDS-polyacrylamide gels.  The 
intensities of the scanned bands were quantified by volume integration after local 
background subtraction by using Bio-Rad Quantity One software. The bound FRG-1 was 
normalized by subtracting the percentage of FRG-1 pelleted without actin.  The binding 
data were analyzed by fitting to the “One site – Specific binding with Hill slope” 
equation, Y=Bmax*Xˆh/(Kd ˆh + Xˆh), using the nonlinear regression function of Prism 5 
(GraphPad Software Inc.).  Y is the bound FRG-1 per F-actin (mol/mol), and X is the 
unbound FRG-1 concentration (µM) of the samples. 
 
Glutaraldehyde cross-linking 
Recombinant FRG-1 protein (0.2 mg/ml) was incubated with 10mM HEPES pH 
7.6, 2 mM MgCl2, and 0.01 % gluraraldehyde in 1 ml at RT.  Samples (50 μl) were 
removed at the indicated time intervals, made 1X with Laemmli SDS-PAGE buffer, 
boiled, and electrophoresed on a 10% SDS-PAGE.  Protein was detected by western 
blotting using the CeFRG-1 antibody described above. 
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Figures 
 
 
 
Figure 3-1: FRG1 is highly conserved evolutionarily.  Deduced amino acid sequence 
alignment of FRG1 homologs using ClustalW shows human FRG1 is 97% identical with 
mouse, 81% identical with Xenopus and 42% identical with C. elegans.  Green residues 
have identity conserved among all four species; yellow residues are similar among all 
four species; unshaded residues are not conserved.  Putative domains characterized for 
the human FRG1 are shown above.  The predicted C. elegans NLS is underlined.  The 
peptide used to generate the FRG-1 antibody is in the blue box.  The last amino acid 
(lysine) before the deletion in the frg-1(tm2803) strain is indicated in red.  
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Figure 3-2: FRG-1 and FRG1 proteins bind and bundle F-actin. Electron 
micrographs of actin bundles formed with recombinant (A, C) C. elegans FRG-1 or (B, 
D) human FRG1. E) Coomassie Blue staining of the purified 30 kDa recombinant human 
FRG1 (Hs) and C. elegans (Ce) FRG-1 proteins. F) Western blot analysis of a 
representative glutaraldehyde cross-linking time course using recombinant FRG-1.  
Monomer (30 kDa), dimer (60 kDa), and tetramer (120 kDa) species were present.  G) A 
sedimentation actin bundling assay was performed at varying concentrations of FRG-1.  
FRG-1 was treated as a dimer with a molecular mass of 60 kDa.  The binding of FRG-1 
dimers to F-actin was saturated at a molar ration of 1:7. (A, B) Bar = 500 nm; (C, D) Bar 
= 200 nm. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 71
 
 
Figure 3-3: Immunostaining identifies endogenous FRG-1 as both a nuclear and 
cytoplasmic protein displaying a pattern indicative of body wall muscle dense 
bodies.  N2 worms immunostained for FRG-1 (A, D, G, J, M and N) in red, co-stained 
with DAPI (B, E, H, and K) in blue, with images merged (C, F, I and L).  In embryo (A-
C), larval (D-I), and adult (J-N) stages, FRG-1 was localized in the DAPI poor regions of 
the nuclei (I and L, arrows).  Cytoplasmic staining for FRG-1 resembled that of body 
wall muscle cell dense bodies (D, M, and N, arrowheads).  Bars = 10 µm 
 
 72
 
 
Figure 3-4:  Characterization of the FRG-1 antibody.  Transgenic animals expressing 
FRG-1::GFP preferentially localize FRG-1 in the nucleus.  Pfrg-1::frg-1::gfp transgenic 
adults were (A and D) immunostained for FRG-1, and (B and E) visualized for FRG-
1::GFP fluorescence.  Transgenic (*) and non-transgenic embryos within the uterus show 
A) the endogenous FRG-1 and B) the FRG-1::GFP transgene product signals C) overlap 
in the transgenic animal and appear to be nuclearly localized.  (D-F) Immunostaining of 
adult Pfrg-1::frg-1::gfp animals for FRG-1 detects both nuclear and cytoplasmic FRG-1 in 
body wall muscle. Bar = 50 µm.  Western blot analysis of (G) transgenically expressed 
FRG-1 from the frg-1::frg-1::gfp worms and (H) endogenous FRG-1. 
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Figure 3-5:  FRG-1 is the only fascin-like domain protein in C. elegans. A search of 
the C. elegans database revealed that FRG-1 is the only fascin domain protein known or 
predicted.  A Pfam database search for human proteins identified four fascin domains in 
both Fascin1 and Fascin2 in addition to one in FRG1.  Phylogeny performed with Clustal 
W. Rooted Phylogenetic Tree from alignment shows that the C. elegans FRG-1 fascin-
like domain is more closely related to its counterpart in human FRG1 than human 
Fascin1 and Fascin2.  Each one of the fascin domains in Fascin1 is more closely related 
to its counterpart in Fascin2. 
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Figure 3-6: FRG-1 associates with the body wall muscle cell dense body, adjacent to 
β-integrin and co-localized with ALP-1. (Neto) Adult animals co-immunostained for 
FRG-1 (A, D, green) and PAT-3/β-integrin (B, E, red) show FRG-1 present at all body 
wall muscle dense bodies (C, arrowheads) while FRG-1 is absent from M-lines (C, 
arrows).  FRG-1 and PAT-3/β-integrin show adjacent, partially overlapping signals at 
dense bodies when merged (C, C’, arrowheads).  (D-F) Confocal images of dense body 
immunostaining.  (G-I) Double transgenic animals for Pmyo-3::frg-1::yfp and Pmyo-3::alp-
1a::cfp  show expression patterns for FRG-1 (G) and ALP-1 (H) are precisely co-
localized in the image merge (I and I’).  (J-L) Mutant C. elegans strain containing a 
homozygous partial deletion for atn-1 was co-immunostained for FRG-1 (J, green) and 
PAT3/β-integrin (K, red) and shows disrupted FRG-1 localization (L).  (M) Model 
depicting FRG-1 localization in dense bodies with the analogous vertebrate components 
[based on (Moerman, 2006) and (Fluck, 2002)].  Bars =20µm.  DGC 
dystrophin/glycoprotein complex; IRC integrin receptor complex 
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Figure 3-7: The frg-1(tm2803) homozygous mutant animals produce a cytoplasmic 
truncated protein that still associates with the dense bodies and bundles F-actin. A) 
Electron micrograph of FRG-1(tm2803) bundled F-actin. Bar = 500 nm. B) 
Immunostaining for FRG-1 on frg-1(tm2803) animals shows that the truncated FRG-
1(tm2803) is still localized at the dense body, however, no nuclear localization was 
detected in any developmental stages. Bar = 10µm.  Phalloidin staining of C) N2 and D) 
frg-1(tm2803) animals show no changes in body wall muscle actin organization. 
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Figure 3-8: Overexpressed FRG-1 preferentially localizes to the nucleus and shows 
neomorphic localizations.  A) Pmyo-3::frg-1::gfp transgenic animals strongly express 
FRG-1::GFP in body wall muscle nuclei and weakly in the dense bodies. Animals 
transgenic for Pfrg-1::frg-1::gfp show visually low (B and D) or high (C and E) levels of 
FRG-1::GFP expression in body wall muscle cells (B and C) and nuclei (D and E).  High 
levels of FRG-1 expression lead to coating of the F-actin filaments (compare C, FRG-1 
stained striations with B, punctate dense body staining) and nuclear aggregates (E, 
arrowheads, compared with D) in addition to normal nucleolar staining (arrows).  Bars = 
10 µm. 
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Figure 3-9:  Overexpression of FRG-1 specifically from the frg-1 promoter disrupts 
the ventral muscle-muscle lateral junctions.  Phalloidin staining on (A) wild type N2 
adults and (B) pRF4(rol-6) transgenic animals show the normal organization and 
structure of the ventral (arrowhead) and dorsal (blue arrows) body-wall and vulval (*) 
muscles.  Transgenic animals overexpressing FRG-1::GFP from the frg-1 promoter 
visualized by phalloidin and GFP merge (C, D, and E) show specific disruption of ventral 
muscle-muscle lateral junctions and absence of some muscle cells (white arrows, bracket 
at vulva) while the dorsal musculature (blue arrows) remains intact.  (F) Transgenic 
animals overexpressing FRG-1::GFP from the myo-3 promoter showed normal muscle 
structure visualized by phalloidin staining.  Diagrams depicting a lateral view (G), and a 
ventral view (H) of a normal and transgenic (bottom) animal’s dorsal (blue arrows) and 
ventral (black arrowheads, normal; black arrows, disrupted) musculature.  Bars = 50 µm. 
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CHAPTER 4: EXPRESSION PROFILE OF ANIMAL MODELS OF 
HUMAN FSHD 
 
Introduction 
            Linkage analysis has associated FSHD1A, the most common form of FSHD, with 
chromosome 4q35 and subtelomeric region.  FSHD patholphysiology results from the 
deletion in an array of tandem repeats called D4Z4s and isease severity is somewhat 
correlated with the number of remaining D4Z4 tandem repeats (Butz, 2003; Hewitt, 
1994; Tupler, 2004). The leading disease model is that the genes adjacent to or within the 
D4Z4 array are epigenetically mis-regulated due to the deletion. Gabellini and colleagues 
showed that several candidate genes in the FSHD critical region, including FRG1, FRG2 
and ANT1, are upregulated in FSHD patient-derived myoblasts.  In addition, an FSHD-
like phenotype is observed only in transgenic mice overexpressing FRG1, which makes 
FRG1 the leading candidate gene for mediating FSHD pathogenesis (Gabellini, 2006).  
FRG1, however, despite mounting functional evidence supporting its role in 
muscle and vasculature development, is still just a candidate for mediating FSHD with 
nothing conclusive (Hanel, 2009; Wuebbles, 2009).  Expression analyses of the 4q35 
region genes have failed to find misregulation of FRG1 and arrays show inconsistent or 
even contradictory results.  For example, one gene expression profile of skeletal muscle 
from FSHD patient samples that did not detect up-regulation of FRG1 found a large 
proportion of differentially expressed genes that are unique for FSHD that had a role in 
angiogenesis, which supports a link between FSHD and retinal vasculopathy (Osborne, 
2007).  Another expression profile of FSHD patients showed impaired muscle fiber 
differentiation and deregulation of genes downstream of MyoD, a critical transcriptional 
regulator during myogenesis (Celegato, 2006).  A hierarchical cluster analysis of 
expression profiles of FSHD patient samples separated them into three groups (Celegato, 
2006). Each group has a discriminated set of genes, including genes that change muscle 
metabolism, genes involved in mitochondrial function, and genes involved in canonical 
signaling pathways.  For example, the activity of NF-κB is up regulated, which could 
explain the down regulation of MyoD and decreased skeletal muscle differentiation.  
Some critical molecular components in the muscle attachment sites such as titin and 
nebulin were also down regulated.  Overall, while the gene primarily responsible for 
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initiating the cascased of deleterious events in FSHD is still inquestion, it has been 
concluded that FSHD pathogenesis involves global mis-regulation of gene expression 
which results in mitochondria malfunction, disrupted muscle metabolism, oxidative 
stress, and decreased ability of muscle differentiation (Celegato, 2006; Winokur, 2003). 
Here, we have addressed the issues of FSHD candidate genes and affected 
pathways by performing genome-wide microarray analyses on muscle from FSHD-like 
Xenopus and Drosophila animal models generated by transgenic overexpression of 
FRG1.  The basis of these experiments is that overexpression of FRG1 in both Xenopus 
and Drosophila lead to a similar, FSHD-like phenotype in respect to muscle function and 
histology.  We aimed to determine if the overexpression of FRG1 also leads to similar 
altered global gene expression patterns as found in FSHD patient-derived muscle.  
Overall, the array data provide 1) for a cross-species comparison between divergent 
species exhibiting similar phenotypes to determine the important, conserved pathways 
affected by overexpression of FRG1, and 2) a comparison with the human FSHD patient 
expression arrays to identify concordantly affected molecular pathways.  Together, these 
data provide insight into how overexpression of FRG1 leads to the FSHD-like phenotype 
and if forced overexpression of FRG1 affects the same pathways that are altered in FSHD 
patients. 
 
Agilent two-color expression array for FSHD-like Xenopus laevis 
Our lab generated two Xenopus models for FSHD by overexpressing FRG1, the 
leading candidate gene for FSHD, under expression control of the muscle-specific 
skeletal actin promoter and the ubiquitously expressing CMV promoter. Both resulted in 
an FSHD-like muscle phenotype with transgenic tadpoles showing unusual swimming 
patterns and abnormal head formation and transgenic adult animals often failed to extend 
their forearms and displayed dystrophic muscle histology.  Similarly, FSHD patients 
show the muscle weakness in specific muscle groups including the triceps and biceps in 
the arms.  Histological analysis of the muscle from FSHD-like Xenopus showed variable 
fiber size and disrupted sarcolemma organization.  In addition, overexpression of FRG1 
during early development specifically affected myogenesis and angiogenesis (Hanel, 
2009; Wuebbles, 2009).  These phenotypes in the Xenopus model are consistent with the 
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clinical symptoms of human FSHD, and validate our vertebrate animal model for further 
gene expression studies to investigate the potential of FRG1 overexpression as a causal 
mechanism of human FSHD pathophysiology.  
 
Experimental Design 
Transgenic Xenopus were generated by standard technique (Kroll, 1999) using 
plasmid constructs containing the skeletal actin promoter regulating expression of either 
FRG1::EGFP (PAFE) or EGFP (PAF) alone.  Animals were scored for being transgenic 
by live visualization of GFP as stage 33-35 tadpoles.  Transgenic and non-transgenic 
animals were separated and allowed to develop into adults and were maintained for two 
years post metamorphosis.  Animals were humanely sacrificed according to approved 
UIUC IACUC protocols and muscle samples were collected from the forearms from 
transgenic animals expressing EGFP or FRG1::EGFP.   Muscle samples from three frogs 
were pooled to minimize variation due to individual animals and treated as one biological 
replicate. There were 6 biological replicates for each treatment group.  Total RNA was 
extracted using Trizol (Invitrogen), treated with DNase, repurified over a Qiagen RNEasy 
column, quantified, and assayed for quality by PCR. The ribosomal RNA was removed 
using rRNA specific magnetic beads (Affymetrix).  RNA samples were sent to the lab of 
Dr. Yun-Bo Shi, NICHD/NIH for performing the microarray hybridization and scanning.  
Labeling, hybridization, and scanning were performed by Dr. Biswajit Das.  For the 
labeling reaction, all the samples were labeled with Cy3 and all the samples were co-
hybridized with a universal reference RNA obtained from multiple stages during 
Xenopus laevis development labeled with Cy5 (Das, 2006).  Samples were then 
hybridized to the Agilent 4x44k Gene Expression array for X. laevis (AMADID# 
015066).   
 
Results 
Raw data from all the replicates were checked for outliers. Briefly, logarithm base 
2 transformed red signal (R) or green signal (G) are visualized in a box plot and an RG  
density plot (Figure 4-1). Within the array, normalization was performed using Loess 
(locally weighted scatterplot smoothing); the normalization between arrays was 
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performed by scaling. Box plots and density plots were visualized after normalization 
(Figure 4-2).  MA plots showed that after normalization the data were symmetrically 
distributed across the horizontal line y=0 (Figure 4-3), where M=log2R- log2G=0, which 
means all the data have been normalized to a reference RNA across all arrays. The 
assumption for the idea of the MA plot is that the majority of the genes would not change 
their expression; in that case you would expected to see most data points distributed 
tightly across the line where Y=0; the data points loosely distributed above or below the 
line y=0 are the probes that show differential expression compared to the reference RNA. 
Data from all the replicates were subjected to a correlation matrix analysis (Figure 4-4) 
and a principal component analysis (Figure 4-5). Sample 6 PAFE failed the initial QC 
(quality control) test. Sample 13 was identified as an outlier and removed from analysis. 
Thus, we were left with 4 biological replicates for each group.   The false discovery rate 
(FDR) method, suggested by Benjamini and Hochberg (Benjamini, Hochberg 1995) was 
used to identify differentially expressed genes in pair-wise comparisons. Finally with the 
FDR adjusted P value cutoff set at 0.05 there were 384 significantly changed probes 
comparing FRG1::EGFP with EGFP, among which 138 probes were significantly down 
regulated and 246 probes were significantly upregulated. These 384 differentially 
expresses probes (Table 4-1) corresponded to 161 genes with annotations and 223 genes 
without annotations.  The microarray expression results were validated by quantitative 
real-time RT-PCR (qRT-PCR) for 41 genes, including FRG1, using RNA from the 
original pools of muscle, yielding a 100% correlation with the microarray expression 
data.  We conclude that the expression microarray data is an accurate accounting of the 
mRNA expression levels. 
Annotation of X. laevis genes was performed by searching for their human 
homologs using the NCBI tBLASTx search program against the Human RefSeq database 
(Das, 2006). To identify over-represented gene ontology (GO), we performed Gene Set 
Enrichment Analysis.  The X. laevis genome is not fully sequenced; therefore it is not 
supported by an organism package in AnnotationDbi in Bioconductor. Therefore we used 
the GO terms of their homology with known human genes as prediction for the GO terms 
of Xenopus genes. Homology mapping was performed using the homology package for 
each organism in Biocondcutor (Figure 4-6).  Hypergeometric testing on GO terms was 
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performed to identify over-represented GO, including biological process, molecular 
function and cellular component.  Hypergeometric testing on KEGG terms was also 
performed to identify over-represented signaling pathways. A list of the GO terms that 
are statistically significant (p ≤ 0.05) can be found in Table 4-2, Table 4-3 and Table 4-4. 
A list of the signaling pathways that are statistically significant (p ≤ 0.05) can be found in 
Table 4-5.  
In addition to the above expression analysis, we also performed cross-species 
expression analysis to compare the expression profile of the FSHD-like Xenopus model 
to a published differential expression profile of FSHD patient samples. Specifically, we 
compared our data with expression profile of FSHD published by Osborne and colleagues 
(Osborne, 2007) because 1) The RNA samples were extracted from FSHD patient 
skeletal muscle, not a patient myoblast cell line; 2) the microarray platform used was the 
Affymetrix HG-U133A/B GeneChip arrays which include the genes of the whole human 
genome, not just skeletal muscle or heart muscle; it is well annotated, therefore easy for 
homology mapping, and 3) our Xenopus model shows FSHD-like phenotype in both 
skeletal muscle and vasculature, which is consistent with their finding that genes 
involved in vascular smooth muscle or endothelial cells are mis-regulated.  If 
overexpression of FRG1 leads to FSHD pathology, through cross-species analysis we 
predict that a similar expression pattern of the important genes that are mis-regulated in 
both FSHD-like Xenopus and human FSHD muscle biopsies would be found.  In 
addition, we predicted that important gene ontology and evolutionarily conserved 
signaling pathways that are involved in FSHD pathogenesis woul be identified.  The 
results are listed in Table 4-6.  
 
Discussion 
The goal of this gene expression analysis was to determine the global gene 
expression pattern in skeletal muscle from two-year old, FRG1 overexpressing, FSHD-
like Xenopus.   This data may provide additional insight into the biological role of FRG1 
by determining the long-term gene expression effects of FRG1 overexpression.  In 
addition, this data was used for a comparison with published gene expression data 
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obtained from FSHD patients to determine if long-term FRG1 overexpression 
recapitulates any aspects of the FSHD-specific muscle gene expression patterns.   
With the FDR adjusted p value cutoff at 0.05 there are 138 probes were 
significantly down regulated by overexpression of frg1 and 246 probes were significantly 
upregulated by overexpression of frg1, which correspond to 161 annotated Xenopus 
laevis genes. Among the list for down regulated genes were Xenopus laevis troponin C 
type 1 (slow) (tnnc1), alpha actin (MGC53823) (Table 4-1), whose decreased expression 
would be expected to lead to muscle atrophy and consistent with the FSHD-like 
phenotype. The hypergeometric test identified over represented GO terms involved in 
amino acid metabolism, mitochondria function and oxidative stress (Table 4-2, Table 4-3 
and Table 4-4), consistent with the fact that FSHD patient muscles show evidence of 
malfunction in mitochondria, oxidative stress-induced apoptosis, and muscle necrosis 
(Lefkowitz, 2005; Sandri, 2001; Slipetz, 1991).  The hypergeometric test for 
overrepresented signaling pathways identified several amino acid metabolism pathways 
(Table 4-5) and is consistent with the fact that FSHD patients have disrupted energy 
metabolism, variable size of muscle fibers and infiltration of fat tissue and connective 
tissues (Arahata, 1995; Lin, 1991). Interestingly we also found that components of the 
mitogen activated protein kinase (MAPK), including MAPKK6 (0.02-fold) and MAPK 
phosphatase 6 (0.02-fold), and Wnt signaling pathways were also perturbed by 
overexpression of FRG1 suggesting FRG1 may be involved in signal transduction.  
The Xenopus ortholog of the Wnt receptor Frizzled (xfz2) was upregulated 5.6-
fold.  As part of the Wnt signaling pathway the Frizzled receptor family is involved in 
angiogenesis and interestingly the FSHD-like Xenopus show vascular defects including 
tortuous veins and spurious angiogenesis (Masckauchan, 2006; Parmalee, 2008; 
Robitaille, 2002; Ye, 2009; Zerlin, 2008).  In addition, 50-70% of FSHD patients show 
retinal vascular abnormality and hearing loss (Brouwer, 1991; Gieron, 1985; Trevisan, 
2008; Yasukohchi, 1988). This phenotype is very similar to Coats’ disease, which is due 
to mutations in Norrin, the ligand for Frizzled-4 (Ye, 2009).  This similarity with Coats’ 
disease has lead to the postulation that FSHD is caused by defective Wnt signaling and is 
supported by this expression array data (Fitzsimons, 1987).  Thus, overexpression of 
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FRG1 may activate the non-canonical Wnt signaling pathway directly or indirectly, and 
cause abnormal transcription of genes that are involved in retinal vascular development.  
To determine if FSHD-like Xenopus generated by overexpression of FRG1 
showed similar altered expression patterns as those in FSHD patients, the Xenopus gene 
expression profile was compared with the gene expression profile specific to FSHD 
patient samples (Osborne, 2007).  First, the Xenopus genes were connected to their 
human homologs through their LocusLink ID using the homology package in 
Bioconductor resulting in 7021 human genes with Xenopus homologs.  In both FSHD 
patients and Xenopus overexpressing FRG1, genes involved in oxidative stress and 
apoptosis, such as p53, were upregulated. Other genes that showed a consistent 
differential expression pattern include mitochondrial solute carrier family 25, heat shock 
protein family DnaJ, and the RAS oncogene family.  The overlapping differential 
expression patterns between the expression profiles of the FSHD-like Xenopus and FSHD 
patients supports overexpression of FRG1 as being causal for FSHD pathogenesis and 
suggests that our frog model can provide insights for human FSHD pathogenesis. 
However, there are non-overlapping differential expression patterns between the Xenopus 
and human arrays which may be due to background non-specific changes, or species 
differences.  For example, changing the expression of a gene such as FRG1 in an animal 
model likely affects many systems and other genes’ expression including those that have 
nothing to do with the FSHD-like phenotype. However, only a small fraction of genes 
likely contribute to the FSHD-like phenotype. These genes predicted to be conserved 
between the different species showing similar phenotypes.  One drawback is that it is not 
clear that FSHD is caused by overexpression of FRG1 so this initial study primarly tests 
if human FSHD patient muscle resembles Xenopus FSHD-like muscle at the gene 
expression level.  The following study using similarly generated FSHD-like Drosophila 
is needed to sort out expression changes specific for the conserved FRG1-directed gene 
expression changes producing the FSHD-like phenotype.   
In conclusion, the expression profile of our Xenopus model for human FSHD 
supports FRG1 as a candidate gene for FSHD pathogenesis. Increase of FRG1 protein 
level in skeletal muscle causes malfunction of mitochondria, impaired muscle 
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differentiation, oxidative stress and misregulation of canonical signaling pathways that 
together could explain both the muscular and the vascular aspects of FSHD pathology.  
 
Expression profile of flightless FSHD-like Drosophila 
Introduction, Experimental Rationale, and Design  
FRG1 is evolutionarily highly conserved from invertebrate to vertebrate (see 
Chapter 1).  Transgenic lines of Drosophila melanogaster containing the cDNA for 
Drosophila FRG1 homolog (CG6480) under control of the GAL4 upstream activating 
sequence were generated.  When these homozygous flies were mated with flies carrying 
the homozygous GAL4 driver for expression in the adult thorax (strain #8171), the 
resulting offspring gradually lost the ability to fly within five to ten days of hatching.  
Histological analysis of the muscle supports these as a model for muscular dystrophy (T. 
Jones, manuscript in preparation).  Two days after hatching, 3 groups of 100 animals for 
each genotype were processed and total RNA was extracted from their thoraxes, which 
consist mainly of striated muscle, resulting in 3 biological replicates for both the strain 
8171 GAL4 control group and the 8171 + FRG1 experimental group.  The RNA was 
DNase treated, further purified by RNA Easy kit (Qiagen), and the integrity of the RNAs 
determined by Bioanalyzer.  These RNAs were used for whole genome expression 
analysis with the Affymetrix Drosophila 3’ expression GeneChip 2.0 microarray 
platform.  The RNA labeling, array hybridization and array scanning were carried out by 
the Keck Center for Comparative and Functional Genomics at UIUC using standard 
Affymetrix reagents and protocols. 
 
Results 
Raw data from all of the array replicates were checked for outliers and 
normalized. Briefly, logarithm base 2 transformed raw data were visualized in a density 
plot and quality of the RNA samples visualized by an RNA degradation plot (Figure 4-7). 
There were 14 probe pairs in each probe set that were ordered from 5’ to 3’ on the x-axis.  
The average intensity for each probe pair was calculated and labeled on the y-axis.  RNA 
degradation starts from the 5’ end; therefore one would expect to see positive slopes for 
all arrays.  All of the arrays showed similar slopes, and the difference of intensity 
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between 5’ and 3’ was not dramatic. We concluded that there was no RNA degradation or 
outliers in our samples.  GCRMA (GeneChip Robust Multi-array Average) normalization 
was then performed for all arrays (Lim, 2007). GCRMA involves three steps: 1) 
background adjustment for optical noise, probe affinity and mismatch (MM) probe pairs, 
2) quantile normalization, and 3) summarization by median polish (Wu, et al, 2004).  
Normalized data were visualized by density plot and scatterplot matrix (Figure 4-8). 
Principal component analysis was performed for normalized data and two groups were 
separated in two-dimensional spaces by plotting the first two principal components 
(Figure 4-9). With the FDR adjusted p value cutoff at ≤0.05 we identified 14 probe sets 
that were down regulated and 35 probe sets that were up-regulated when comparing 
FRG1 overexpression animals with the GAL4 8171 driver line alone animals (Table 4-7). 
Hierarchical cluster analysis was performed for differentially expressed genes. Five 
clusters were identified with a height cutoff at 6 and labeled on a scaled heatmap with 
different colors (Figure 4-10).  The published human FSHD microarray data indicated 
that in FSHD the differentially expressed genes were not enriched on Chromosome 4 but 
distributed globally on all chromosomes (Osborne, 2007). Similarly, the Drosophila 
chromosome location map shows that the differentially expressed genes were distributed 
on all chromosomes indicating overexpresion of FRG1 affected gene expression across 
the genome (Figure 4-11).  The annotation data file is available on Affymetrix website. 
Similarly, hypergeometric testing on GO terms was performed to identify over 
represented GOs including biological process, molecular function and cellular 
component. Hypergeometric testing on KEGG terms was also performed to identify over 
represented signaling pathways. A list of the GO terms that are statistically significant (p 
≤ 0.05) or less can be found in Table2-4.  A list of the signaling pathways that are 
statistically significant (p ≤ 0.05) is found in Table 5.  
 
Discussion 
The purpose of these Drosophila gene expression studies is two-fold.  First, 
determining the gene expression changes in FRG1 overexpressing FSHD-like flies will 
provide insight into FRG1’s biological role and how overexpression of FRG1 leads to the 
flightless phenotype.  Secondly, these results, when combined with the FSHD-like 
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Xenopus expression data and compared with the FSHD patient expression data, will help 
determine the viability of persuing FRG1 as mediating the FSHD patient phenotype.  The 
rationale being that although previous data shows that overexpression of FRG1 in fly and 
frog gives similar histological and physiological effects as seen in FSHD patients, the 
mechanisms could be different and unrelated; however, if the gene expression profiles 
overlap from such diverse species, it would lend strong support for FRG1 as mediating 
FSHD pathophysiology.  
A total of six arrays with three biological replicates for each of two treatment 
groups (control, 8171 and FSHD-like, 8171-FRG1) were analyzed. All these arrays 
passed quality control and showed no RNA degradation. After GCRMA normalization 
data were visualized in density plot, scatter plot matrix, principal component analysis, 
hierarchical cluster and heatmap. With FDR adjusted p value cut off at ≤0.05 we 
identified 49 differentially expressed probe sets, corresponding to 33 unique Entrez IDs 
(TABLE 4-7).  Gene set enrichment analysis identified both common and unique over-
represented GO terms between FSHD-like Xenopus and Drosophila with biological 
process, mitochondrial function and metabolic process over-represented in both species. 
What is unique for Drosophila was the involvement of the organelles such as the 
endoplasmic reticulum (ER) and the Golgi.  For over-represented cellular component, 
mitochondrial components and cell surface components were shown in both Drosophila 
and Xenopus.  For over-represented molecular function, genes involved in oxidative 
stress, such as superoxide dismutase and cytochrome c reductase, were found in FSHD-
like Drosophila.  Thus, oxidative stress was identified in both animal models for FSHD 
as well as FSHD patients (Osborne, 2007).  For the signaling pathway analysis, the Notch 
signaling pathway was over represented.  In particular, the Drosophila gene pen-2, or 
presenilin enhancer, a molecule in the Notch signaling pathway, was down regulated in 
the animals overexpressing FRG1.  
The core components of the Notch signaling pathway are evolutionarily 
conserved from C. elegans, to Drosophila, to mammals. C. elegans has two Notch 
proteins: LIN-12 and GLP-1, which are type I transmembrane protein. Both proteins are 
functionally redundant. There are three cleavage sites in LIN-12/Notch. Vertebrate Notch 
is cleaved by furin at the first cleavage site and there is evidence that this may also be 
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true for C. elegans. For C. elegans and Drosophila, ligand binding triggers the cleavage 
at site 2 and releases the extracellular domain, which triggers γ-secretase cleavage at site 
3 and releases the intracellular domain. Genetic screening in C. elegans identified three 
molecular components in the protein complex for site 3 cleavage. The Pen-2 protein 
binds to this complex and enhances γ-secretase activity (Greenwald, 2005). The 
activation of Notch signaling enhances β-integrin affinity for its ligand, which results in 
increases of vascular endothelial cell adhesion.  Thus, Notch signaling has a critical role 
in the vascular system (Karsan, 2008).  Our study of FRG1 in C. elegans showed that 
FRG1 is localized in dense bodies, a structure associated with integrin complex.  
Overexpression of FRG1 in Drosophila results in down regulation of pen-2, a molecular 
component in Notch signaling pathway. It indicates that FRG1 could be involved in 
regulation of vascular development through affecting the Notch signaling pathway in 
vertebrates.  
A cross-species analysis between human, FSHD patient specific expression and 
the FSHD-like Drosophila specific expression was performed. However, the analysis was 
quite limited since only 15 Drosophila genes from the FHSD-like specific expression list 
have a clear human homolog.  This resulted in only one gene, cytochrome C reductase, 
being differentially expressed in both FSHD-like Drosophila and the FSHD patient 
microarray. Overall, what is common among the FSHD-like Drosophila, Xenopus, and 
human patients is oxidative stress, mitochondria malfunction and energy metabolism.  
Together, these data further support a role for FRG1 in FSHD pathophysiology but are 
not conclusive. 
 
Cross talk between Notch and Wnt signaling pathway 
Due to its high similarities with Coat’s Disease, aberrant signaling has long been 
proposed to be a part of FSHD pathophysiology (Fitzsimons, 1987).  The Wnt and Notch 
signaling pathways have critical roles during early development. Wnt signaling interacts 
with many other signaling pathways, among which Wnt has consistent interaction with 
Notch signaling.  The interaction between Wnt and Notch signaling was first identified in 
Drosophila wing development. In Drosophila, the pre-patterning is mediated by Wnt and 
later inhibited by Notch signaling. These two signals are used iteratively for wing 
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formation, which is very sensitive to the dosage of Wnt and Notch. In this event Wnt 
signaling activates Notch signaling and they are mutually dependent (Brennan, 1999a; 
Brennan, 1999b).  The loss of Notch can rescue the loss of Wnt phenotype. Other studies 
show that these two signaling pathways also interact in an antagonistic manner. Loss-of –
function of Notch results in increases of Wnt signaling. Studies in Drosophila identified 
Armadillo, the homolog of vertebrate β-catenin, as a target for Notch in mediating the 
interaction with Wnt signaling (Hayward, 2008).  
Other molecules that mediate the interaction between Wnt and Notch are the 
presenilins (PSs). Presenilins are part of the protein complex that cleaves site 3 in Notch 
and β-amyloid precursor protein (APP). PS1 functions as a negative regulator of the 
Wnt/β-catenin signaling pathway. PS1 can bind GSK3β and enhance phosphorylation of 
β-catenin. Studies also show that PS1 is need for ubiquitination of β-catenin. Both 
machineries increase the degradation of β-catenin and down regulate the Wnt signaling 
pathway (De Strooper, 2001). Studies also show that Wnt regulates retinal stem cell 
proliferation and differentiation with Notch signaling pathway (Das, 2008). In our 
expression profile of animal models of FSHD, overexpression of FRG1 increases the 
expression of xfz2, a cell surface receptor of Wnt signaling pathway, in Xenopus; 
meanwhile, overexpression of FRG1 decreases the expression of pen-2, a presenilin 
enhancer in Notch signaling pathway, in Drosophila. Our data support that FRG1 
potentially affects signaling these signaling pathways and changes in FRG1 expression 
levels would perturb the canonical Wnt and Notch signaling pathways.  If FRG1 were to 
be determined to mediate FSHD patholphysiology, the FRG1-mediated changes to the 
Wnt and Notch singlaing pathways described here could help to explain why 50-70% of 
FSHD patients also have retinal vasculopathy and hearing loss.   
In summary, FRG-1 is part of a vital, conserved muscle structure associated with 
many myopathies. Our animal models for human FSHD support FRG1 as the leading 
candidate gene for FSHD pathogenesis. Each animal model has its own advantages, 
through cross-species expression analysis we were able to identify the evolutionarily 
conserved molecules and signaling pathways affected by FRG1 overexpression and 
potentially involved in FSHD disease pathology.  
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Figure  4-1. 
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c)                      
 
Figure  4-1 (Continued). 
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Figure  4-1 (Continued). Check outlier after normalization. a) Boxplot, b) density 
plot, c) principal component analysis, which indicates that sample 13 (rename to 
“outlier”) is an outlier; d) Scatterplot matrix. Sample 13 (outlier) shows weak correlation 
with other biological replicates.  
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a) 
 
b) 
 
Figure 4-2. a) Box plot and b) density plot for normalized data after removing 
outlier (FRG1EGFP13).   
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Figure 4-3. MA plot for normalized data.  
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Figure 4-4. Scatter plot matrix for normalized data.  
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a) 
 
b) 
 
Figure 4-5. Principal component analysis for normalized data. a) Screen plot and b) 
plot for the first two PCs.  
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Figure 4-6. Work flow for mapping Xenopus genes to their human homolog.  
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Figure 4-7.  a) Density plot and b) RNA degradation plot for raw data.  
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a) 
 
b) 
 
Figure 4-8. Density plot (a) and scatterplot matrix (b) after GCRMA normalization. 
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Figure 4-9. Principal component analysis after normalization.  
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a) 
 
Figure 4-10. 
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b) 
 
Figure 4-10 (Continued). a) Hierarchical cluster and b) Scaled heatmap for 
differentially expressed probes.  
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a) 
 
b) 
 
 
Figure 4-11. Chromosome location map. a) Chromosome location map for 
differentially expressed genes in Drosophila model of human FSHD (Xia) comparing 
with b) published human chromosomal position genes that are mis-regulated in FSHD 
patient samples (Osborne, 2007). FRG1 is highlighted in green in Drosophila 
chromosome location map in a).  
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Table 4-1. Differentially expressed probes with FDR adjusted P value cut off at 0.05. 
ProbeName GeneName SystematicName Description logFC t P.Value adj.P.Val 
A_10_P003064 abhd1 NM_001087032 ref|Xenopus laevis 
abhydrolase domain 
containing 3 (abhd1), mRNA 
[NM_001087032] 
1.652376 8.107908 1.72E-06 0.018476 
A_10_P003064 abhd1 NM_001087032 ref|Xenopus laevis 
abhydrolase domain 
containing 3 (abhd1), mRNA 
[NM_001087032] 
1.640446 7.963406 2.10E-06 0.018476 
A_10_P017778 MGC132191 NM_001096657 ref|Xenopus laevis 
hypothetical protein 
MGC132191 (MGC132191), 
mRNA [NM_001096657] 
-1.26154 -7.93646 2.18E-06 0.018476 
A_10_P003524 MGC69006 NM_001086397 ref|Xenopus laevis 
hypothetical protein 
MGC69006 (MGC69006), 
mRNA [NM_001086397] 
1.275345 7.891387 2.32E-06 0.018476 
A_10_P009054 FKBP1B BC086462 gb|Xenopus laevis similar to 
FK506 binding protein 1B, 
12.6 kDa, mRNA (cDNA 
clone MGC:98316 
IMAGE:7008517), complete 
cds [BC086462] 
-1.61276 -7.88309 2.34E-06 0.018476 
A_10_P003524 MGC69006 NM_001086397 ref|Xenopus laevis 
hypothetical protein 
MGC69006 (MGC69006), 
mRNA [NM_001086397] 
1.283452 7.757747 2.80E-06 0.018476 
A_10_P017778 MGC132191 NM_001096657 ref|Xenopus laevis 
hypothetical protein 
MGC132191 (MGC132191), 
mRNA [NM_001096657] 
-1.23648 -7.72935 2.91E-06 0.018476 
A_10_P009054 FKBP1B BC086462 gb|Xenopus laevis similar to 
FK506 binding protein 1B, 
12.6 kDa, mRNA (cDNA 
clone MGC:98316 
IMAGE:7008517), complete 
cds [BC086462] 
-1.57813 -7.58115 3.60E-06 0.019984 
A_10_P025484 A_10_P0254
84 
A_10_P025484 Unknown 1.597692 7.391029 4.74E-06 0.022998 
A_10_P020801 LOC733275 BX855294 gb|BX855294 Wellcome 
CRC pSK egg Xenopus laevis 
cDNA clone 
IMAGp998A228239 ; 
IMAGE:3377565 5', mRNA 
sequence [BX855294] 
1.233962 7.241953 5.91E-06 0.022998 
A_10_P003089 MGC53832 NM_001086196 ref|Xenopus laevis similar to 
fatty acid Coenzyme A ligase 
(MGC53832), mRNA 
[NM_001086196] 
1.600244 7.120914 7.08E-06 0.022998 
A_10_P003089 MGC53832 NM_001086196 ref|Xenopus laevis similar to 
fatty acid Coenzyme A ligase 
(MGC53832), mRNA 
[NM_001086196] 
1.595419 7.090616 7.41E-06 0.022998 
A_10_P010970 LOC1000372
06 
NM_001097895 ref|Xenopus laevis 
hypothetical protein 
LOC100037206 
(LOC100037206), mRNA 
[NM_001097895] 
2.083197 7.05659 7.80E-06 0.022998 
A_10_P025484 A_10_P0254
84 
A_10_P025484 Unknown 1.587771 7.055748 7.81E-06 0.022998 
A_10_P020801 LOC733275 BX855294 gb|BX855294 Wellcome 
CRC pSK egg Xenopus laevis 
cDNA clone 
IMAGp998A228239 ; 
IMAGE:3377565 5', mRNA 
sequence [BX855294] 
1.253835 7.0327 8.08E-06 0.022998 
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Table 4-1. Differentially expressed probes with FDR adjusted P value cut off at 0.05 
(Continued). 
 
ProbeName GeneName SystematicName Description logFC t P.Value adj.P.Val 
A_10_P010970 LOC1000372
06 
NM_001097895 ref|Xenopus laevis 
hypothetical protein 
LOC100037206 
(LOC100037206), mRNA 
[NM_001097895] 
1.906395 6.946407 9.21E-06 0.022998 
A_10_P002833 hccs-a NM_001087111 ref|Xenopus laevis 
holocytochrome c synthase 
(cytochrome c heme-lyase) 
(hccs-a), mRNA 
[NM_001087111] 
1.346418 6.878529 1.02E-05 0.022998 
A_10_P003088 MGC53823 NM_001086195 ref|Xenopus laevis similar to 
actin alpha (MGC53823), 
mRNA [NM_001086195] 
-2.00595 -6.85986 1.05E-05 0.022998 
A_10_P004260 MGC83094 NM_001091086 ref|Xenopus laevis 
hypothetical protein 
MGC83094 (MGC83094), 
mRNA [NM_001091086] 
1.299662 6.848954 1.07E-05 0.022998 
A_10_P006829 mrpl15 NM_001093374 ref|Xenopus laevis 
mitochondrial ribosomal 
protein L15 (mrpl15), nuclear 
gene encoding mitochondrial 
protein, mRNA 
[NM_001093374] 
1.238711 6.758114 1.23E-05 0.022998 
A_10_P008275 LOC494792 NM_001094625 ref|Xenopus laevis 
hypothetical LOC494792 
(LOC494792), mRNA 
[NM_001094625] 
-1.15734 -6.75299 1.24E-05 0.022998 
A_10_P008377 MGC81921 NM_001096791 ref|Xenopus laevis DNA-
dependent protein kinase 
catalytic subunit-interacting 
protein 2 (MGC81921), 
mRNA [NM_001096791] 
-1.86512 -6.74713 1.25E-05 0.022998 
A_10_P002833 hccs-a NM_001087111 ref|Xenopus laevis 
holocytochrome c synthase 
(cytochrome c heme-lyase) 
(hccs-a), mRNA 
[NM_001087111] 
1.406968 6.735119 1.27E-05 0.022998 
A_10_P003088 MGC53823 NM_001086195 ref|Xenopus laevis similar to 
actin alpha (MGC53823), 
mRNA [NM_001086195] 
-1.98803 -6.69446 1.36E-05 0.022998 
A_10_P003317 mrps17 NM_001087434 ref|Xenopus laevis 
mitochondrial ribosomal 
protein S17 (mrps17), nuclear 
gene encoding mitochondrial 
protein, mRNA 
[NM_001087434] 
1.611153 6.638337 1.48E-05 0.022998 
A_10_P008893 LOC495431 NM_001095086 ref|Xenopus laevis 
hypothetical LOC495431 
(LOC495431), mRNA 
[NM_001095086] 
1.559182 6.631072 1.50E-05 0.022998 
A_10_P004260 MGC83094 NM_001091086 ref|Xenopus laevis 
hypothetical protein 
MGC83094 (MGC83094), 
mRNA [NM_001091086] 
1.282291 6.595678 1.58E-05 0.022998 
A_10_P001921 TC412584 TC412584 tc|Rep: GCN1-like protein 1 
(HsGCN1). - Xenopus 
tropicalis, partial (5%) 
[TC412584] 
1.951275 6.566334 1.66E-05 0.022998 
A_10_P026983 xrp1 NM_001090558 ref|Xenopus laevis 
ribonucleoprotein (xrp1), 
mRNA [NM_001090558] 
1.30556 6.564694 1.66E-05 0.022998 
A_10_P002829 gamt NM_001087223 ref|Xenopus laevis 
Guanidinoacetate 
-1.62669 -6.55567 1.69E-05 0.022998 
 109
Table 4-1. Differentially expressed probes with FDR adjusted P value cut off at 0.05 
(Continued). 
 
ProbeName GeneName SystematicName Description logFC t P.Value adj.P.Val 
methyltransferase (gamt), 
mRNA [NM_001087223] 
A_10_P026983 xrp1 NM_001090558 ref|Xenopus laevis 
ribonucleoprotein (xrp1), 
mRNA [NM_001090558] 
1.388233 6.540268 1.73E-05 0.022998 
A_10_P006829 mrpl15 NM_001093374 ref|Xenopus laevis 
mitochondrial ribosomal 
protein L15 (mrpl15), nuclear 
gene encoding mitochondrial 
protein, mRNA 
[NM_001093374] 
1.273759 6.539668 1.73E-05 0.022998 
A_10_P014005 DR725919 DR725919 gb|AGENCOURT_54828067 
NICHD_XGC_Emb10 
Xenopus laevis cDNA clone 
IMAGE:7980097 5', mRNA 
sequence [DR725919] 
0.953545 6.531513 1.75E-05 0.022998 
A_10_P025742 CK798956 CK798956 gb|AGENCOURT_18790172 
NICHD_XGC_Te2N 
Xenopus laevis cDNA clone 
IMAGE:7202559 5', mRNA 
sequence [CK798956] 
1.507628 6.526272 1.77E-05 0.022998 
A_10_P025512 A_10_P0255
12 
A_10_P025512 Unknown 1.323948 6.509697 1.81E-05 0.022998 
A_10_P002829 gamt NM_001087223 ref|Xenopus laevis 
Guanidinoacetate 
methyltransferase (gamt), 
mRNA [NM_001087223] 
-1.56932 -6.44343 2.01E-05 0.024207 
A_10_P004441 MGC82231 NM_001091511 ref|Xenopus laevis 
hypothetical protein 
MGC82231 (MGC82231), 
mRNA [NM_001091511] 
0.830553 6.43532 2.04E-05 0.024207 
A_10_P005855 MGC83592 NM_001092537 ref|Xenopus laevis 
MGC83592 protein 
(MGC83592), mRNA 
[NM_001092537] 
-1.37395 -6.3978 2.16E-05 0.024207 
A_10_P020086 BX847608 BX847608 gb|BX847608 Wellcome 
CRC pRN3 oocyte Xenopus 
laevis cDNA clone 
IMAGp998I028394 ; 
IMAGE:3437257 5', mRNA 
sequence [BX847608] 
1.136906 6.366866 2.27E-05 0.024207 
A_10_P005504 MGC80625 NM_001092264 ref|Xenopus laevis 
MGC80625 protein 
(MGC80625), mRNA 
[NM_001092264] 
-1.17889 -6.36521 2.28E-05 0.024207 
A_10_P008275 LOC494792 NM_001094625 ref|Xenopus laevis 
hypothetical LOC494792 
(LOC494792), mRNA 
[NM_001094625] 
-1.126 -6.35649 2.31E-05 0.024207 
A_10_P024932 CF287106 CF287106 gb|AGENCOURT_15182019 
NICHD_XGC_Emb4 
Xenopus laevis cDNA clone 
IMAGE:5514169 5', mRNA 
sequence [CF287106] 
-1.028 -6.32298 2.44E-05 0.024207 
A_10_P003245 MGC64256 NM_001086254 ref|Xenopus laevis cardiac 
troponin C (MGC64256), 
mRNA [NM_001086254] 
-1.2485 -6.29378 2.56E-05 0.024207 
A_10_P008893 LOC495431 NM_001095086 ref|Xenopus laevis 
hypothetical LOC495431 
(LOC495431), mRNA 
[NM_001095086] 
1.564097 6.272806 2.65E-05 0.024207 
 110
Table 4-1. Differentially expressed probes with FDR adjusted P value cut off at 0.05 
(Continued). 
 
ProbeName GeneName SystematicName Description logFC t P.Value adj.P.Val 
A_10_P003194 dj462o23.2 NM_001086912 ref|Xenopus laevis 
hypothetical protein 
MGC53912 (dj462o23.2), 
mRNA [NM_001086912] 
-1.11066 -6.23497 2.81E-05 0.024207 
A_10_P002909 MGC64447 NM_001086350 ref|Xenopus laevis 
hypothetical protein 
MGC64447 (MGC64447), 
mRNA [NM_001086350] 
1.332887 6.22635 2.85E-05 0.024207 
A_10_P003477 oxnad1 NM_001086375 ref|Xenopus laevis 
oxidoreductase NAD-binding 
domain-containing protein 1 
(oxnad1), mRNA 
[NM_001086375] 
1.638459 6.213673 2.91E-05 0.024207 
A_10_P003317 mrps17 NM_001087434 ref|Xenopus laevis 
mitochondrial ribosomal 
protein S17 (mrps17), nuclear 
gene encoding mitochondrial 
protein, mRNA 
[NM_001087434] 
1.608521 6.205007 2.95E-05 0.024207 
A_10_P002909 MGC64447 NM_001086350 ref|Xenopus laevis 
hypothetical protein 
MGC64447 (MGC64447), 
mRNA [NM_001086350] 
1.342354 6.192797 3.01E-05 0.024207 
A_10_P004180 chchd4a NM_001091201 ref|Xenopus laevis coiled-
coil-helix-coiled-coil-helix 
domain containing 4 
(chchd4a), nuclear gene 
encoding mitochondrial 
protein, mRNA 
[NM_001091201] 
1.610472 6.188208 3.03E-05 0.024207 
A_10_P001427 TC387057 TC387057 tc|Rep: CG41561-PA - 
Drosophila melanogaster 
(Fruit fly), partial (6%) 
[TC387057] 
-1.01864 -6.18377 3.06E-05 0.024207 
A_10_P006325 MGC84451 NM_001092934 ref|Xenopus laevis 
MGC84451 protein 
(MGC84451), mRNA 
[NM_001092934] 
-1.15106 -6.16303 3.16E-05 0.024207 
A_10_P006325 MGC84451 NM_001092934 ref|Xenopus laevis 
MGC84451 protein 
(MGC84451), mRNA 
[NM_001092934] 
-1.14026 -6.14734 3.24E-05 0.024207 
A_10_P020086 BX847608 BX847608 gb|BX847608 Wellcome 
CRC pRN3 oocyte Xenopus 
laevis cDNA clone 
IMAGp998I028394 ; 
IMAGE:3437257 5', mRNA 
sequence [BX847608] 
1.086457 6.14361 3.26E-05 0.024207 
A_10_P020378 BX850617 BX850617 gb|BX850617 
NICHD_XGC_Sp1 Xenopus 
laevis cDNA clone 
IMAGp998M1210939 ; 
IMAGE:4964915 5', mRNA 
sequence [BX850617] 
1.043172 6.135122 3.31E-05 0.024207 
A_10_P002490 MGC53103 NM_001086017 ref|Xenopus laevis similar to 
prohibitin (MGC53103), 
mRNA [NM_001086017] 
1.001181 6.129325 3.34E-05 0.024207 
A_10_P021303 MGC115435 NM_001096575 ref|Xenopus laevis 
hypothetical protein 
MGC115435 (MGC115435), 
mRNA [NM_001096575] 
1.238858 6.121483 3.38E-05 0.024207 
A_10_P003194 dj462o23.2 NM_001086912 ref|Xenopus laevis 
hypothetical protein 
-1.17202 -6.1101 3.45E-05 0.024207 
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Table 4-1. Differentially expressed probes with FDR adjusted P value cut off at 0.05 
(Continued). 
 
ProbeName GeneName SystematicName Description logFC t P.Value adj.P.Val 
MGC53912 (dj462o23.2), 
mRNA [NM_001086912] 
A_10_P026576 CV077028 CV077028 gb|AGENCOURT_31443090 
NICHD_XGC_Te2 Xenopus 
laevis cDNA clone 
IMAGE:7391561 5', mRNA 
sequence [CV077028] 
1.005973 6.106757 3.46E-05 0.024207 
A_10_P022926 CB564765 CB564765 gb|AGENCOURT_13325038 
NICHD_XGC_Tad2 Xenopus 
laevis cDNA clone 
IMAGE:6875760 3', mRNA 
sequence [CB564765] 
2.419269 6.093842 3.54E-05 0.024207 
A_10_P014529 BJ084667 BJ084667 gb|BJ084667 NIBB Mochii 
normalized Xenopus tailbud 
library Xenopus laevis cDNA 
clone XL100b04 3', mRNA 
sequence [BJ084667] 
-0.84751 -6.0911 3.55E-05 0.024207 
A_10_P017794 BQ730684 BQ730684 gb|AGENCOURT_8216611 
NICHD XGC Emb4 Xenopus 
laevis cDNA clone 
IMAGE:4930104 5', mRNA 
sequence [BQ730684] 
0.986257 6.087739 3.57E-05 0.024207 
A_10_P004180 chchd4a NM_001091201 ref|Xenopus laevis coiled-
coil-helix-coiled-coil-helix 
domain containing 4 
(chchd4a), nuclear gene 
encoding mitochondrial 
protein, mRNA 
[NM_001091201] 
1.555466 6.085896 3.58E-05 0.024207 
A_10_P005855 MGC83592 NM_001092537 ref|Xenopus laevis 
MGC83592 protein 
(MGC83592), mRNA 
[NM_001092537] 
-1.32512 -6.08335 3.60E-05 0.024207 
A_10_P024932 CF287106 CF287106 gb|AGENCOURT_15182019 
NICHD_XGC_Emb4 
Xenopus laevis cDNA clone 
IMAGE:5514169 5', mRNA 
sequence [CF287106] 
-0.99153 -6.08258 3.60E-05 0.024207 
A_10_P008273 chchd4b NM_001094623 ref|Xenopus laevis coiled-
coil-helix-coiled-coil-helix 
domain containing 4 
(chchd4b), nuclear gene 
encoding mitochondrial 
protein, mRNA 
[NM_001094623] 
1.653803 6.073394 3.66E-05 0.024207 
A_10_P025512 A_10_P0255
12 
A_10_P025512 Unknown 1.283879 6.04884 3.81E-05 0.024207 
A_10_P009566 MGC99219 NM_001095834 ref|Xenopus laevis 
hypothetical protein 
MGC99219 (MGC99219), 
mRNA [NM_001095834] 
0.86247 6.041347 3.86E-05 0.024207 
A_10_P007536 MGC81821 NM_001094019 ref|Xenopus laevis 
MGC81821 protein 
(MGC81821), mRNA 
[NM_001094019] 
-0.96815 -6.03504 3.90E-05 0.024207 
A_10_P007147 hadh2 NM_001093599 ref|Xenopus laevis 
hydroxyacyl-Coenzyme A 
dehydrogenase, type II 
(hadh2), mRNA 
[NM_001093599] 
1.344353 6.03242 3.91E-05 0.024207 
A_10_P008639 bhmt NM_001094947 ref|Xenopus laevis betaine--
homocysteine S-
methyltransferase 1 (bhmt), 
-1.52625 -6.02209 3.98E-05 0.024207 
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Table 4-1. Differentially expressed probes with FDR adjusted P value cut off at 0.05 
(Continued). 
 
ProbeName GeneName SystematicName Description logFC t P.Value adj.P.Val 
mRNA [NM_001094947] 
A_10_P008670 LOC495209 NM_001094895 ref|Xenopus laevis 
hypothetical LOC495209 
(LOC495209), mRNA 
[NM_001094895] 
1.910997 6.01587 4.02E-05 0.024207 
A_10_P004441 MGC82231 NM_001091511 ref|Xenopus laevis 
hypothetical protein 
MGC82231 (MGC82231), 
mRNA [NM_001091511] 
0.801652 6.010151 4.06E-05 0.024207 
A_10_P008377 MGC81921 NM_001096791 ref|Xenopus laevis DNA-
dependent protein kinase 
catalytic subunit-interacting 
protein 2 (MGC81921), 
mRNA [NM_001096791] 
-1.7944 -6.00699 4.08E-05 0.024207 
A_10_P001921 TC412584 TC412584 tc|Rep: GCN1-like protein 1 
(HsGCN1). - Xenopus 
tropicalis, partial (5%) 
[TC412584] 
1.652973 6.005857 4.09E-05 0.024207 
A_10_P020351 MGC154884 NM_001096945 ref|Xenopus laevis 
hypothetical protein 
MGC154884 (MGC154884), 
mRNA [NM_001096945] 
1.588491 5.994683 4.16E-05 0.02423 
A_10_P001964 LOC1001583
66 
NM_001127811 ref|Xenopus laevis 
hypothetical protein 
LOC100158366 
(LOC100158366), mRNA 
[NM_001127811] 
-1.28486 -5.98079 4.26E-05 0.02423 
A_10_P006532 MGC78962 NM_001093160 ref|Xenopus laevis 
MGC78962 protein 
(MGC78962), mRNA 
[NM_001093160] 
-0.73949 -5.96175 4.40E-05 0.02423 
A_10_P003245 MGC64256 NM_001086254 ref|Xenopus laevis cardiac 
troponin C (MGC64256), 
mRNA [NM_001086254] 
-1.17886 -5.9603 4.41E-05 0.02423 
A_10_P008639 bhmt NM_001094947 ref|Xenopus laevis betaine--
homocysteine S-
methyltransferase 1 (bhmt), 
mRNA [NM_001094947] 
-1.50992 -5.95932 4.42E-05 0.02423 
A_10_P021303 MGC115435 NM_001096575 ref|Xenopus laevis 
hypothetical protein 
MGC115435 (MGC115435), 
mRNA [NM_001096575] 
1.21966 5.931631 4.62E-05 0.02423 
A_10_P007335 MGC85462 NM_001093864 ref|Xenopus laevis 
MGC85462 protein 
(MGC85462), mRNA 
[NM_001093864] 
0.876932 5.930042 4.63E-05 0.02423 
A_10_P002490 MGC53103 NM_001086017 ref|Xenopus laevis similar to 
prohibitin (MGC53103), 
mRNA [NM_001086017] 
0.98414 5.925391 4.67E-05 0.02423 
A_10_P009415 MGC85151 NM_001095753 ref|Xenopus laevis 
hypothetical protein 
MGC85151 (MGC85151), 
mRNA [NM_001095753] 
1.254265 5.925369 4.67E-05 0.02423 
A_10_P000505 PDCD9 NM_001088690 ref|Xenopus laevis PDCD9 
protein (PDCD9), mRNA 
[NM_001088690] 
1.01008 5.918745 4.72E-05 0.02423 
A_10_P015868 BJ643499 BJ643499 gb|BJ643499 NIBB Mochii 
normalized Xenopus early 
gastrula library Xenopus 
laevis cDNA clone XL217e08 
3', mRNA sequence 
[BJ643499] 
-1.05978 -5.91711 4.74E-05 0.02423 
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Table 4-1. Differentially expressed probes with FDR adjusted P value cut off at 0.05 
(Continued). 
 
ProbeName GeneName SystematicName Description logFC t P.Value adj.P.Val 
A_10_P000505 PDCD9 NM_001088690 ref|Xenopus laevis PDCD9 
protein (PDCD9), mRNA 
[NM_001088690] 
0.948076 5.915624 4.75E-05 0.02423 
A_10_P001427 TC387057 TC387057 tc|Rep: CG41561-PA - 
Drosophila melanogaster 
(Fruit fly), partial (6%) 
[TC387057] 
-0.98298 -5.90873 4.80E-05 0.024231 
A_10_P009020 LOC495682 NM_001095161 ref|Xenopus laevis 
hypothetical LOC495682 
(LOC495682), mRNA 
[NM_001095161] 
1.084127 5.873295 5.09E-05 0.02523 
A_10_P009335 LOC496326 NM_001095480 ref|Xenopus laevis 
hypothetical LOC496326 
(LOC496326), mRNA 
[NM_001095480] 
1.902792 5.86564 5.16E-05 0.02523 
A_10_P007147 hadh2 NM_001093599 ref|Xenopus laevis 
hydroxyacyl-Coenzyme A 
dehydrogenase, type II 
(hadh2), mRNA 
[NM_001093599] 
1.356175 5.857466 5.23E-05 0.02523 
A_10_P008941 Xubc14 BC085030 gb|Xenopus laevis cDNA 
clone MGC:97892 
IMAGE:7008714, complete 
cds [BC085030] 
0.752262 5.856397 5.24E-05 0.02523 
A_10_P001964 LOC1001583
66 
NM_001127811 ref|Xenopus laevis 
hypothetical protein 
LOC100158366 
(LOC100158366), mRNA 
[NM_001127811] 
-1.28543 -5.85062 5.29E-05 0.02523 
A_10_P016369 LOC1001583
93 
NM_001127837 ref|Xenopus laevis 
hypothetical protein 
LOC100158393 
(LOC100158393), mRNA 
[NM_001127837] 
1.24659 5.844937 5.34E-05 0.02523 
A_10_P007378 mthfsd NM_001092984 ref|Xenopus laevis 
hypothetical protein 
LOC446264 (mthfsd), mRNA 
[NM_001092984] 
-0.83893 -5.8376 5.41E-05 0.025273 
A_10_P003636 MGC68865 NM_001086478 ref|Xenopus laevis 
hypothetical protein 
MGC68865 (MGC68865), 
mRNA [NM_001086478] 
-1.70858 -5.83008 5.47E-05 0.025326 
A_10_P007939 MGC86272 NM_001094340 ref|Xenopus laevis 
MGC86272 protein 
(MGC86272), mRNA 
[NM_001094340] 
-1.06428 -5.81304 5.63E-05 0.02574 
A_10_P004478 MGC83251 NM_001091397 ref|Xenopus laevis 
hypothetical protein 
MGC83251 (MGC83251), 
mRNA [NM_001091397] 
1.934123 5.808088 5.68E-05 0.02574 
A_10_P024787 A_10_P0247
87 
A_10_P024787 Unknown -1.05744 -5.79808 5.78E-05 0.025912 
A_10_P019831 LOC779080 BC123331 gb|Xenopus laevis 
hypothetical protein 
LOC779080, mRNA (cDNA 
clone IMAGE:7009370), 
partial cds [BC123331] 
0.930762 5.785547 5.90E-05 0.026198 
A_10_P008957 LOC495474 NM_001095121 ref|Xenopus laevis 
hypothetical LOC495474 
(LOC495474), mRNA 
[NM_001095121] 
1.103941 5.764861 6.11E-05 0.026499 
A_10_P021360 MGC115379 NM_001096018 ref|Xenopus laevis 
hypothetical protein 
1.389441 5.754023 6.22E-05 0.026499 
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(Continued). 
 
ProbeName GeneName SystematicName Description logFC t P.Value adj.P.Val 
MGC115379 (MGC115379), 
mRNA [NM_001096018] 
A_10_P016258 BP686352 BP686352 gb|BP686352 Osada Taira 
anterior neuroectoderm 
(ANE) pCS105 cDNA library 
Xenopus laevis cDNA clone 
XL451a03ex 5', mRNA 
sequence [BP686352] 
1.289471 5.749612 6.27E-05 0.026499 
A_10_P025742 CK798956 CK798956 gb|AGENCOURT_18790172 
NICHD_XGC_Te2N 
Xenopus laevis cDNA clone 
IMAGE:7202559 5', mRNA 
sequence [CK798956] 
1.476488 5.746546 6.30E-05 0.026499 
A_10_P008027 MGC82075 NM_001094410 ref|Xenopus laevis 
MGC82075 protein 
(MGC82075), mRNA 
[NM_001094410] 
1.065702 5.743718 6.33E-05 0.026499 
A_10_P008027 MGC82075 NM_001094410 ref|Xenopus laevis 
MGC82075 protein 
(MGC82075), mRNA 
[NM_001094410] 
1.056141 5.743685 6.33E-05 0.026499 
A_10_P015247 TC400619 TC400619 tc|Rep: nicotinate 
phosphoribosyltransferase 
domain containing 1 - 
Xenopus tropicalis, partial 
(36%) [TC400619] 
1.036748 5.736985 6.40E-05 0.026499 
A_10_P013451 BJ044908 BJ044908 gb|BJ044908 NIBB Mochii 
normalized Xenopus neurula 
library Xenopus laevis cDNA 
clone XL002h12 3', mRNA 
sequence [BJ044908] 
0.993278 5.729375 6.48E-05 0.026499 
A_10_P007335 MGC85462 NM_001093864 ref|Xenopus laevis 
MGC85462 protein 
(MGC85462), mRNA 
[NM_001093864] 
0.832169 5.727589 6.50E-05 0.026499 
A_10_P007381 MGC80816 NM_001093911 ref|Xenopus laevis 
MGC80816 protein 
(MGC80816), mRNA 
[NM_001093911] 
1.052054 5.719252 6.60E-05 0.02663 
A_10_P003477 oxnad1 NM_001086375 ref|Xenopus laevis 
oxidoreductase NAD-binding 
domain-containing protein 1 
(oxnad1), mRNA 
[NM_001086375] 
1.596805 5.688621 6.95E-05 0.027556 
A_10_P005913 MGC81794 NM_001092573 ref|Xenopus laevis 
MGC81794 protein 
(MGC81794), mRNA 
[NM_001092573] 
1.319363 5.68398 7.00E-05 0.027556 
A_10_P009566 MGC99219 NM_001095834 ref|Xenopus laevis 
hypothetical protein 
MGC99219 (MGC99219), 
mRNA [NM_001095834] 
0.828937 5.672358 7.14E-05 0.027556 
A_10_P026576 CV077028 CV077028 gb|AGENCOURT_31443090 
NICHD_XGC_Te2 Xenopus 
laevis cDNA clone 
IMAGE:7391561 5', mRNA 
sequence [CV077028] 
0.884125 5.672135 7.14E-05 0.027556 
A_10_P019831 LOC779080 BC123331 gb|Xenopus laevis 
hypothetical protein 
LOC779080, mRNA (cDNA 
clone IMAGE:7009370), 
partial cds [BC123331] 
0.890541 5.671308 7.15E-05 0.027556 
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ProbeName GeneName SystematicName Description logFC t P.Value adj.P.Val 
A_10_P008273 chchd4b NM_001094623 ref|Xenopus laevis coiled-
coil-helix-coiled-coil-helix 
domain containing 4 
(chchd4b), nuclear gene 
encoding mitochondrial 
protein, mRNA 
[NM_001094623] 
1.566929 5.66769 7.20E-05 0.027556 
A_10_P004605 MGC84566 NM_001091342 ref|Xenopus laevis 
hypothetical protein 
MGC84566 (MGC84566), 
mRNA [NM_001091342] 
1.009925 5.658862 7.31E-05 0.027733 
A_10_P009020 LOC495682 NM_001095161 ref|Xenopus laevis 
hypothetical LOC495682 
(LOC495682), mRNA 
[NM_001095161] 
1.033634 5.650471 7.41E-05 0.027892 
A_10_P005332 MGC82625 NM_001092145 ref|Xenopus laevis 
MGC82625 protein 
(MGC82625), mRNA 
[NM_001092145] 
1.095588 5.628027 7.70E-05 0.028577 
A_10_P025245 LOC1000371
94 
NM_001097885 ref|Xenopus laevis 
hypothetical protein 
LOC100037194 
(LOC100037194), mRNA 
[NM_001097885] 
1.204023 5.623046 7.77E-05 0.028577 
A_10_P009247 LOC496174 NM_001095390 ref|Xenopus laevis 
hypothetical LOC496174 
(LOC496174), mRNA 
[NM_001095390] 
1.184324 5.62146 7.79E-05 0.028577 
A_10_P007880 MGC84466 NM_001094300 ref|Xenopus laevis 
MGC84466 protein 
(MGC84466), mRNA 
[NM_001094300] 
1.00838 5.598544 8.10E-05 0.029271 
A_10_P004478 MGC83251 NM_001091397 ref|Xenopus laevis 
hypothetical protein 
MGC83251 (MGC83251), 
mRNA [NM_001091397] 
1.911398 5.593121 8.17E-05 0.029271 
A_10_P008176 LOC494724 NM_001094563 ref|Xenopus laevis 
hypothetical LOC494724 
(LOC494724), mRNA 
[NM_001094563] 
-1.35758 -5.593 8.17E-05 0.029271 
A_10_P024076 CD324874 CD324874 gb|AGENCOURT_14163999 
NICHD_XGC_Eye1 Xenopus 
laevis cDNA clone 
IMAGE:6949378 3', mRNA 
sequence [CD324874] 
-2.73525 -5.58382 8.30E-05 0.029496 
A_10_P015247 TC400619 TC400619 tc|Rep: nicotinate 
phosphoribosyltransferase 
domain containing 1 - 
Xenopus tropicalis, partial 
(36%) [TC400619] 
0.974407 5.559253 8.66E-05 0.030517 
A_10_P003461 MGC68850 NM_001086369 ref|Xenopus laevis 
hypothetical protein 
MGC68850 (MGC68850), 
mRNA [NM_001086369] 
1.441719 5.553473 8.75E-05 0.030578 
A_10_P003636 MGC68865 NM_001086478 ref|Xenopus laevis 
hypothetical protein 
MGC68865 (MGC68865), 
mRNA [NM_001086478] 
-1.6007 -5.5365 9.00E-05 0.031058 
A_10_P025845 MGC99303 NM_001098444 ref|Xenopus laevis 
hypothetical protein 
MGC99303 (MGC99303), 
mRNA [NM_001098444] 
0.906145 5.535261 9.02E-05 0.031058 
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ProbeName GeneName SystematicName Description logFC t P.Value adj.P.Val 
A_10_P016369 LOC1001583
93 
NM_001127837 ref|Xenopus laevis 
hypothetical protein 
LOC100158393 
(LOC100158393), mRNA 
[NM_001127837] 
1.258768 5.527215 9.15E-05 0.031248 
A_10_P005445 MGC80435 NM_001092215 ref|Xenopus laevis 
MGC80435 protein 
(MGC80435), mRNA 
[NM_001092215] 
-0.93847 -5.51606 9.32E-05 0.031609 
A_10_P009304 LOC496259 NM_001095440 ref|Xenopus laevis 
hypothetical LOC496259 
(LOC496259), mRNA 
[NM_001095440] 
0.891593 5.490642 9.74E-05 0.032449 
A_10_P026213 A_10_P0262
13 
A_10_P026213 Unknown 0.913113 5.483778 9.86E-05 0.032449 
A_10_P025845 MGC99303 NM_001098444 ref|Xenopus laevis 
hypothetical protein 
MGC99303 (MGC99303), 
mRNA [NM_001098444] 
0.857887 5.468185 0.000101 0.032449 
A_10_P009415 MGC85151 NM_001095753 ref|Xenopus laevis 
hypothetical protein 
MGC85151 (MGC85151), 
mRNA [NM_001095753] 
1.218532 5.468112 0.000101 0.032449 
A_10_P017616 A_10_P0176
16 
A_10_P017616 Unknown 0.928898 5.467827 0.000101 0.032449 
A_10_P009247 LOC496174 NM_001095390 ref|Xenopus laevis 
hypothetical LOC496174 
(LOC496174), mRNA 
[NM_001095390] 
1.138852 5.46717 0.000101 0.032449 
A_10_P005399 MGC83560 NM_001092185 ref|Xenopus laevis 
MGC83560 protein 
(MGC83560), mRNA 
[NM_001092185] 
-1.19576 -5.46707 0.000101 0.032449 
A_10_P006532 MGC78962 NM_001093160 ref|Xenopus laevis 
MGC78962 protein 
(MGC78962), mRNA 
[NM_001093160] 
-0.70242 -5.46305 0.000102 0.032449 
A_10_P008957 LOC495474 NM_001095121 ref|Xenopus laevis 
hypothetical LOC495474 
(LOC495474), mRNA 
[NM_001095121] 
1.087509 5.462217 0.000102 0.032449 
A_10_P016314 TC406017 TC406017 Unknown 1.327526 5.447848 0.000105 0.033028 
A_10_P009064 LOC495834 NM_001095191 ref|Xenopus laevis 
hypothetical LOC495834 
(LOC495834), mRNA 
[NM_001095191] 
0.903346 5.442615 0.000106 0.033093 
A_10_P007738 MGC81730 NM_001094176 ref|Xenopus laevis 
MGC81730 protein 
(MGC81730), mRNA 
[NM_001094176] 
1.100083 5.438553 0.000107 0.033093 
A_10_P017949 TC388288 TC388288 tc|Rep: MGC114896 protein - 
Xenopus laevis (African 
clawed frog), complete 
[TC388288] 
0.961271 5.416496 0.000111 0.033519 
A_10_P025968 TC388499 TC388499 tc|Rep: BMP-2-inducible 
protein kinase  (BIKe). - 
Xenopus tropicalis, partial 
(30%) [TC388499] 
0.971291 5.413176 0.000111 0.033519 
A_10_P024341 LOC1000371
11 
BC155896 gb|Xenopus laevis cDNA 
clone MGC:181787 
IMAGE:8075402, complete 
cds [BC155896] 
1.144064 5.411906 0.000112 0.033519 
 117
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ProbeName GeneName SystematicName Description logFC t P.Value adj.P.Val 
A_10_P021360 MGC115379 NM_001096018 ref|Xenopus laevis 
hypothetical protein 
MGC115379 (MGC115379), 
mRNA [NM_001096018] 
1.364743 5.411342 0.000112 0.033519 
A_10_P006053 MGC84083 NM_001092708 ref|Xenopus laevis 
MGC84083 protein 
(MGC84083), mRNA 
[NM_001092708] 
-1.77597 -5.39903 0.000114 0.033519 
A_10_P005332 MGC82625 NM_001092145 ref|Xenopus laevis 
MGC82625 protein 
(MGC82625), mRNA 
[NM_001092145] 
1.044233 5.395263 0.000115 0.033519 
A_10_P020825 BX855559 BX855559 gb|BX855559 Soares NXEG 
Xenopus laevis cDNA clone 
IMAGp998F1811402 ; 
IMAGE:5162129 5', mRNA 
sequence [BX855559] 
0.717252 5.394315 0.000115 0.033519 
A_10_P008964 LOC495477 NM_001095123 ref|Xenopus laevis 
hypothetical LOC495477 
(LOC495477), mRNA 
[NM_001095123] 
1.308307 5.391695 0.000116 0.033519 
A_10_P005445 MGC80435 NM_001092215 ref|Xenopus laevis 
MGC80435 protein 
(MGC80435), mRNA 
[NM_001092215] 
-0.97264 -5.39062 0.000116 0.033519 
A_10_P020307 TC373831 TC373831 tc|Rep: Mitochondrial 28S 
ribosomal protein S5 (S5mt) 
(MRP-S5). - Xenopus 
tropicalis, partial (88%) 
[TC373831] 
1.380755 5.382276 0.000117 0.033519 
A_10_P000609 bves-A NM_001087672 ref|Xenopus laevis blood 
vessel epicardial substance 
(bves-A), mRNA 
[NM_001087672] 
-1.42079 -5.37662 0.000119 0.033519 
A_10_P008675 LOC495212 NM_001094896 ref|Xenopus laevis 
hypothetical LOC495212 
(LOC495212), mRNA 
[NM_001094896] 
0.860365 5.37473 0.000119 0.033519 
A_10_P010434 A_10_P0104
34 
A_10_P010434 Unknown 1.049751 5.373832 0.000119 0.033519 
A_10_P007738 MGC81730 NM_001094176 ref|Xenopus laevis 
MGC81730 protein 
(MGC81730), mRNA 
[NM_001094176] 
1.161443 5.368613 0.00012 0.033519 
A_10_P008015 MGC81928 NM_001094400 ref|Xenopus laevis 
MGC81928 protein 
(MGC81928), mRNA 
[NM_001094400] 
1.381859 5.368492 0.00012 0.033519 
A_10_P025957 CK800145 CK800145 gb|AGENCOURT_18791109 
NICHD_XGC_Te2N 
Xenopus laevis cDNA clone 
IMAGE:7203868 5', mRNA 
sequence [CK800145] 
1.024485 5.365761 0.000121 0.033519 
A_10_P002594 rangap1 NM_001086761 ref|Xenopus laevis RAN 
GTPase activating protein 1 
(rangap1), mRNA 
[NM_001086761] 
1.218874 5.363293 0.000121 0.033519 
A_10_P005583 MGC80777 NM_001092329 ref|Xenopus laevis 
MGC80777 protein 
(MGC80777), mRNA 
[NM_001092329] 
0.904141 5.362766 0.000122 0.033519 
A_10_P008805 LOC495364 NM_001095027 ref|Xenopus laevis 
hypothetical LOC495364 
0.844 5.355243 0.000123 0.033751 
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ProbeName GeneName SystematicName Description logFC t P.Value adj.P.Val 
(LOC495364), mRNA 
[NM_001095027] 
A_10_P001192 A_10_P0011
92 
A_10_P001192 Unknown -0.90407 -5.35078 0.000124 0.033805 
A_10_P025162 CF546987 CF546987 gb|AGENCOURT_15571141 
NICHD_XGC_Kid1 Xenopus 
laevis cDNA clone 
IMAGE:7008368 5', mRNA 
sequence [CF546987] 
-1.0061 -5.34185 0.000126 0.034126 
A_10_P009304 LOC496259 NM_001095440 ref|Xenopus laevis 
hypothetical LOC496259 
(LOC496259), mRNA 
[NM_001095440] 
0.871801 5.335758 0.000127 0.03425 
A_10_P025162 CF546987 CF546987 gb|AGENCOURT_15571141 
NICHD_XGC_Kid1 Xenopus 
laevis cDNA clone 
IMAGE:7008368 5', mRNA 
sequence [CF546987] 
-1.00462 -5.33117 0.000128 0.03425 
A_10_P009334 LOC496325 NM_001095479 ref|Xenopus laevis 
hypothetical LOC496325 
(LOC496325), mRNA 
[NM_001095479] 
-0.81573 -5.32792 0.000129 0.03425 
A_10_P013988 BJ068535 BJ068535 gb|BJ068535 NIBB Mochii 
normalized Xenopus tailbud 
library Xenopus laevis cDNA 
clone XL106p22 5', mRNA 
sequence [BJ068535] 
-1.27043 -5.32299 0.00013 0.03425 
A_10_P006495 MGC84640 NM_001093137 ref|Xenopus laevis 
MGC84640 protein 
(MGC84640), mRNA 
[NM_001093137] 
1.066702 5.319986 0.000131 0.03425 
A_10_P005399 MGC83560 NM_001092185 ref|Xenopus laevis 
MGC83560 protein 
(MGC83560), mRNA 
[NM_001092185] 
-1.23867 -5.31587 0.000132 0.03425 
A_10_P020124 TC378007 TC378007 tc|Rep: SVOP-like - Xenopus 
tropicalis, partial (10%) 
[TC378007] 
-0.69923 -5.31417 0.000132 0.03425 
A_10_P009096 nme4b NM_001095218 ref|Xenopus laevis non-
metastatic cells 4, protein 
expressed in b (nme4b), 
mRNA [NM_001095218] 
-0.95209 -5.30673 0.000134 0.03425 
A_10_P014005 DR725919 DR725919 gb|AGENCOURT_54828067 
NICHD_XGC_Emb10 
Xenopus laevis cDNA clone 
IMAGE:7980097 5', mRNA 
sequence [DR725919] 
0.787919 5.306402 0.000134 0.03425 
A_10_P007378 mthfsd NM_001092984 ref|Xenopus laevis 
hypothetical protein 
LOC446264 (mthfsd), mRNA 
[NM_001092984] 
-0.8514 -5.30583 0.000134 0.03425 
A_10_P007381 MGC80816 NM_001093911 ref|Xenopus laevis 
MGC80816 protein 
(MGC80816), mRNA 
[NM_001093911] 
0.997811 5.299868 0.000136 0.034411 
A_10_P020378 BX850617 BX850617 gb|BX850617 
NICHD_XGC_Sp1 Xenopus 
laevis cDNA clone 
IMAGp998M1210939 ; 
IMAGE:4964915 5', mRNA 
sequence [BX850617] 
0.974019 5.281843 0.00014 0.035044 
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A_10_P005193 MGC80246 NM_001092030 ref|Xenopus laevis 
MGC80246 protein 
(MGC80246), mRNA 
[NM_001092030] 
-1.20566 -5.28048 0.00014 0.035044 
A_10_P008913 LOC495447 NM_001095100 ref|Xenopus laevis 
hypothetical LOC495447 
(LOC495447), mRNA 
[NM_001095100] 
-0.86029 -5.27703 0.000141 0.035044 
A_10_P008941 Xubc14 BC085030 gb|Xenopus laevis cDNA 
clone MGC:97892 
IMAGE:7008714, complete 
cds [BC085030] 
0.711346 5.275913 0.000141 0.035044 
A_10_P008015 MGC81928 NM_001094400 ref|Xenopus laevis 
MGC81928 protein 
(MGC81928), mRNA 
[NM_001094400] 
1.373247 5.273333 0.000142 0.035044 
A_10_P024341 LOC1000371
11 
BC155896 gb|Xenopus laevis cDNA 
clone MGC:181787 
IMAGE:8075402, complete 
cds [BC155896] 
1.124972 5.268945 0.000143 0.035119 
A_10_P002453 MGC52920 NM_001086007 ref|Xenopus laevis 
hypothetical protein 
MGC52920 (MGC52920), 
mRNA [NM_001086007] 
0.958443 5.258249 0.000146 0.035587 
A_10_P020350 LOC1001013
05 
NM_001099890 ref|Xenopus laevis 
hypothetical protein 
LOC100101305 
(LOC100101305), mRNA 
[NM_001099890] 
0.980314 5.244393 0.000149 0.036263 
A_10_P007980 MGC81550 NM_001094368 ref|Xenopus laevis 
MGC81550 protein 
(MGC81550), mRNA 
[NM_001094368] 
-0.83601 -5.2329 0.000152 0.036303 
A_10_P007015 uap1 NM_001093499 ref|Xenopus laevis UDP-N-
acteylglucosamine 
pyrophosphorylase 1 (uap1), 
mRNA [NM_001093499] 
-0.75189 -5.22831 0.000154 0.036303 
A_10_P026075 A_10_P0260
75 
A_10_P026075 Unknown -0.96712 -5.22811 0.000154 0.036303 
A_10_P008805 LOC495364 NM_001095027 ref|Xenopus laevis 
hypothetical LOC495364 
(LOC495364), mRNA 
[NM_001095027] 
0.826496 5.225529 0.000154 0.036303 
A_10_P023078 A_10_P0230
78 
A_10_P023078 Unknown -1.18022 -5.22489 0.000155 0.036303 
A_10_P024464 CD330023 CD330023 gb|AGENCOURT_14166046 
NICHD_XGC_Brn1 Xenopus 
laevis cDNA clone 
IMAGE:6951193 5', mRNA 
sequence [CD330023] 
-0.83369 -5.22295 0.000155 0.036303 
A_10_P005485 MGC80581 NM_001092246 ref|Xenopus laevis 
MGC80581 protein 
(MGC80581), mRNA 
[NM_001092246] 
1.13001 5.222394 0.000155 0.036303 
A_10_P004373 MGC81068 NM_001091474 ref|Xenopus laevis 
hypothetical protein 
MGC81068 (MGC81068), 
mRNA [NM_001091474] 
0.892393 5.215416 0.000157 0.036559 
A_10_P016326 BP688728 BP688728 gb|BP688728 Osada Taira 
anterior neuroectoderm 
(ANE) pCS105 cDNA library 
Xenopus laevis cDNA clone 
XL458e18ex 5', mRNA 
0.820926 5.203412 0.000161 0.037027 
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ProbeName GeneName SystematicName Description logFC t P.Value adj.P.Val 
sequence [BP688728] 
A_10_P002808 kif2c NM_001086845 ref|Xenopus laevis kinesin 
family member 2C (kif2c), 
mRNA [NM_001086845] 
-2.16537 -5.20038 0.000161 0.037027 
A_10_P002997 MGC68650 NM_001090187 ref|Xenopus laevis propionyl-
CoA carboxylase 
(MGC68650), mRNA 
[NM_001090187] 
0.988331 5.199321 0.000162 0.037027 
A_10_P004111 MGC81140 NM_001091222 ref|Xenopus laevis 
hypothetical protein 
MGC81140 (MGC81140), 
mRNA [NM_001091222] 
0.89744 5.192709 0.000164 0.037145 
A_10_P011156 TC373007 TC373007 tc|Rep: 39S ribosomal protein 
L14, mitochondrial precursor 
- Bos taurus (Bovine), partial 
(79%) [TC373007] 
0.841825 5.191696 0.000164 0.037145 
A_10_P009790 TC405162 TC405162 Unknown 1.199595 5.188569 0.000165 0.037161 
A_10_P007383 BC079696 BC079696 gb|Xenopus laevis cDNA 
clone IMAGE:5514594 
[BC079696] 
1.51629 5.176412 0.000168 0.037647 
A_10_P001372 TC394003 TC394003 Unknown 0.866219 5.175461 0.000169 0.037647 
A_10_P000609 bves-A NM_001087672 ref|Xenopus laevis blood 
vessel epicardial substance 
(bves-A), mRNA 
[NM_001087672] 
-1.37975 -5.16147 0.000173 0.038395 
A_10_P016314 TC406017 TC406017 Unknown 1.30578 5.157719 0.000174 0.038459 
A_10_P024885 A_10_P0248
85 
A_10_P024885 Unknown 0.697072 5.145416 0.000178 0.038846 
A_10_P002778 LOC398448 BC108873 gb|Xenopus laevis similar to 
splicing factor, arginine 
[BC108873] 
-0.87278 -5.14458 0.000178 0.038846 
A_10_P017302 MGC131341 BP739676 gb|BP739676 Osada Taira 
anterior neuroectoderm 
(ANE) pCS105 cDNA library 
Xenopus laevis cDNA clone 
XL520k17ex 3', mRNA 
sequence [BP739676] 
0.83383 5.139855 0.00018 0.038846 
A_10_P002131 LOC496406 NM_001095551 ref|Xenopus laevis 
Ena/VASP-like protein H 
isoform (LOC496406), 
mRNA [NM_001095551] 
-1.32409 -5.13843 0.00018 0.038846 
A_10_P003461 MGC68850 NM_001086369 ref|Xenopus laevis 
hypothetical protein 
MGC68850 (MGC68850), 
mRNA [NM_001086369] 
1.318143 5.138154 0.00018 0.038846 
A_10_P025498 LOC496036 NM_001095303 ref|Xenopus laevis 
hypothetical LOC496036 
(LOC496036), mRNA 
[NM_001095303] 
-0.80841 -5.13116 0.000182 0.039004 
A_10_P021668 CA982713 CA982713 gb|AGENCOURT_11240638 
Wellcome [CA982713] 
0.806653 5.128228 0.000183 0.039004 
A_10_P002997 MGC68650 NM_001090187 ref|Xenopus laevis propionyl-
CoA carboxylase 
(MGC68650), mRNA 
[NM_001090187] 
0.976842 5.127682 0.000184 0.039004 
A_10_P024109 A_10_P0241
09 
A_10_P024109 Unknown 0.945682 5.118746 0.000187 0.039094 
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A_10_P005193 MGC80246 NM_001092030 ref|Xenopus laevis 
MGC80246 protein 
(MGC80246), mRNA 
[NM_001092030] 
-1.17439 -5.11825 0.000187 0.039094 
A_10_P023941 MGC114802 NM_001096181 ref|Xenopus laevis 
hypothetical protein 
MGC114802 (MGC114802), 
mRNA [NM_001096181] 
-0.76727 -5.11739 0.000187 0.039094 
A_10_P020727 BC155963 BC155963 gb|Xenopus laevis cDNA 
clone IMAGE:8075198 
[BC155963] 
0.95318 5.115686 0.000188 0.039094 
A_10_P009108 LOC495963 NM_001095230 ref|Xenopus laevis 
hypothetical LOC495963 
(LOC495963), mRNA 
[NM_001095230] 
-0.99177 -5.10951 0.00019 0.039339 
A_10_P025957 CK800145 CK800145 gb|AGENCOURT_18791109 
NICHD_XGC_Te2N 
Xenopus laevis cDNA clone 
IMAGE:7203868 5', mRNA 
sequence [CK800145] 
1.002356 5.105483 0.000191 0.039413 
A_10_P010250 LOC1001013
15 
NM_001099897 ref|Xenopus laevis 
hypothetical protein 
LOC100101315 
(LOC100101315), mRNA 
[NM_001099897] 
1.318818 5.097398 0.000194 0.039413 
A_10_P005215 MGC80307 NM_001092051 ref|Xenopus laevis 
MGC80307 protein 
(MGC80307), mRNA 
[NM_001092051] 
1.328964 5.096759 0.000194 0.039413 
A_10_P003689 MGC68884 NM_001086530 ref|Xenopus laevis 
hypothetical protein 
MGC68884 (MGC68884), 
mRNA [NM_001086530] 
1.00782 5.096751 0.000194 0.039413 
A_10_P015868 BJ643499 BJ643499 gb|BJ643499 NIBB Mochii 
normalized Xenopus early 
gastrula library Xenopus 
laevis cDNA clone XL217e08 
3', mRNA sequence 
[BJ643499] 
-0.77608 -5.09544 0.000194 0.039413 
A_10_P007418 LOC397789 NM_001087883 ref|Xenopus laevis 
calcium/calmodulin-
dependent kinase type II 
beta'-subunit (LOC397789), 
mRNA [NM_001087883] 
-1.70337 -5.08904 0.000197 0.039432 
A_10_P017302 MGC131341 BP739676 gb|BP739676 Osada Taira 
anterior neuroectoderm 
(ANE) pCS105 cDNA library 
Xenopus laevis cDNA clone 
XL520k17ex 3', mRNA 
sequence [BP739676] 
0.770447 5.085947 0.000198 0.039432 
A_10_P026553 LOC733433 BC108630 gb|Xenopus laevis 
hypothetical protein 
LOC733433, mRNA (cDNA 
clone IMAGE:7393351), 
partial cds [BC108630] 
1.138602 5.084105 0.000198 0.039432 
A_10_P006053 MGC84083 NM_001092708 ref|Xenopus laevis 
MGC84083 protein 
(MGC84083), mRNA 
[NM_001092708] 
-1.67169 -5.07994 0.0002 0.039432 
A_10_P015136 LOC1001376
31 
NM_001114782 ref|Xenopus laevis 
hypothetical protein 
LOC100137631 
(LOC100137631), mRNA 
1.032112 5.078134 0.0002 0.039432 
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[NM_001114782] 
A_10_P022809 A_10_P0228
09 
A_10_P022809 Unknown -0.66995 -5.07772 0.000201 0.039432 
A_10_P007980 MGC81550 NM_001094368 ref|Xenopus laevis 
MGC81550 protein 
(MGC81550), mRNA 
[NM_001094368] 
-0.84138 -5.07745 0.000201 0.039432 
A_10_P016258 BP686352 BP686352 gb|BP686352 Osada Taira 
anterior neuroectoderm 
(ANE) pCS105 cDNA library 
Xenopus laevis cDNA clone 
XL451a03ex 5', mRNA 
sequence [BP686352] 
1.174471 5.069206 0.000204 0.039446 
A_10_P007375 MGC80300 NM_001093907 ref|Xenopus laevis 
MGC80300 protein 
(MGC80300), mRNA 
[NM_001093907] 
0.67215 5.068574 0.000204 0.039446 
A_10_P008913 LOC495447 NM_001095100 ref|Xenopus laevis 
hypothetical LOC495447 
(LOC495447), mRNA 
[NM_001095100] 
-0.82184 -5.06765 0.000204 0.039446 
A_10_P002808 kif2c NM_001086845 ref|Xenopus laevis kinesin 
family member 2C (kif2c), 
mRNA [NM_001086845] 
-2.14938 -5.06738 0.000204 0.039446 
A_10_P006245 MGC81911 NM_001092872 ref|Xenopus laevis 
MGC81911 protein 
(MGC81911), mRNA 
[NM_001092872] 
0.839005 5.059325 0.000207 0.039842 
A_10_P003289 MGC64313 NM_001086294 ref|Xenopus laevis 
hypothetical protein 
MGC64313 (MGC64313), 
mRNA [NM_001086294] 
-0.79987 -5.05539 0.000209 0.03995 
A_10_P025535 LOC1000371
13 
NM_001097823 ref|Xenopus laevis 
hypothetical protein 
LOC100037113 
(LOC100037113), mRNA 
[NM_001097823] 
0.967632 5.049588 0.000211 0.03997 
A_10_P003001 BC046379 BC046379 gb|Xenopus laevis, clone 
IMAGE:5542876, mRNA 
[BC046379] 
0.952348 5.0451 0.000213 0.03997 
A_10_P026057 CK804953 CK804953 gb|AGENCOURT_19152231 
NICHD_XGC_Te2 Xenopus 
laevis cDNA clone 
IMAGE:7211781 5', mRNA 
sequence [CK804953] 
0.938927 5.044451 0.000213 0.03997 
A_10_P009124 nudt19 NM_001095247 ref|Xenopus laevis 
Nucleoside diphosphate-
linked moiety X motif 19, 
mitochondrial precursor 
(nudt19), nuclear gene 
encoding mitochondrial 
protein, mRNA 
[NM_001095247] 
0.758438 5.042034 0.000214 0.03997 
A_10_P003859 MGC68559 NM_001090024 ref|Xenopus laevis 
hypothetical protein 
MGC68559 (MGC68559), 
mRNA [NM_001090024] 
-0.77139 -5.04033 0.000214 0.03997 
A_10_P007939 MGC86272 NM_001094340 ref|Xenopus laevis 
MGC86272 protein 
(MGC86272), mRNA 
[NM_001094340] 
-0.8775 -5.03961 0.000215 0.03997 
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A_10_P005913 MGC81794 NM_001092573 ref|Xenopus laevis 
MGC81794 protein 
(MGC81794), mRNA 
[NM_001092573] 
1.230498 5.037748 0.000215 0.03997 
A_10_P005902 MGC115132 NM_001095905 ref|Xenopus laevis 
hypothetical protein 
MGC115132 (MGC115132), 
mRNA [NM_001095905] 
-1.15748 -5.03423 0.000217 0.03997 
A_10_P020106 BX847818 BX847818 gb|BX847818 Soares NXEG 
Xenopus laevis cDNA clone 
IMAGp998G1210553 ; 
IMAGE:4678307 5', mRNA 
sequence [BX847818] 
1.392368 5.031674 0.000218 0.03997 
A_10_P002594 rangap1 NM_001086761 ref|Xenopus laevis RAN 
GTPase activating protein 1 
(rangap1), mRNA 
[NM_001086761] 
1.238287 5.031418 0.000218 0.03997 
A_10_P007927 MGC85590 NM_001094330 ref|Xenopus laevis 
MGC85590 protein 
(MGC85590), mRNA 
[NM_001094330] 
-0.91579 -5.02867 0.000219 0.040001 
A_10_P012154 BG347956 BG347956 gb|de71h01.y1 Kirschner 
embryo St10 14 Xenopus 
laevis cDNA clone 
IMAGE:3517296 5', mRNA 
sequence [BG347956] 
-0.92367 -5.02617 0.00022 0.040015 
A_10_P007927 MGC85590 NM_001094330 ref|Xenopus laevis 
MGC85590 protein 
(MGC85590), mRNA 
[NM_001094330] 
-0.94101 -5.01624 0.000224 0.040255 
A_10_P022926 CB564765 CB564765 gb|AGENCOURT_13325038 
NICHD_XGC_Tad2 Xenopus 
laevis cDNA clone 
IMAGE:6875760 3', mRNA 
sequence [CB564765] 
2.397068 5.013719 0.000225 0.040255 
A_10_P006263 MGC82002 NM_001092887 ref|Xenopus laevis 
MGC82002 protein 
(MGC82002), mRNA 
[NM_001092887] 
0.846016 5.01322 0.000225 0.040255 
A_10_P016223 TC375146 TC375146 tc|Rep: LOC100124857 
protein - Xenopus tropicalis 
(Western clawed frog) 
(Silurana tropicalis), complete 
[TC375146] 
1.16533 5.010085 0.000226 0.040255 
A_10_P025716 MGC80374 NM_001092076 ref|Xenopus laevis 
MGC80374 protein 
(MGC80374), mRNA 
[NM_001092076] 
1.013036 5.009179 0.000227 0.040255 
A_10_P023940 TC378973 TC378973 Unknown 1.316782 5.00433 0.000229 0.040255 
A_10_P009576 MGC85135 NM_001096528 ref|Xenopus laevis 
hypothetical protein 
MGC85135 (MGC85135), 
mRNA [NM_001096528] 
0.761635 5.001855 0.00023 0.040255 
A_10_P020323 BX850062 BX850062 gb|BX850062 Wellcome 
CRC pRN3 St19 26 Xenopus 
laevis cDNA clone 
IMAGp998B238636 ; 
IMAGE:3548086 5', mRNA 
sequence [BX850062] 
0.628029 5.001047 0.00023 0.040255 
A_10_P003225 uqcrc1 NM_001086245 ref|Xenopus laevis ubiquinol-
cytochrome c reductase core 
protein I (uqcrc1), mRNA 
[NM_001086245] 
0.762481 5.000219 0.00023 0.040255 
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A_10_P017616 A_10_P0176
16 
A_10_P017616 Unknown 0.843992 4.998567 0.000231 0.040255 
A_10_P022392 CB559907 CB559907 gb|AGENCOURT_13054468 
NICHD_XGC_Kid1 Xenopus 
laevis cDNA clone 
IMAGE:4032390 5', mRNA 
sequence [CB559907] 
1.69796 4.996389 0.000232 0.040255 
A_10_P002095 LOC407751 NM_001091005 ref|Xenopus laevis metaxin 3 
(LOC407751), mRNA 
[NM_001091005] 
-0.63818 -4.99444 0.000233 0.040255 
A_10_P007880 MGC84466 NM_001094300 ref|Xenopus laevis 
MGC84466 protein 
(MGC84466), mRNA 
[NM_001094300] 
0.968535 4.993764 0.000233 0.040255 
A_10_P017794 BQ730684 BQ730684 gb|AGENCOURT_8216611 
NICHD XGC Emb4 Xenopus 
laevis cDNA clone 
IMAGE:4930104 5', mRNA 
sequence [BQ730684] 
0.905811 4.987799 0.000235 0.040529 
A_10_P020323 BX850062 BX850062 gb|BX850062 Wellcome 
CRC pRN3 St19 26 Xenopus 
laevis cDNA clone 
IMAGp998B238636 ; 
IMAGE:3548086 5', mRNA 
sequence [BX850062] 
0.68642 4.984411 0.000237 0.040618 
A_10_P004915 timm23 NM_001091593 ref|Xenopus laevis 
Mitochondrial import inner 
membrane translocase subunit 
Tim23 (timm23), mRNA 
[NM_001091593] 
0.962224 4.977171 0.00024 0.04078 
A_10_P003236 MGC53422 NM_001086249 ref|Xenopus laevis 
hypothetical protein 
MGC53422 (MGC53422), 
mRNA [NM_001086249] 
0.867994 4.976472 0.00024 0.04078 
A_10_P005152 MGC80131 NM_001091994 ref|Xenopus laevis 
MGC80131 protein 
(MGC80131), mRNA 
[NM_001091994] 
-1.09549 -4.97576 0.000241 0.04078 
A_10_P007418 LOC397789 NM_001087883 ref|Xenopus laevis 
calcium/calmodulin-
dependent kinase type II 
beta'-subunit (LOC397789), 
mRNA [NM_001087883] 
-1.50885 -4.96992 0.000243 0.040989 
A_10_P026031 CK804709 CK804709 gb|AGENCOURT_19152092 
NICHD_XGC_Te2 Xenopus 
laevis cDNA clone 
IMAGE:7211509 5', mRNA 
sequence [CK804709] 
0.749802 4.968651 0.000244 0.040989 
A_10_P006444 bcap29 NM_001093099 ref|Xenopus laevis B-cell 
receptor-associated protein 29 
(bcap29), mRNA 
[NM_001093099] 
-1.2201 -4.96554 0.000245 0.041063 
A_10_P015705 BJ639398 BJ639398 gb|BJ639398 NIBB Mochii 
normalized Xenopus early 
gastrula library Xenopus 
laevis cDNA clone 
XL202b08 3', mRNA 
sequence [BJ639398] 
-0.89945 -4.95859 0.000248 0.041421 
A_10_P009108 LOC495963 NM_001095230 ref|Xenopus laevis 
hypothetical LOC495963 
(LOC495963), mRNA 
[NM_001095230] 
-1.00828 -4.95352 0.00025 0.041601 
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A_10_P025245 LOC1000371
94 
NM_001097885 ref|Xenopus laevis 
hypothetical protein 
LOC100037194 
(LOC100037194), mRNA 
[NM_001097885] 
1.21475 4.952 0.000251 0.041601 
A_10_P025493 TC393468 TC393468 tc|Rep: Inner membrane 
protein OXA1L, 
mitochondrial precursor 
(Oxidase assembly 1-like 
protein) (OXA1-like protein) 
(OXA1Hs) (Ohsako). - 
Xenopus tropicalis, partial 
(91%) [TC393468] 
0.784023 4.941061 0.000256 0.04221 
A_10_P007795 fam50-b NM_001096104 ref|Xenopus laevis Protein 
FAM50A B (fam50-b), 
mRNA [NM_001096104] 
0.796225 4.938562 0.000257 0.04221 
A_10_P004981 MGC82342 NM_001091932 ref|Xenopus laevis 
MGC82342 protein 
(MGC82342), mRNA 
[NM_001091932] 
0.844672 4.937699 0.000258 0.04221 
A_10_P005485 MGC80581 NM_001092246 ref|Xenopus laevis 
MGC80581 protein 
(MGC80581), mRNA 
[NM_001092246] 
1.130928 4.929219 0.000262 0.042614 
A_10_P026351 CO384479 CO384479 gb|AGENCOURT_26186018 
Blumberg_Cho Xenopus 
laevis cDNA clone 
IMAGE:7297372 5', mRNA 
sequence [CO384479] 
0.722778 4.926881 0.000263 0.042614 
A_10_P005215 MGC80307 NM_001092051 ref|Xenopus laevis 
MGC80307 protein 
(MGC80307), mRNA 
[NM_001092051] 
1.181164 4.925478 0.000263 0.042614 
A_10_P005902 MGC115132 NM_001095905 ref|Xenopus laevis 
hypothetical protein 
MGC115132 (MGC115132), 
mRNA [NM_001095905] 
-1.1546 -4.92258 0.000265 0.042614 
A_10_P025716 MGC80374 NM_001092076 ref|Xenopus laevis 
MGC80374 protein 
(MGC80374), mRNA 
[NM_001092076] 
0.988565 4.92222 0.000265 0.042614 
A_10_P001589 BC129639 BC129639 gb|Xenopus laevis cDNA 
clone IMAGE:8532958 
[BC129639] 
0.657134 4.920074 0.000266 0.042625 
A_10_P006780 mthfd2 NM_001093337 ref|Xenopus laevis methylene 
tetrahydrofolate 
dehydrogenase (NAD+ 
dependent), 
methenyltetrahydrofolate 
cyclohydrolase (mthfd2), 
mRNA [NM_001093337] 
-1.04038 -4.91616 0.000268 0.042709 
A_10_P002453 MGC52920 NM_001086007 ref|Xenopus laevis 
hypothetical protein 
MGC52920 (MGC52920), 
mRNA [NM_001086007] 
0.951985 4.914979 0.000268 0.042709 
A_10_P001928 Shc1 NM_001090463 ref|Xenopus laevis src 
homology collagen (Shc1), 
mRNA [NM_001090463] 
-0.97586 -4.91014 0.000271 0.042928 
A_10_P008407 LOC495024 NM_001094730 ref|Xenopus laevis 
hypothetical LOC495024 
(LOC495024), mRNA 
[NM_001094730] 
-1.10238 -4.90694 0.000272 0.042971 
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A_10_P007484 MGC86474 NM_001093990 ref|Xenopus laevis 
MGC86474 protein 
(MGC86474), mRNA 
[NM_001093990] 
1.346789 4.90507 0.000273 0.042971 
A_10_P025900 MGC132241 NM_001096346 ref|Xenopus laevis 
hypothetical protein 
MGC132241 (MGC132241), 
mRNA [NM_001096346] 
1.156564 4.902943 0.000274 0.042971 
A_10_P013202 BI478309 BI478309 gb|dai12h08.x1 NICHD XGC 
Emb4 Xenopus laevis cDNA 
clone IMAGE:4959231 3', 
mRNA sequence [BI478309] 
0.680687 4.898375 0.000276 0.042971 
A_10_P003289 MGC64313 NM_001086294 ref|Xenopus laevis 
hypothetical protein 
MGC64313 (MGC64313), 
mRNA [NM_001086294] 
-0.80247 -4.89804 0.000277 0.042971 
A_10_P002080 RTN2 NM_001095545 ref|Xenopus laevis RTN2-A 
(RTN2), mRNA 
[NM_001095545] 
-1.07831 -4.89781 0.000277 0.042971 
A_10_P012154 BG347956 BG347956 gb|de71h01.y1 Kirschner 
embryo St10 14 Xenopus 
laevis cDNA clone 
IMAGE:3517296 5', mRNA 
sequence [BG347956] 
-0.88244 -4.89212 0.00028 0.043262 
A_10_P008176 LOC494724 NM_001094563 ref|Xenopus laevis 
hypothetical LOC494724 
(LOC494724), mRNA 
[NM_001094563] 
-1.31957 -4.88966 0.000281 0.043303 
A_10_P015581 BJ052207 BJ052207 gb|BJ052207 NIBB Mochii 
normalized Xenopus neurula 
library Xenopus laevis cDNA 
clone XL040l23 3', mRNA 
sequence [BJ052207] 
-0.93997 -4.8847 0.000283 0.043509 
A_10_P008295 fam136a NM_001094654 ref|Xenopus laevis 
hypothetical LOC494828 
(fam136a), mRNA 
[NM_001094654] 
1.34264 4.883196 0.000284 0.043509 
A_10_P022392 CB559907 CB559907 gb|AGENCOURT_13054468 
NICHD_XGC_Kid1 Xenopus 
laevis cDNA clone 
IMAGE:4032390 5', mRNA 
sequence [CB559907] 
1.902055 4.875297 0.000288 0.043735 
A_10_P012603 LOC1001748
05 
NM_001130949 ref|Xenopus laevis 
hypothetical protein 
LOC100174805 
(LOC100174805), mRNA 
[NM_001130949] 
-0.81762 -4.8747 0.000289 0.043735 
A_10_P005115 MGC79100 NM_001091968 ref|Xenopus laevis 
MGC79100 protein 
(MGC79100), mRNA 
[NM_001091968] 
1.141078 4.873679 0.000289 0.043735 
A_10_P015940 BM179429 BM179429 gb|dai44g09.x1 NICHD XGC 
Sp1 Xenopus laevis cDNA 
clone IMAGE:4964561 3' 
similar to TR:Q9ULG9 
Q9ULG9 KIAA1251 
PROTEIN ;, mRNA sequence 
[BM179429] 
-1.12384 -4.87204 0.00029 0.043735 
A_10_P008750 LOC495306 NM_001094973 ref|Xenopus laevis 
hypothetical LOC495306 
(LOC495306), mRNA 
[NM_001094973] 
1.494989 4.870847 0.000291 0.043735 
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A_10_P004508 MGC83726 NM_001091504 ref|Xenopus laevis 
hypothetical protein 
MGC83726 (MGC83726), 
mRNA [NM_001091504] 
0.673126 4.867727 0.000292 0.043755 
A_10_P007484 MGC86474 NM_001093990 ref|Xenopus laevis 
MGC86474 protein 
(MGC86474), mRNA 
[NM_001093990] 
1.43603 4.866842 0.000293 0.043755 
A_10_P013988 BJ068535 BJ068535 gb|BJ068535 NIBB Mochii 
normalized Xenopus tailbud 
library Xenopus laevis cDNA 
clone XL106p22 5', mRNA 
sequence [BJ068535] 
-1.31278 -4.86303 0.000295 0.043909 
A_10_P003249 anxa1 NM_001086675 ref|Xenopus laevis annexin 
A1 (anxa1), mRNA 
[NM_001086675] 
-0.96924 -4.85717 0.000298 0.044228 
A_10_P003236 MGC53422 NM_001086249 ref|Xenopus laevis 
hypothetical protein 
MGC53422 (MGC53422), 
mRNA [NM_001086249] 
0.8786 4.849783 0.000302 0.044653 
A_10_P000089 MGC64562 NM_001086339 ref|Xenopus laevis 
mitochondrial carrier 
homolog 2 (MGC64562), 
nuclear gene encoding 
mitochondrial protein, mRNA 
[NM_001086339] 
0.686856 4.839916 0.000307 0.044653 
A_10_P009334 LOC496325 NM_001095479 ref|Xenopus laevis 
hypothetical LOC496325 
(LOC496325), mRNA 
[NM_001095479] 
-0.91801 -4.8394 0.000308 0.044653 
A_10_P025894 TC372421 TC372421 tc|Rep: LOC443690 protein - 
Xenopus laevis (African 
clawed frog), partial (12%) 
[TC372421] 
0.997102 4.839369 0.000308 0.044653 
A_10_P026553 LOC733433 BC108630 gb|Xenopus laevis 
hypothetical protein 
LOC733433, mRNA (cDNA 
clone IMAGE:7393351), 
partial cds [BC108630] 
1.11763 4.838113 0.000308 0.044653 
A_10_P011692 BX849994 BX849994 gb|BX849994 Wellcome 
CRC pRN3 head Xenopus 
laevis cDNA clone 
IMAGp998A068731 ; 
IMAGE:3579917 5', mRNA 
sequence [BX849994] 
0.846953 4.836182 0.000309 0.044653 
A_10_P024770 CF271159 CF271159 gb|AGENCOURT_15190349 
NICHD_XGC_Sp1 Xenopus 
laevis cDNA clone 
IMAGE:5511751 5', mRNA 
sequence [CF271159] 
-1.19118 -4.83599 0.000309 0.044653 
A_10_P023941 MGC114802 NM_001096181 ref|Xenopus laevis 
hypothetical protein 
MGC114802 (MGC114802), 
mRNA [NM_001096181] 
-0.71481 -4.83443 0.00031 0.044653 
A_10_P006028 MGC84007 NM_001092675 ref|Xenopus laevis 
MGC84007 protein 
(MGC84007), mRNA 
[NM_001092675] 
-0.75117 -4.83396 0.000311 0.044653 
A_10_P000174 xV2R1 NM_001091027 ref|Xenopus laevis 
pheromone receptor-like 
(xV2R1), mRNA 
[NM_001091027] 
-1.07654 -4.83254 0.000311 0.044653 
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ProbeName GeneName SystematicName Description logFC t P.Value adj.P.Val 
A_10_P006468 MGC83912 NM_001093118 ref|Xenopus laevis 
MGC83912 protein 
(MGC83912), mRNA 
[NM_001093118] 
-1.79436 -4.8319 0.000312 0.044653 
A_10_P002054 AY336492 AY336492 gb|Xenopus laevis mRNA 
sequence [AY336492] 
0.880365 4.827033 0.000314 0.044903 
A_10_P013451 BJ044908 BJ044908 gb|BJ044908 NIBB Mochii 
normalized Xenopus neurula 
library Xenopus laevis cDNA 
clone XL002h12 3', mRNA 
sequence [BJ044908] 
0.962288 4.823492 0.000316 0.044982 
A_10_P003689 MGC68884 NM_001086530 ref|Xenopus laevis 
hypothetical protein 
MGC68884 (MGC68884), 
mRNA [NM_001086530] 
0.981784 4.821222 0.000318 0.044982 
A_10_P003001 BC046379 BC046379 gb|Xenopus laevis, clone 
IMAGE:5542876, mRNA 
[BC046379] 
0.905045 4.817944 0.00032 0.044982 
A_10_P020778 TC397330 TC397330 tc|Rep: ITIM-containing 
receptor MAFA-L - Homo 
sapiens (Human), partial 
(16%) [TC397330] 
1.781926 4.817673 0.00032 0.044982 
A_10_P000330 xfz2 NM_001090360 ref|Xenopus laevis frizzled-2 
(xfz2), mRNA 
[NM_001090360] 
0.751973 4.817249 0.00032 0.044982 
A_10_P024464 CD330023 CD330023 gb|AGENCOURT_14166046 
NICHD_XGC_Brn1 Xenopus 
laevis cDNA clone 
IMAGE:6951193 5', mRNA 
sequence [CD330023] 
-0.80188 -4.8149 0.000321 0.045032 
A_10_P008964 LOC495477 NM_001095123 ref|Xenopus laevis 
hypothetical LOC495477 
(LOC495477), mRNA 
[NM_001095123] 
1.198122 4.807047 0.000326 0.045533 
A_10_P007536 MGC81821 NM_001094019 ref|Xenopus laevis 
MGC81821 protein 
(MGC81821), mRNA 
[NM_001094019] 
-0.90843 -4.80366 0.000328 0.04554 
A_10_P016223 TC375146 TC375146 tc|Rep: LOC100124857 
protein - Xenopus tropicalis 
(Western clawed frog) 
(Silurana tropicalis), complete 
[TC375146] 
1.109951 4.803501 0.000328 0.04554 
A_10_P006974 MGC80384 NM_001093465 ref|Xenopus laevis 
MGC80384 protein 
(MGC80384), mRNA 
[NM_001093465] 
0.878361 4.798095 0.000331 0.045846 
A_10_P003791 MGC68583 NM_001089807 ref|Xenopus laevis 
glucokinase regulator 
(MGC68583), mRNA 
[NM_001089807] 
-1.25922 -4.79308 0.000334 0.045932 
A_10_P005152 MGC80131 NM_001091994 ref|Xenopus laevis 
MGC80131 protein 
(MGC80131), mRNA 
[NM_001091994] 
-1.0589 -4.79236 0.000335 0.045932 
A_10_P024076 CD324874 CD324874 gb|AGENCOURT_14163999 
NICHD_XGC_Eye1 Xenopus 
laevis cDNA clone 
IMAGE:6949378 3', mRNA 
sequence [CD324874] 
-2.51775 -4.79194 0.000335 0.045932 
A_10_P005338 MGC82638 NM_001092149 ref|Xenopus laevis 
MGC82638 protein 
(MGC82638), mRNA 
0.77747 4.789729 0.000336 0.045974 
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ProbeName GeneName SystematicName Description logFC t P.Value adj.P.Val 
[NM_001092149] 
A_10_P009723 A_10_P0097
23 
A_10_P009723 Unknown -0.86511 -4.78555 0.000339 0.046066 
A_10_P012820 A_10_P0128
20 
A_10_P012820 Unknown 1.014849 4.785246 0.000339 0.046066 
A_10_P020795 BX855244 BX855244 gb|BX855244 
NICHD_XGC_Brn1 Xenopus 
laevis cDNA clone 
IMAGp998P1310583 ; 
IMAGE:4740732 5', mRNA 
sequence [BX855244] 
-0.60997 -4.78089 0.000342 0.04629 
A_10_P008659 spns1 NM_001094889 ref|Xenopus laevis 
hypothetical LOC495202 
(spns1), mRNA 
[NM_001094889] 
0.876421 4.775593 0.000345 0.04633 
A_10_P003130 ola1 NM_001086211 ref|Xenopus laevis Obg-like 
ATPase 1 (ola1), mRNA 
[NM_001086211] 
-0.87082 -4.77516 0.000345 0.04633 
A_10_P005441 MGC80425 NM_001092211 ref|Xenopus laevis 
MGC80425 protein 
(MGC80425), mRNA 
[NM_001092211] 
1.100829 4.774107 0.000346 0.04633 
A_10_P011156 TC373007 TC373007 tc|Rep: 39S ribosomal protein 
L14, mitochondrial precursor 
- Bos taurus (Bovine), partial 
(79%) [TC373007] 
0.816596 4.773029 0.000347 0.04633 
A_10_P003745 MGC68596 NM_001086575 ref|Xenopus laevis similar to 
electron-transfer-flavoprotein 
(MGC68596), mRNA 
[NM_001086575] 
0.84099 4.772089 0.000347 0.04633 
A_10_P006974 MGC80384 NM_001093465 ref|Xenopus laevis 
MGC80384 protein 
(MGC80384), mRNA 
[NM_001093465] 
0.87207 4.767826 0.00035 0.046333 
A_10_P005066 MGC83239 NM_001091953 ref|Xenopus laevis 
MGC83239 protein 
(MGC83239), mRNA 
[NM_001091953] 
-0.70008 -4.76738 0.00035 0.046333 
A_10_P008372 LOC494992 NM_001094699 ref|Xenopus laevis 
hypothetical LOC494992 
(LOC494992), mRNA 
[NM_001094699] 
1.156846 4.767121 0.000351 0.046333 
A_10_P020727 BC155963 BC155963 gb|Xenopus laevis cDNA 
clone IMAGE:8075198 
[BC155963] 
0.98934 4.760727 0.000355 0.046378 
A_10_P026080 A_10_P0260
80 
A_10_P026080 Unknown -1.06289 -4.75845 0.000356 0.046378 
A_10_P025601 mrps24-b CK797743 gb|AGENCOURT_18793767 
NICHD_XGC_Te2N 
Xenopus laevis cDNA clone 
IMAGE:7204483 5', mRNA 
sequence [CK797743] 
1.028575 4.757607 0.000357 0.046378 
A_10_P002778 LOC398448 BC108873 gb|Xenopus laevis similar to 
splicing factor, arginine 
[BC108873] 
-0.86268 -4.75687 0.000357 0.046378 
A_10_P003784 MGC68508 NM_001089814 ref|Xenopus laevis 
hypothetical protein 
MGC68508 (MGC68508), 
mRNA [NM_001089814] 
-1.07389 -4.7566 0.000357 0.046378 
A_10_P004373 MGC81068 NM_001091474 ref|Xenopus laevis 
hypothetical protein 
MGC81068 (MGC81068), 
0.797529 4.755543 0.000358 0.046378 
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ProbeName GeneName SystematicName Description logFC t P.Value adj.P.Val 
mRNA [NM_001091474] 
A_10_P008670 LOC495209 NM_001094895 ref|Xenopus laevis 
hypothetical LOC495209 
(LOC495209), mRNA 
[NM_001094895] 
1.601963 4.753821 0.000359 0.046378 
A_10_P009576 MGC85135 NM_001096528 ref|Xenopus laevis 
hypothetical protein 
MGC85135 (MGC85135), 
mRNA [NM_001096528] 
0.734717 4.753645 0.000359 0.046378 
A_10_P008659 spns1 NM_001094889 ref|Xenopus laevis 
hypothetical LOC495202 
(spns1), mRNA 
[NM_001094889] 
0.859803 4.749596 0.000362 0.046585 
A_10_P004915 timm23 NM_001091593 ref|Xenopus laevis 
Mitochondrial import inner 
membrane translocase subunit 
Tim23 (timm23), mRNA 
[NM_001091593] 
0.885956 4.746395 0.000364 0.046671 
A_10_P008367 LOC494987 NM_001094694 ref|Xenopus laevis 
hypothetical LOC494987 
(LOC494987), mRNA 
[NM_001094694] 
1.128012 4.744279 0.000365 0.046671 
A_10_P005973 MGC82078 NM_001092630 ref|Xenopus laevis 
MGC82078 protein 
(MGC82078), mRNA 
[NM_001092630] 
-0.97055 -4.74229 0.000367 0.046671 
A_10_P000831 A_10_P0008
31 
A_10_P000831 Unknown 0.801502 4.742247 0.000367 0.046671 
A_10_P026075 A_10_P0260
75 
A_10_P026075 Unknown -0.99506 -4.74068 0.000368 0.046671 
A_10_P006659 MGC81080 NM_001093246 ref|Xenopus laevis 
MGC81080 protein 
(MGC81080), mRNA 
[NM_001093246] 
1.053841 4.729974 0.000375 0.046882 
A_10_P020243 TC387226 TC387226 tc|Rep: Zgc:86599 - Danio 
rerio (Zebrafish) 
(Brachydanio rerio), partial 
(80%) [TC387226] 
1.000129 4.729455 0.000375 0.046882 
A_10_P008940 LOC495464 NM_001095116 ref|Xenopus laevis 
hypothetical LOC495464 
(LOC495464), mRNA 
[NM_001095116] 
-1.83329 -4.72935 0.000376 0.046882 
A_10_P008407 LOC495024 NM_001094730 ref|Xenopus laevis 
hypothetical LOC495024 
(LOC495024), mRNA 
[NM_001094730] 
-1.06098 -4.72917 0.000376 0.046882 
A_10_P025900 MGC132241 NM_001096346 ref|Xenopus laevis 
hypothetical protein 
MGC132241 (MGC132241), 
mRNA [NM_001096346] 
1.164424 4.729093 0.000376 0.046882 
A_10_P008295 fam136a NM_001094654 ref|Xenopus laevis 
hypothetical LOC494828 
(fam136a), mRNA 
[NM_001094654] 
1.297168 4.728305 0.000376 0.046882 
A_10_P005583 MGC80777 NM_001092329 ref|Xenopus laevis 
MGC80777 protein 
(MGC80777), mRNA 
[NM_001092329] 
0.847891 4.727306 0.000377 0.046882 
A_10_P003745 MGC68596 NM_001086575 ref|Xenopus laevis similar to 
electron-transfer-flavoprotein 
(MGC68596), mRNA 
[NM_001086575] 
0.79288 4.725806 0.000378 0.046882 
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ProbeName GeneName SystematicName Description logFC t P.Value adj.P.Val 
A_10_P015581 BJ052207 BJ052207 gb|BJ052207 NIBB Mochii 
normalized Xenopus neurula 
library Xenopus laevis cDNA 
clone XL040l23 3', mRNA 
sequence [BJ052207] 
-0.89031 -4.72318 0.00038 0.046976 
A_10_P025901 MGC83321 NM_001093371 ref|Xenopus laevis 
MGC83321 protein 
(MGC83321), mRNA 
[NM_001093371] 
1.045702 4.720966 0.000381 0.047034 
A_10_P008768 LOC495326 NM_001094992 ref|Xenopus laevis 
hypothetical LOC495326 
(LOC495326), mRNA 
[NM_001094992] 
-0.63711 -4.71862 0.000383 0.047105 
A_10_P006318 MGC84421 NM_001092928 ref|Xenopus laevis 
MGC84421 protein 
(MGC84421), mRNA 
[NM_001092928] 
-0.7006 -4.71446 0.000386 0.047333 
A_10_P006957 mec-12 NM_001094468 ref|Xenopus laevis mec-12 
protein (mec-12), mRNA 
[NM_001094468] 
-0.86142 -4.70935 0.000389 0.047645 
A_10_P005831 MGC83017 NM_001092524 ref|Xenopus laevis 
MGC83017 protein 
(MGC83017), mRNA 
[NM_001092524] 
1.314919 4.706078 0.000392 0.047749 
A_10_P002406 uqcrc2 NM_001086932 ref|Xenopus laevis Ubiquinol-
cytochrome C reductase 
complex (uqcrc2), mRNA 
[NM_001086932] 
0.956075 4.705137 0.000392 0.047749 
A_10_P000831 A_10_P0008
31 
A_10_P000831 Unknown 0.815635 4.70049 0.000396 0.047855 
A_10_P020778 TC397330 TC397330 tc|Rep: ITIM-containing 
receptor MAFA-L - Homo 
sapiens (Human), partial 
(16%) [TC397330] 
1.642085 4.69982 0.000396 0.047855 
A_10_P006825 Thrap3 NM_001103187 ref|Xenopus laevis thyroid 
hormone receptor-associated 
protein, 150 kDa subunit 
(Thrap3), mRNA 
[NM_001103187] 
-1.30773 -4.69801 0.000398 0.047855 
A_10_P026351 CO384479 CO384479 gb|AGENCOURT_26186018 
Blumberg_Cho Xenopus 
laevis cDNA clone 
IMAGE:7297372 5', mRNA 
sequence [CO384479] 
0.772762 4.697953 0.000398 0.047855 
A_10_P002350 shmt1 NM_001086887 ref|Xenopus laevis serine 
hydroxymethyltransferase 1 
(soluble) (shmt1), mRNA 
[NM_001086887] 
-0.84123 -4.69337 0.000401 0.048127 
A_10_P011039 A_10_P0110
39 
A_10_P011039 Unknown -0.66131 -4.68912 0.000404 0.04833 
A_10_P020428 BX851203 BX851203 gb|BX851203 Wellcome 
CRC pRN3 St13 17 egg 
animal cap Xenopus laevis 
cDNA clone 
IMAGp998A098661 ; 
IMAGE:3557648 5', mRNA 
sequence [BX851203] 
0.925099 4.688113 0.000405 0.04833 
A_10_P005066 MGC83239 NM_001091953 ref|Xenopus laevis 
MGC83239 protein 
(MGC83239), mRNA 
[NM_001091953] 
-0.76069 -4.68645 0.000406 0.048347 
A_10_P007703 MGC80725 NM_001094143 ref|Xenopus laevis 
MGC80725 protein 
1.118589 4.683657 0.000408 0.048465 
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ProbeName GeneName SystematicName Description logFC t P.Value adj.P.Val 
(MGC80725), mRNA 
[NM_001094143] 
A_10_P010056 BE508205 BE508205 gb|dc07d01.x1 NICHD XGC 
Li1 Xenopus laevis cDNA 
clone IMAGE:3396385 3', 
mRNA sequence [BE508205] 
0.861078 4.678747 0.000412 0.048772 
A_10_P020307 TC373831 TC373831 tc|Rep: Mitochondrial 28S 
ribosomal protein S5 (S5mt) 
(MRP-S5). - Xenopus 
tropicalis, partial (88%) 
[TC373831] 
1.271937 4.667876 0.00042 0.049434 
A_10_P004183 MGC81351 NM_001091103 ref|Xenopus laevis 
hypothetical protein 
MGC81351 (MGC81351), 
mRNA [NM_001091103] 
-0.68697 -4.66649 0.000421 0.049434 
A_10_P020170 TC398298 TC398298 Unknown 0.582363 4.66473 0.000423 0.049434 
A_10_P000402 polrmt-a NM_001087518 ref|Xenopus laevis 
polymerase (RNA) 
mitochondrial (DNA 
directed) (polrmt-a), nuclear 
gene encoding mitochondrial 
protein, mRNA 
[NM_001087518] 
0.884477 4.664557 0.000423 0.049434 
A_10_P020350 LOC1001013
05 
NM_001099890 ref|Xenopus laevis 
hypothetical protein 
LOC100101305 
(LOC100101305), mRNA 
[NM_001099890] 
1.253026 4.664133 0.000423 0.049434 
A_10_P006444 bcap29 NM_001093099 ref|Xenopus laevis B-cell 
receptor-associated protein 29 
(bcap29), mRNA 
[NM_001093099] 
-1.18963 -4.6602 0.000426 0.04966 
A_10_P003784 MGC68508 NM_001089814 ref|Xenopus laevis 
hypothetical protein 
MGC68508 (MGC68508), 
mRNA [NM_001089814] 
-1.05862 -4.65842 0.000427 0.049692 
A_10_P006825 Thrap3 NM_001103187 ref|Xenopus laevis thyroid 
hormone receptor-associated 
protein, 150 kDa subunit 
(Thrap3), mRNA 
[NM_001103187] 
-1.29655 -4.65458 0.00043 0.049912 
A_10_P008846 LOC495403 NM_001095061 ref|Xenopus laevis 
hypothetical LOC495403 
(LOC495403), mRNA 
[NM_001095061] 
-0.97323 -4.65304 0.000432 0.049923 
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Table 4-2: Overrepresented Biological Process with P value less or equal to 0.05 
GOBPID Pvalue OddsRatio ExpCount Count Size Term 
GO:0046121 0.000385 178.8679 0.034404 2 3
deoxyribonucleoside 
catabolic process 
GO:0006082 0.000388 3.531975 4.529817 13 395
organic acid metabolic 
process 
GO:0006629 0.000487 3.173653 5.917431 15 516 lipid metabolic process 
GO:0034440 0.000946 10.54566 0.447248 4 39 lipid oxidation 
GO:0006631 0.001523 4.655527 1.731651 7 151 fatty acid metabolic process 
GO:0034656 0.001881 44.68868 0.068807 2 6
nucleobase, nucleoside 
and nucleotide catabolic 
process 
GO:0006635 0.002746 12.375 0.286697 3 25 fatty acid beta-oxidation 
GO:0046148 0.003079 11.83445 0.298165 3 26
pigment biosynthetic 
process 
GO:0009060 0.004655 10.07265 0.344037 3 30 aerobic respiration 
GO:0019752 0.00493 3.147186 3.313376 9 306
carboxylic acid metabolic 
process 
GO:0046907 0.005433 6.291667 0.717639 4 68 intracellular transport 
GO:0042180 0.006014 2.864378 4.056196 10 372
cellular ketone metabolic 
process 
GO:0034654 0.006647 19.84067 0.126147 2 11
nucleobase, nucleoside, 
nucleotide and nucleic acid 
biosynthetic process 
GO:0046112 0.006647 19.84067 0.126147 2 11
nucleobase biosynthetic 
process 
GO:0009653 0.006721 2.669335 4.78211 11 417
anatomical structure 
morphogenesis 
GO:0044242 0.008108 5.555556 0.802752 4 70
cellular lipid catabolic 
process 
GO:0070727 0.009698 3.62291 1.84633 6 161
cellular macromolecule 
localization 
GO:0006779 0.010758 14.87107 0.16055 2 14
porphyrin biosynthetic 
process 
GO:0046320 0.010758 14.87107 0.16055 2 14
regulation of fatty acid 
oxidation 
GO:0000266 0.011468 Inf 0.011468 1 1 mitochondrial fission 
GO:0006145 0.011468 Inf 0.011468 1 1
purine base catabolic 
process 
GO:0006214 0.011468 Inf 0.011468 1 1 thymidine catabolic process 
GO:0006713 0.011468 Inf 0.011468 1 1
glucocorticoid catabolic 
process 
GO:0015910 0.011468 Inf 0.011468 1 1
peroxisomal long-chain 
fatty acid import 
GO:0019060 0.011468 Inf 0.011468 1 1
intracellular transport of 
viral proteins in host cell 
GO:0030970 0.011468 Inf 0.011468 1 1
retrograde protein 
transport, ER to cytosol 
GO:0032972 0.011468 Inf 0.011468 1 1
regulation of muscle 
filament sliding speed 
GO:0046655 0.011468 Inf 0.011468 1 1 folic acid metabolic process 
GO:0048034 0.011468 Inf 0.011468 1 1
heme O biosynthetic 
process 
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(Continued). 
GOBPID Pvalue OddsRatio ExpCount Count Size Term 
GO:0050666 0.011468 Inf 0.011468 1 1
regulation of homocysteine 
metabolic process 
GO:0050774 0.011468 Inf 0.011468 1 1
negative regulation of 
dendrite morphogenesis 
GO:0051708 0.011468 Inf 0.011468 1 1
intracellular protein 
transport in other organism 
during symbiotic interaction 
GO:0042168 0.012323 13.72424 0.172018 2 15 heme metabolic process 
GO:0055008 0.012323 13.72424 0.172018 2 15
cardiac muscle tissue 
morphogenesis 
GO:0006730 0.012741 6.780288 0.493119 3 43
one-carbon metabolic 
process 
GO:0009116 0.012741 6.780288 0.493119 3 43
nucleoside metabolic 
process 
GO:0030048 0.01398 12.74124 0.183486 2 16
actin filament-based 
movement 
GO:0060048 0.015729 11.88931 0.194954 2 17 cardiac muscle contraction 
GO:0006399 0.016211 6.158654 0.538991 3 47 tRNA metabolic process 
GO:0046395 0.016414 4.456241 0.986239 4 86
carboxylic acid catabolic 
process 
GO:0003015 0.019129 5.761866 0.573394 3 50 heart process 
GO:0033013 0.01949 10.48613 0.21789 2 19
tetrapyrrole metabolic 
process 
GO:0007283 0.020163 5.640625 0.584862 3 51 spermatogenesis 
GO:0006752 0.021498 9.901468 0.229358 2 20
group transfer coenzyme 
metabolic process 
GO:0044237 0.022287 2.000926 21.06257 28 2188 cellular metabolic process 
GO:0006210 0.022807 87.77778 0.022936 1 2 thymine catabolic process 
GO:0006212 0.022807 87.77778 0.022936 1 2 uracil catabolic process 
GO:0006420 0.022807 87.77778 0.022936 1 2
arginyl-tRNA 
aminoacylation 
GO:0006431 0.022807 87.77778 0.022936 1 2
methionyl-tRNA 
aminoacylation 
GO:0006521 0.022807 87.77778 0.022936 1 2
regulation of cellular amino 
acid metabolic process 
GO:0006601 0.022807 87.77778 0.022936 1 2
creatine biosynthetic 
process 
GO:0006626 0.022807 87.77778 0.022936 1 2
protein targeting to 
mitochondrion 
GO:0006784 0.022807 87.77778 0.022936 1 2
heme a biosynthetic 
process 
GO:0006853 0.022807 87.77778 0.022936 1 2 carnitine shuttle 
GO:0006895 0.022807 87.77778 0.022936 1 2
Golgi to endosome 
transport 
GO:0006975 0.022807 87.77778 0.022936 1 2
DNA damage induced 
protein phosphorylation 
GO:0007412 0.022807 87.77778 0.022936 1 2 axon target recognition 
GO:0015838 0.022807 87.77778 0.022936 1 2 betaine transport 
GO:0017004 0.022807 87.77778 0.022936 1 2
cytochrome complex 
assembly 
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Table 4-2: Overrepresented Biological Process with P value less or equal to 0.05 
(Continued). 
GOBPID Pvalue OddsRatio ExpCount Count Size Term 
GO:0019896 0.022807 87.77778 0.022936 1 2
axon transport of 
mitochondrion 
GO:0030240 0.022807 87.77778 0.022936 1 2
muscle thin filament 
assembly 
GO:0046125 0.022807 87.77778 0.022936 1 2
pyrimidine 
deoxyribonucleoside 
metabolic process 
GO:0046135 0.022807 87.77778 0.022936 1 2
pyrimidine nucleoside 
catabolic process 
GO:0050773 0.022807 87.77778 0.022936 1 2
regulation of dendrite 
development 
GO:0051180 0.022807 87.77778 0.022936 1 2 vitamin transport 
GO:0015908 0.025759 8.907547 0.252294 2 22 fatty acid transport 
GO:0006886 0.02721 3.188949 1.711783 5 152
intracellular protein 
transport 
GO:0009056 0.02727 1.97122 8.188073 14 714 catabolic process 
GO:0010565 0.031665 7.88796 0.281602 2 25
regulation of cellular ketone 
metabolic process 
GO:0050905 0.032731 7.740771 0.286697 2 25 neuromuscular process 
GO:0006222 0.034018 43.87963 0.034404 1 3 UMP biosynthetic process 
GO:0006565 0.034018 43.87963 0.034404 1 3 L-serine catabolic process 
GO:0007031 0.034018 43.87963 0.034404 1 3 peroxisome organization 
GO:0008535 0.034018 43.87963 0.034404 1 3
respiratory chain complex 
IV assembly 
GO:0009173 0.034018 43.87963 0.034404 1 3
pyrimidine ribonucleoside 
monophosphate metabolic 
process 
GO:0015695 0.034018 43.87963 0.034404 1 3 organic cation transport 
GO:0042762 0.034018 43.87963 0.034404 1 3
regulation of sulfur 
metabolic process 
GO:0043171 0.034018 43.87963 0.034404 1 3 peptide catabolic process 
GO:0051181 0.034018 43.87963 0.034404 1 3 cofactor transport 
GO:0007018 0.037743 7.118491 0.309633 2 27
microtubule-based 
movement 
GO:0044270 0.039306 4.283883 0.756881 3 66
nitrogen compound 
catabolic process 
GO:0018130 0.040353 6.843251 0.321101 2 28
heterocycle biosynthetic 
process 
GO:0006003 0.045102 29.24691 0.045872 1 4
fructose 2,6-bisphosphate 
metabolic process 
GO:0006207 0.045102 29.24691 0.045872 1 4
'de novo' pyrimidine base 
biosynthetic process 
GO:0009130 0.045102 29.24691 0.045872 1 4
pyrimidine nucleoside 
monophosphate 
biosynthetic process 
GO:0016579 0.045102 29.24691 0.045872 1 4 protein deubiquitination 
GO:0019048 0.045102 29.24691 0.045872 1 4 virus-host interaction 
GO:0030433 0.045102 29.24691 0.045872 1 4
ER-associated protein 
catabolic process 
GO:0042921 0.045102 29.24691 0.045872 1 4 glucocorticoid receptor 
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Table 4-2: Overrepresented Biological Process with P value less or equal to 0.05 
(Continued). 
GOBPID Pvalue OddsRatio ExpCount Count Size Term 
signaling pathway 
GO:0045739 0.045102 29.24691 0.045872 1 4
positive regulation of DNA 
repair 
GO:0055003 0.045102 29.24691 0.045872 1 4 cardiac myofibril assembly 
GO:0006220 0.04577 6.351752 0.344037 2 30
pyrimidine nucleotide 
metabolic process 
GO:0044238 0.046774 1.809313 19.23364 25 2058 primary metabolic process 
GO:0055114 0.047111 2.291433 3.346317 7 304 oxidation reduction 
GO:0022900 0.048845 3.906355 0.825688 3 72 electron transport chain 
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Table 4-3: Overrepresented Cellular Component with p value less or equal to 0.05 
GOCCID Pvalue OddsRatio ExpCount Count Size Term 
GO:0005739 2.11E-08 6.090883 5.0057 20 456 mitochondrion 
GO:0005622 3.45E-08 24.75618 35.18261 51 3205 intracellular 
GO:0005737 1.15E-07 7.249905 29.55119 47 2692 cytoplasm 
GO:0043229 9.61E-06 4.193721 27.86067 43 2538 intracellular organelle 
GO:0031966 8.21E-05 13.37798 0.461589 5 45 mitochondrial membrane 
GO:0043227 0.000839 2.945802 18.57327 29 2034 
membrane-bounded 
organelle 
GO:0044422 0.000854 2.525207 14.87439 26 1355 organelle part 
GO:0031967 0.000863 4.593109 2.059526 8 197 organelle envelope 
GO:0005777 0.002205 8.223404 0.559848 4 51 peroxisome 
GO:0005778 0.004051 26.73143 0.098797 2 9 peroxisomal membrane 
GO:0044438 0.008534 16.99636 0.142706 2 13 microbody part 
GO:0005742 0.010977 Inf 0.010977 1 1 
mitochondrial outer 
membrane translocase 
complex 
GO:0016507 0.010977 Inf 0.010977 1 1 
fatty acid beta-oxidation 
multienzyme complex 
GO:0031307 0.010977 Inf 0.010977 1 1 
integral to mitochondrial 
outer membrane 
GO:0042643 0.010977 Inf 0.010977 1 1 actomyosin, actin part 
GO:0031968 0.017016 6.041685 0.548871 3 50 
organelle outer 
membrane 
GO:0005783 0.020568 2.440918 4.160439 9 379 endoplasmic reticulum 
GO:0001741 0.021837 91.84314 0.021955 1 2 XY body 
GO:0005779 0.021837 91.84314 0.021955 1 2 
integral to peroxisomal 
membrane 
GO:0070435 0.021837 91.84314 0.021955 1 2 Shc-EGFR complex 
GO:0030131 0.023732 9.33 0.241503 2 22 clathrin adaptor complex 
GO:0005743 0.026526 3.216312 1.701499 5 155 
mitochondrial inner 
membrane 
GO:0000138 0.032579 45.91176 0.032932 1 3 Golgi trans cisterna 
GO:0001673 0.032579 45.91176 0.032932 1 3 male germ cell nucleus 
GO:0005905 0.03483 7.456 0.29639 2 27 coated pit 
GO:0005759 0.038251 3.382054 1.281461 4 119 mitochondrial matrix 
GO:0005623 0.041338 Inf 48.92632 52 4457 cell 
GO:0000803 0.043205 30.60131 0.04391 1 4 sex chromosome 
GO:0005861 0.043205 30.60131 0.04391 1 4 troponin complex 
GO:0005829 0.044367 1.909906 7.113363 12 648 cytosol 
GO:0031300 0.046879 3.97873 0.812328 3 74 
intrinsic to organelle 
membrane 
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Table 4-4. Overrepresented Molecular Function with p value less or equal to 0.05 
GOMFID Pvalue OddsRatio ExpCount Count Size Term 
GO:0003857 0.001894 44.50926 0.069036 2 6 
3-hydroxyacyl-CoA 
dehydrogenase activity 
GO:0004300 0.001894 44.50926 0.069036 2 6 
enoyl-CoA hydratase 
activity 
GO:0003824 0.005408 2.364609 17.42548 26 1808 catalytic activity 
GO:0005159 0.005516 22.23611 0.115061 2 10 
insulin-like growth factor 
receptor binding 
GO:0004222 0.009351 16.16162 0.149579 2 13 
metalloendopeptidase 
activity 
GO:0004137 0.011506 Inf 0.011506 1 1 
deoxycytidine kinase 
activity 
GO:0004139 0.011506 Inf 0.011506 1 1 
deoxyribose-phosphate 
aldolase activity 
GO:0004159 0.011506 Inf 0.011506 1 1 
dihydrouracil 
dehydrogenase (NAD+) 
activity 
GO:0004408 0.011506 Inf 0.011506 1 1 
holocytochrome-c 
synthase activity 
GO:0004487 0.011506 Inf 0.011506 1 1 
methylenetetrahydrofolate 
dehydrogenase (NAD+) 
activity 
GO:0004655 0.011506 Inf 0.011506 1 1 
porphobilinogen synthase 
activity 
GO:0008240 0.011506 Inf 0.011506 1 1 
tripeptidyl-peptidase 
activity 
GO:0008495 0.011506 Inf 0.011506 1 1 
protoheme IX 
farnesyltransferase 
activity 
GO:0008665 0.011506 Inf 0.011506 1 1 
2'-phosphotransferase 
activity 
GO:0008709 0.011506 Inf 0.011506 1 1 
7-alpha-hydroxysteroid 
dehydrogenase activity 
GO:0016287 0.011506 Inf 0.011506 1 1 
glycerone-phosphate O-
acyltransferase activity 
GO:0016508 0.011506 Inf 0.011506 1 1 
long-chain-enoyl-CoA 
hydratase activity 
GO:0016509 0.011506 Inf 0.011506 1 1 
long-chain-3-hydroxyacyl-
CoA dehydrogenase 
activity 
GO:0017113 0.011506 Inf 0.011506 1 1 
dihydropyrimidine 
dehydrogenase (NADP+) 
activity 
GO:0030731 0.011506 Inf 0.011506 1 1 
guanidinoacetate N-
methyltransferase activity 
GO:0047015 0.011506 Inf 0.011506 1 1 
3-hydroxy-2-
methylbutyryl-CoA 
dehydrogenase activity 
GO:0047150 0.011506 Inf 0.011506 1 1 
betaine-homocysteine S-
methyltransferase activity 
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Table 4-4. Overrepresented Molecular Function with p value less or equal to 0.05 
(Continued). 
GOMFID Pvalue OddsRatio ExpCount Count Size Term 
GO:0047620 0.011506 Inf 0.011506 1 1 
acylglycerol kinase 
activity 
GO:0016835 0.012863 6.751415 0.494761 3 43 
carbon-oxygen lyase 
activity 
GO:0016747 0.014154 4.667653 0.943497 4 82 
transferase activity, 
transferring acyl groups 
other than amino-acyl 
groups 
GO:0070011 0.014749 3.768081 1.46127 5 127 
peptidase activity, acting 
on L-amino acid peptides 
GO:0001729 0.022882 87.45455 0.023012 1 2 ceramide kinase activity 
GO:0004158 0.022882 87.45455 0.023012 1 2 
dihydroorotate oxidase 
activity 
GO:0004421 0.022882 87.45455 0.023012 1 2 
hydroxymethylglutaryl-
CoA synthase activity 
GO:0004477 0.022882 87.45455 0.023012 1 2 
methenyltetrahydrofolate 
cyclohydrolase activity 
GO:0004488 0.022882 87.45455 0.023012 1 2 
methylenetetrahydrofolate 
dehydrogenase (NADP+) 
activity 
GO:0004658 0.022882 87.45455 0.023012 1 2 
propionyl-CoA 
carboxylase activity 
GO:0004814 0.022882 87.45455 0.023012 1 2 
arginine-tRNA ligase 
activity 
GO:0004825 0.022882 87.45455 0.023012 1 2 
methionine-tRNA ligase 
activity 
GO:0005046 0.022882 87.45455 0.023012 1 2 KDEL sequence binding 
GO:0008474 0.022882 87.45455 0.023012 1 2 
palmitoyl-(protein) 
hydrolase activity 
GO:0008898 0.022882 87.45455 0.023012 1 2 
homocysteine S-
methyltransferase activity 
GO:0031013 0.022882 87.45455 0.023012 1 2 troponin I binding 
GO:0031014 0.022882 87.45455 0.023012 1 2 troponin T binding 
GO:0035259 0.022882 87.45455 0.023012 1 2 
glucocorticoid receptor 
binding 
GO:0008168 0.026023 5.081524 0.644339 3 56 methyltransferase activity 
GO:0008374 0.028186 8.447972 0.264639 2 23 O-acyltransferase activity 
GO:0016874 0.029798 2.7666 2.370249 6 206 ligase activity 
GO:0003985 0.034129 43.71818 0.034518 1 3 
acetyl-CoA C-
acetyltransferase activity 
GO:0004768 0.034129 43.71818 0.034518 1 3 
stearoyl-CoA 9-
desaturase activity 
GO:0005068 0.034129 43.71818 0.034518 1 3 
transmembrane receptor 
protein tyrosine kinase 
adaptor protein activity 
GO:0008242 0.034129 43.71818 0.034518 1 3 omega peptidase activity 
GO:0016491 0.041967 2.111649 4.705979 9 409 oxidoreductase activity 
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Table 4-4. Overrepresented Molecular Function with p value less or equal to 0.05 
(Continued). 
GOMFID Pvalue OddsRatio ExpCount Count Size Term 
GO:0008565 0.043297 6.562414 0.333676 2 29 protein transporter activity 
GO:0003873 0.04525 29.13939 0.046024 1 4 
6-phosphofructo-2-kinase 
activity 
GO:0003988 0.04525 29.13939 0.046024 1 4 
acetyl-CoA C-
acyltransferase activity 
GO:0004095 0.04525 29.13939 0.046024 1 4 
carnitine O-
palmitoyltransferase 
activity 
GO:0004177 0.04525 29.13939 0.046024 1 4 aminopeptidase activity 
GO:0004886 0.04525 29.13939 0.046024 1 4 retinoid-X receptor activity
 
 
 
 
 
 
 
Table 4-5. Overrepresented Signaling Pathway with p value less or equal to 0.05 
 
 
 
 
 
 
 
 
KEGGID Pvalue OddsRatio ExpCount Count Size Term
1040 7.57E-05 22.1086 0.237145 4 21 Biosynthesis of unsaturated fatty acids
3320 0.000929 7.531902 0.767897 5 68 PPAR signaling pathway
280 0.001416 9.351923 0.496874 4 44 Valine, leucine and isoleucine degradation
62 0.003358 30.2284 0.090341 2 8 Fatty acid elongation in mitochondria
260 0.004463 10.22222 0.338778 3 30 Glycine, serine and threonine metabolism
4260 0.009346 5.310989 0.835652 4 74 Cardiac muscle contraction
860 0.010736 7.246773 0.462997 3 41 Porphyrin and chlorophyll metabolism
71 0.011471 7.059507 0.474289 3 42 Fatty acid metabolism
670 0.013581 12.93386 0.180682 2 16 One carbon pool by folate
5014 0.023654 5.280479 0.621093 3 55 Amyotrophic lateral sclerosis (ALS)
1100 0.024189 1.857256 12.2073 19 1081 Metabolic pathways
410 0.025039 9.042593 0.248437 2 22 beta-Alanine metabolism
4920 0.039305 4.279776 0.756604 3 67 Adipocytokine signaling pathway
4142 0.040026 3.320859 1.298649 4 115 Lysosome
640 0.050055 6.016049 0.361363 2 32 Propanoate metabolism
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Table 4-6. Cross-species analysis. The genes that show up-regulation in both Xenopus 
and human are highlighted in green; the genes that show down-regulation in both 
Xenopus and human are highlighted in red; the rest of them are genes that are regulated in 
opposite direction. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GeneName SystematicName logFC adj.P.Val protein_id Common name
FSHD 
patient gene_title in E1/E2
MGC80384 NM_001093465 0.88 0.046 NP_057483
p53-inducible cell-survival factor; TP53 
regulated inhibitor of apoptosis 1 (TRIAP1) +
tumor protein p53 inducible nuclear 
protein 2
MGC82075 NM_001094410 1.07 0.026 NP_775742
mitochondrial, solute carrier family 25, 
member 26 (SLC25A26) +
solute carrier family 25 (mitochondrial 
carrier; phosphate carrier), member 23
MGC81794 NM_001092573 1.32 0.028 NP_060668
DnaJ (Hsp40) subfamily C, member 11 
(DNAJC11) +
DnaJ (Hsp40) homolog, subfamily B, 
member 4
abhd1 NM_001087032 1.65 0.018 NP_612213 abhydrolase domain containing 3 (ABHD3) +
abhydrolase domain containing 2
LOC1000372
06 NM_001097895 2.08 0.023 NP_005138
DnaJ (Hsp40) subfamily A, member 3 
(DNAJA3) +
DnaJ (Hsp40) homolog, subfamily B, 
member 4
MGC80435 NM_001092215 -0.94 0.032
NP_001129
134
RAB7L1, member RAS oncogene family-
like 1 (RAB7L) -
RAB10, member RAS oncogene family
MGC81351 NM_001091103 -0.69 0.049 NP_079337
leucine rich repeat containing 8 family, 
member E (LRRC8E) -
Leucine rich repeat containing 7
MGC84451 NM_001092934 -1.15 0.024 NP_003396
tyrosine 3-monooxygenase/tryptophan 5-
monooxygenase activation protein, 14-3-3 
eta polypeptide; YWHAH) -
tyrosine 3-monooxygenase/tryptophan 5-
monooxygenase activation protein, 
epsilon polypeptide
MGC53823 NM_001086195 -2.01 0.023 NP_005150 alpha actin, cardiac muscle (ACTC1) + alpha actin, cardiac muscle 
anxa1 NM_001086675 -0.97 0.044 NP_000691 annexin A1 (anxa1) + Annexin A4
MGC85135 NM_001096528 0.76 0.040 NP_003434
zinc finger and BTB domain containing 17 
(ZBTB17) -
zinc finger and BTB domain containing 20
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Table 4-7. Differentially expressed genes with FDR adjusted p ≤ 0.05. 
probe_id Gene.Symbol logFC AveExpr t P.Value adj.P.Val 
1641174_at RFeSP 7.069927 5.954747 70.39309 7.34E-08 0.001392 
1631101_at  CG6480 4.349746 9.184376 43.10005 6.29E-07 0.005956 
1628052_at Cyp6a17 5.469898 5.192328 37.59298 1.14E-06 0.007067 
1637545_at CG1837 5.723598 5.806807 35.36791 1.49E-06 0.007067 
1641538_at CG30017 2.795461 4.084287 30.68686 2.77E-06 0.01051 
1636431_at CG8768 4.191012 7.309587 27.97339 4.15E-06 0.013118 
1632063_s_at CG11357 -3.32199 5.694567 -25.9791 5.73E-06 0.015522 
1637955_a_at CG1827 0.764728 7.205576 24.47163 7.44E-06 0.016606 
1641301_at Pif1A 0.411429 4.58646 24.10687 7.94E-06 0.016606 
1634246_at CG11319 4.580648 5.99319 23.30767 9.20E-06 0.016606 
1637602_at Edem1 4.616311 5.082838 23.05798 9.64E-06 0.016606 
1640103_s_at CG17224 3.105918 8.748293 22.3701 1.10E-05 0.017366 
AFFX-CreX-5_at --- 0.206413 14.94331 21.58683 1.28E-05 0.018718 
1632986_a_at CG15088 1.019383 4.68989 21.13311 1.41E-05 0.019062 
1638687_at CG40298 4.538275 4.755426 20.29924 1.68E-05 0.01973 
1633465_at Cp7Fa -1.23712 3.010346 -20.0484 1.77E-05 0.01973 
1629362_at mthl8 -1.67606 3.188087 -20.0249 1.78E-05 0.01973 
1633009_a_at CG6640 5.593827 6.9478 19.7876 1.87E-05 0.01973 
1629760_s_at --- 6.218815 6.159622 18.80811 2.34E-05 0.021412 
1635705_at CG12858 3.418971 4.587067 18.75085 2.37E-05 0.021412 
1624224_at --- 0.728234 6.254435 18.7402 2.37E-05 0.021412 
1634124_at CG30428 1.036816 6.550903 17.72329 3.02E-05 0.026029 
1638716_a_at CG10725 -8.36802 7.712359 -16.9704 3.65E-05 0.030044 
1628617_at dro4 -5.27215 9.920712 -16.4794 4.14E-05 0.032621 
1624864_s_at dock 3.665935 5.047635 16.33258 4.30E-05 0.032621 
1636909_at CG4078 -1.05495 3.991721 -15.6944 5.11E-05 0.035964 
1630307_at Cpr64Ad 2.28249 5.30878 15.68587 5.12E-05 0.035964 
1634594_at CG17738 2.329732 4.54267 15.38668 5.57E-05 0.037685 
1639983_at CG34290 2.018684 5.846892 14.61295 6.95E-05 0.04545 
1626966_s_at --- 4.190177 5.633164 14.41863 7.37E-05 0.046542 
1626667_at miple -3.7984 7.126027 -14.0706 8.18E-05 0.046879 
1625428_at CG13707 -1.56792 4.610531 -14.0319 8.28E-05 0.046879 
1641235_at CG14102 2.136413 5.841115 13.85754 8.74E-05 0.046879 
1635500_a_at pros 1.619407 7.789966 13.80551 8.88E-05 0.046879 
1640075_a_at path -3.35882 9.005333 -13.8054 8.88E-05 0.046879 
1622906_at CG9027 3.452583 4.732071 13.63171 9.38E-05 0.046879 
1639667_at --- 1.824238 3.299644 13.61987 9.41E-05 0.046879 
1635628_s_at Nipsnap -0.26328 10.57289 -13.5821 9.53E-05 0.046879 
1627436_s_at Pdp1 -2.06098 8.39244 -13.4571 9.91E-05 0.046879 
1630568_at CG34040 5.503528 4.972904 13.37857 0.000102 0.046879 
1637469_at pen-2 -0.57308 7.189034 -13.3525 0.000103 0.046879 
1630072_a_at CG10096 -2.37598 7.704532 -13.3109 0.000104 0.046879 
1640448_x_at --- 2.339501 3.563791 13.13273 0.00011 0.048515 
1630419_a_at CG7300 3.93903 6.300019 13.04711 0.000113 0.048761 
1627324_at lola 3.27845 5.994899 12.96729 0.000116 0.048949 
1623782_at SCAP 4.136644 6.264481 12.74196 0.000125 0.049752 
1623894_a_at CG8086 0.648871 7.047705 12.73514 0.000126 0.049752 
1630411_at CG9945 1.106967 6.003906 12.69322 0.000127 0.049752 
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Table 4-7. Differentially expressed genes with FDR adjusted p ≤ 0.05 
(Continued). 
probe_id Gene.Symbol logFC AveExpr t P.Value adj.P.Val 
1626411_at l(1)G0193 -0.48245 8.811053 -12.664 0.000129 0.049752 
 
 
 
Table 4-8. Overrepresented Biological Process with p value less or equal to 0.05. 
 
 
 
 
Table 4-9. Overrepresented Cellular Component with p value less or equal to 0.05. 
 
 
 
 
 
 
 
GOCCID Pvalue OddsRatio ExpCount Count Size Term
GO:0009288 0.023907 51.53333 0.024139 1 6 bacterial-type flagellum
GO:0045180 0.027838 42.9375 0.028162 1 7 basal cortex
GO:0005750 0.04341 25.74583 0.044255 1 11 mitochondrial respiratory chain complex III
GO:0009986 0.04341 25.74583 0.044255 1 11 cell surface
GOBPID Pvalue OddsRatio ExpCount Count Size Term
GO:0035103 0.010068 154.125 0.010101 1 3 sterol regulatory element binding protein cleavage
GO:0000042 0.013403 102.7361 0.013468 1 4 protein targeting to Golgi
GO:0030433 0.013403 102.7361 0.013468 1 4 ER-associated protein catabolic process
GO:0006984 0.016727 77.04167 0.016835 1 5 ER-nuclear signaling pathway
GO:0007406 0.016727 77.04167 0.016835 1 5 negative regulation of neuroblast proliferation
GO:0050896 0.021097 2.953478 2.922559 7 868 response to stimulus
GO:0051704 0.022096 5.532686 0.609428 3 181 multi-organism process
GO:0001539 0.023342 51.34722 0.023569 1 7 ciliary or flagellar motility
GO:0006801 0.023342 51.34722 0.023569 1 7 superoxide metabolic process
GO:0007409 0.02406 5.347826 0.62963 3 187 axonogenesis
GO:0007402 0.026633 44.00595 0.026936 1 8 ganglion mother cell fate determination
GO:0009166 0.029914 38.5 0.030303 1 9 nucleotide catabolic process
GO:0006891 0.033184 34.21759 0.03367 1 10 intra-Golgi vesicle-mediated transport
GO:0007584 0.036444 30.79167 0.037037 1 11 response to nutrient
GO:0010001 0.036444 30.79167 0.037037 1 11 glial cell differentiation
GO:0042676 0.036444 30.79167 0.037037 1 11 compound eye cone cell fate commitment
GO:0006122 0.039693 27.98864 0.040404 1 12 mitochondrial electron transport, ubiquinol to cytochrome c
GO:0001964 0.042932 25.65278 0.043771 1 13 startle response
GO:0031987 0.042932 25.65278 0.043771 1 13 locomotion involved in locomotory behavior
GO:0042023 0.042932 25.65278 0.043771 1 13 DNA endoreduplication
GO:0048854 0.042932 25.65278 0.043771 1 13 brain morphogenesis
GO:0016199 0.04616 23.67628 0.047138 1 14 axon midline choice point recognition
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Table 4-10. Overrepresented Molecular Function with p value less or equal to 0.05. 
 
 
 
 
Table 4-11: Overrepresented signaling pathway with p value less or equal to 0.05. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
KEGGID Pvalue OddsRatio ExpCount Count Size Term
4711 0.028068 46.66667 0.028369 1 10 Circadian rhythm - fly
511 0.047323 26.1625 0.048227 1 17 Other glycan degradation
4330 0.058182 20.89 0.059574 1 21 Notch signaling pathway
GOMFID Pvalue OddsRatio ExpCount Count Size Term
GO:0003948 0.010218 150.9821 0.010252 1 3 N4-(beta-N-acetylglucosaminyl)-L-asparaginase activity
GO:0004850 0.010218 150.9821 0.010252 1 3 uridine phosphorylase activity
GO:0004784 0.013602 100.6429 0.01367 1 4 superoxide dismutase activity
GO:0005275 0.015494 11.52675 0.191374 2 56 amine transmembrane transporter activity
GO:0004571 0.016975 75.47321 0.017087 1 5 mannosyl-oligosaccharide 1,2-alpha-mannosidase activity
GO:0017032 0.016975 75.47321 0.017087 1 5 potassium:amino acid symporter activity
GO:0008499 0.023686 50.30357 0.023922 1 7 UDP-galactose:beta-N-acetylglucosamine beta-1,3-galactosyltransferase activity
GO:0051537 0.027025 43.11224 0.027339 1 8 2 iron, 2 sulfur cluster binding
GO:0003756 0.033671 33.52381 0.034174 1 10 protein disulfide isomerase activity
GO:0005070 0.033671 33.52381 0.034174 1 10 SH3/SH2 adaptor activity
GO:0008121 0.033671 33.52381 0.034174 1 10 ubiquinol-cytochrome-c reductase activity
GO:0005158 0.036977 30.16786 0.037591 1 11 insulin receptor binding
GO:0016679 0.043557 25.13393 0.044426 1 13 oxidoreductase activity, acting on diphenols and related substances as donors
GO:0008239 0.04683 23.1978 0.047844 1 14 dipeptidyl-peptidase activity
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CHAPTER 5: C. ELEGANS AS A MODEL ORGANISM TO STUDY 
GENES CRITICAL FOR MUSCLE DEVELOPMENT AND 
INSIGHTS INTO FSHD 
  
Implications of PAT-9 identification  
 We isolated the pat-9 gene through SNP mapping, candidate genes searching, and 
confirmed that T27b1.2 is pat-9 by RNA interference, transformation rescuing, and 
identification of the splice site mutation. Bioinformatics identified 3 putative C2H2 zinc 
fingers in PAT-9 amino acid sequence and pat-9 is expressed at every early stage during 
development and the protein is exclusively localized in nuclei through all developmental 
stages. In addition, yeast one-hybrid and ChIP indicate PAT-9 is a DNA binding protein 
with specific sites in the promoters of several genes.  These data all suggest PAT-9 is a 
muscle-specific transcription factor.   
 Genetic screens for mutants with disrupted muscle attachment sites identified 
several genes that are critical for proper muscle function.  All of the previously identified 
and characterized Pat genes encode proteins located at muscle attachment sites in C. 
elegans, which are analogues to vertebrate focal adhesion in both protein components and 
structure.  In all Pats, including Pat-9, the muscle attachments are still formed but 
myofilament organization is disrupted.  However, some animals can still develop into 
adults showing uncoordinated and slow locomotion, a phenotype that is called Unc 
(uncoordinated). Certain genes, depending on their mutation can be Unc and Pat. For 
example, a splice-site mutation of unc-97 showed an Unc phenotype, but a null allele or 
RNAi knockdown produces a Pat phenotype.  
 The assembly of a muscle attachment shows a distinct dependence pathway for 
the dense body and M line. The study of the assembly pathway is mainly focused on the 
protein’s physical interactions at attachment sites. However, some proteins have 
localizations at the attachment site and in the nucleus.  An UNC-97::GFP fusion protein 
shows that this transgene product localized at both muscle attachment sites and body wall 
muscle nuclei. UNC-97’s expression and function in muscle attachment sites are 
thoroughly studied, but its nuclear function is not fully understood (Norman, 2007). 
Another newly identified protein in Unc family is called UNC-98. UNC-98 has 4 putative 
C2H2 zinc finger domains and is localized at both M-line and nuclei. Its nuclear function 
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is not clear, but functional domain study shows that these 4 C2H2 zinc fingers are 
indispensible for UNC-98 localization at muscle attachment sites and its interaction with 
UNC-97 (Mercer, 2003).  Here, we showed that PAT-9 is a C2H2 zinc finger protein that 
is localized exclusively in body wall muscle nuclei, making PAT-9 unique among the Pat 
mutants. Interestingly, Pat-9 mutants show a severe Pat phenotype. It suggests that 
transcriptional regulation plays a critical role in assembly of muscle attachments and this 
aspect of muscle attachment site assembly has not been thoroughly studied. To begin to 
determine the genes regulated by PAT-9, we tested several protein components for their 
expression and localization at muscle attachment sites, including UNC-52/perlecan, PAT-
3/beta-integrin, PAT-4/ILK, DEB-1/vinculin and MYO-3/MHC-A. All these protein 
components were expressed, but their assembly was disrupted. Although we could not 
identify genes regulated by PAT-9 directly we conclude that PAT-9 is crucial and 
probably functions at the most upstream of muscle attachment assembly pathway 
(Chapter 2).  
 Based on recently published transcription factor-DNA interaction database 
(Barrasa, 2007), PAT-9 (also called ztf-19) is predicted to bind to the promoter of tbx-2 
(Roy Chowdhuri, 2006).  TBX-2 is expressed from early embryo stage to adult and is 
specifically required for development of ABa-derived pharyngeal muscles; RNAi reveals 
that tbx-2 is critical for early larval development (Mercer, 2003; Norman, 2007; Roy 
Chowdhuri, 2006). Interestingly, tbx-2::gfp expression was also observed in body wall 
muscles at bean stage and later, in 2- to 3-fold embryos, the same expression pattern seen 
for pat-9, and muscle defects in tbx-2 mutants occuring at those embryo stage are also 
observed. Both transcription factors are indispensable for embryogenesis and early larval 
development. We hypothesize that PAT-9 regulates tbx-2 expression, and likely the 
expression of other genes. The function of PAT-9, as a C2H2 zinc finger transcription 
factor, is still not fully understood. The assembly of muscle attachments is regulated by 
both transcriptional regulators and proper organization of proteins in cytoplasm. Our 
study shows that PAT-9 is indispensible for the integrity of muscle attachment sites at 
transcription level. 
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Implications of the FRG-1 analysis 
FRG1 and Cell Adhesion 
            In vertebrates, overexpression of facioscapulohumeral muscular dystrophy 
(FSHD) region gene 1 (FRG1) recapitulates the pathophysiology exhibited by FSHD 
patients, though FRG1’s role in FSHD is still controversial and no precise function for 
FRG1 has been described in any organism.  To gain insight into FRG1’s function and 
potential role in FSHD, we analyzed the highly conserved C. elegans ortholog, frg-1.  C. 
elegans body wall muscles contain two distinct subcellular pools of FRG-1; nuclear 
FRG-1, concentrated in the nucleoli, and cytoplasmic FRG-1 associated with the Z-
disk/costamere-like structures called dense bodies.  Functionally, we demonstrate that 
FRG-1 is an F-actin bundling protein, consistent with its localization to dense bodies, and 
this activity is conserved with the human FRG1 (Chapter 3).  This is particularly 
intriguing because it places FRG-1 alongside the list of dense body components whose 
vertebrate orthologs are involved in myriad myopathies associated with disrupted 
costameres and Z-disks (Hoffman, 1988; Hoffman, 1987).  Thus, this study on the C. 
elegans FRG-1, identifying it as a previously unknown component of muscle 
attachments, may have profound implications for understanding muscle development and 
disease. 
  
FRG1 and RNA biogenesis 
            Our studies in C. elegans have shown that overexpressed FRG-1 preferentially 
accumulated in the nucleus and, when overexpressed specifically from the frg-1 
promoter, disrupted the adult ventral muscle structure and organization. In vertebrate cell 
culture, FRG1 has been shown to localize in the nucleolus, Cajal bodies, and nuclear 
speckles, which suggested a role for FRG1 in RNA biogenesis (van Koningsbruggen, 
2004). The nucleolus is involved in ribosomal RNA biogenesis and ribosome assembly. 
Cajal bodies are involved in post-transcriptional modification of spliceosomal small 
nuclear RNAs (snRNAs) and small nucleolar RNAs (snoRNA).  RNA inhibition analysis 
shows that FRG1 redistributed from the above organelles to nucleoplasm, providing 
evidence for FRG1’s involvement in RNA biogenesis. FRG1 is co-localized with 
PABPN1 and SMN. Both genes are involved in RNA biogenesis and are involved in 
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oculopharyngeal muscular dystrophy (OPMD) and spinal muscular atrophy (SMA) 
respectively (van Koningsbruggen, 2004). Novel Cajal body and speckle proteins have 
been identified as binding partners of FRG1, which further confirm FRG1’s role in RNA 
biogenesis (van Koningsbruggen, 2007).  Gabellini and colleagues found that specific 
pre-mRNAs undergo aberrant alternative splicing in both transgenic mice overexpressing 
frg1 and in FSHD patient samples (Gabellini, 2006). FSHD myoblasts display both 
alternative splicing and down regulation of mRNA stability of The Fragile X Mental 
retardation-Related 1 (FXR1), a gene with a critical function in myogenesis (Davidovic, 
2008). Therefore, our evidence indicating that mis-regulation of FRG1 will result in 
improper accumulation of FRG1 in nuclei, suggests a mechanism linking FRG1 
expression levels to global mis-regulation of RNA biogenesis.  
 
FRG1 affects signaling pathways 
            FRG1 has a critical role in angiogenesis illustrated by knocking down frg1 levels 
in Xenopus resulting in the loss of much of the vitalline vascular network and intersomitic 
veins as well as a thinner post-cardinal vein.  Conversely, overexpression of frg1 results 
in abnormal vascular development manifested as increased angiogenesis and spurious 
vascular branching in Xenopus (Wuebbles, 2009). Interestingly, 50-70% of FSHD 
patients developed retinal vasculopathy in addition to the myopathy indicating a vascular 
aspect to the disease (Gieron, 1985), consistent with the frg1 overexpression phenotype 
and  similar to the clinical expression of Coats’ disease. Coats’ disease is linked to the 
mutation in Norrin, a ligand for frizzled-4, part of the canonical Wnt signaling pathway. 
In the Xenopus expression profile, overexpression of FRG1 results in mis-regulation of 
Xenopus frizzled-2 (xfz2), a homologue to human frizzled-4, which provides a strong 
evidence for FRG1’s involvement in Wnt signaling pathway (Chapter 4). In Xenopus, 
xfz2 is a transmembrane receptor in the Wnt signaling pathway. The Wnt signaling 
pathway is critical for many cellular processes, including proliferation, polarity, 
branching, apoptosis. All these processes are involved in vascular development 
(Masckauchan, 2006). Interestingly, in our Drosophila expression profile pen-2 
(presenilin enhancer), a Notch signaling molecule, is down regulated due to 
overexpression of FRG1. The interaction between Wnt and Notch signaling has been 
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identified in studies of Drosophila wing development. It is possible that FRG1, just like 
β-catenin and presenilin, functions downstream of Wnt and Notch signaling pathway and 
mediates the cross talk between these two signaling pathways.  
 
Translational impact to FSHD 
 Here, we have found a conserved activity for FRG1, actin bundling, and identified 
FRG-1 as associated with the C. elegans body wall muscle dense body, a highly 
conserved structure required for muscle function, the components of which have 
vertebrate orthologs intimately involved in numerous myopathies, rendering FRG1 the 
only FSHD candidate gene with a direct link to muscle structure.  Increasing the levels of 
FRG-1, as proposed for FSHD, affects its subcellular distribution and disrupts the lateral 
muscle-muscle attachments of the ventral muscle quadrants in C. elegans. Considering 
the high conservation between dense body components and their vertebrate counterparts 
(Moerman, 2006), the evolutionarily conserved muscle phenotype of overexpressed 
FRG1 orthologs in Xenopus, M. musculus, and now C. elegans (Gabellini, 2006; Hanel, 
2009), and the conserved actin bundling activity with the human FRG1 protein, we 
propose that FRG1 is likely to localize and function similarly in human muscle, 
supporting the model whereby increases in FRG1 protein levels within the muscle and 
associated tissues lead to FSHD pathology, potentially mediated by changes in the 
subcellular localization of FRG1 resulting in altered or neomorphic functions.  
Mis-regulation of FRG1 expression leads to improper localization, mis-regulation of 
RNA biogenesis, and disruption of canonical signaling pathways involved in 
angiogenesis, together leading to the complex FSHD pathophysiology. 
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